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List of abbreviations
ACORN a classification of residential
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CI confidence interval*
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M male*
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*
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Background
This review examines the clinical effectiveness and
cost-effectiveness of hand-held inhalers to deliver
medication for the routine management of chronic
asthma in children aged between 5 and 15 years.
Asthma is a common disease of the airways, with a
prevalence of treated asthma in 5–15-year-olds of
around 12% and an actual prevalence in the com-
munity as high as 23%. Treatment for the condition
is predominantly by inhalation of medication. There
are three main types of inhaler device, pressurised
metered dose, breath actuated, and dry powder, with
the option of the attachment of a spacer to the first
two devices under some prescribed circumstances.
Two recent reviews have examined the clinical and
cost-effectiveness evidence on inhaler devices, but
one was for children aged under 5 years and the
comparison in the second was made between pres-
surised metered dose inhalers and other types only.
Objectives
This review examines the clinical effectiveness and
cost-effectiveness of manual pressurised metered
dose inhalers, breath-actuated metered dose
inhalers, and breath-actuated dry powder inhalers,
with and without spacers as appropriate, to deliver
medication for the routine management of chronic
asthma in children aged between 5 and 15 years.
Methods
Two previous HTA reviews have compared the
effectiveness of inhaler devices, one focusing on
asthma in children aged under 5 years and the
other on asthma and chronic obstructive airways
disease in all age groups. For the current review, a
literature search was carried out to identify all
evidence relating to the use of inhalers in older
children with chronic asthma. A search of in-vitro
studies undertaken for one of the previous reviews
was also updated.
The data sources used were: 15 electronic biblio-
graphic databases; the reference lists of one of the
previous HTA reports and other relevant articles;
health services research-related internet resources;
and all sponsor submissions.
Studies were selected according to strict inclusion
and exclusion criteria, and relevant information
concerning effectiveness and patient compliance
and preference was extracted directly on to an
extraction/evidence table. Quality assurance 
was monitored.
Economic evaluation was undertaken by reviewing
existing cost-effective evidence. Further economic
modelling was carried out, and tables constructed
to determine device cost-minimisation and
incremental quality-adjusted life-year (QALY)
thresholds between devices.
Results
Number and quality of studies, and
direction of evidence
Fourteen randomised controlled studies were
identified relating to the clinical effectiveness of
inhaler devices for delivering β2-agonists. A further
five were on devices delivering corticosteroids and
one concerned the delivery of cromoglicate.
Overall, there were no differences in clinical
efficacy between inhaler devices, but a pressurised
metered dose inhaler with a spacer would appear
to be more effective than one without. These
findings endorse those of a previous HTA review
but extend them to other inhaler devices.
Seven randomised controlled trials examined the
impact on clinical effectiveness of using a non-
chlorofluorocarbon (CFC) propellant in place of 
a CFC propellant in metered dose inhalers, both
pressurised and breath activated, although only one
study considered the latter type. No differences were
found between inhalers containing either propellant.
A further 30 studies of varying quality, from 12 ran-
domised controlled trials to non-controlled studies,
were identified that concerned the impact of use 
by, and preference for, inhaler type, and treatment
adherence in children. Differences between the
studies, and limitations in comparative data between
various inhaler device types, make it difficult to draw
any firm conclusions from this evidence.
Executive summary
Executive summary
iv
Summary of benefits
No obvious benefits for one inhaler device type
over another for use in children aged 5–15 years
were identified.
Costs and cost per quality-adjusted
life-year
Two approaches have been taken: cost-minimisation
and QALY threshold. In the QALY threshold
approach, additional QALYs that each device must
produce compared with a cheaper device to achieve
an acceptable cost per QALY were calculated. Using
the cheapest and most expensive devices for deliver-
ing 200 µg of beclometasone per day, assuming no
cost offset for any device, and a threshold of £5000,
the largest QALY needed was 0.00807. With such 
a small QALY increase, no intervention can be
categorically rejected as not cost-effective.
Conclusions
Generalisability of findings
On the available evidence there are no obvious
benefits for one inhaler device over another 
when used by children aged 5–15 years with
chronic asthma. However, the evidence, in the
majority of cases, was compiled on children 
with mild to moderate asthma and restricted 
to a limited number of drugs. Therefore the
findings may not be generalisable to those at 
the more severe end of the spectrum of the 
disease or to inhaler devices delivering some 
of the drugs used in the management of asthma.
Need for further research
Many of the previous studies are likely to 
have been underpowered. Further clinical 
trials with a robust methodology, sufficient 
power and qualitative components are needed 
to demonstrate any differences in clinical 
resource use and patients’ asthma symptoms.
Further studies should also include the 
behavioural aspects of patients towards their
medication and its delivery mechanisms. 
It is acknowledged that sufficient power may 
prove impractical owing to the large numbers 
of patients required.
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Description of underlying 
health problem
Definition of the condition
Asthma is a common chronic inflammatory
reversible disease of the airways associated with
recurrent day-to-day symptoms and acute exacer-
bations. It affects the lower airways, manifesting as
airway obstruction with mucosal inflammation as a
major contributor. The resultant narrowing of the
airways (bronchoconstriction) leads to a reduction
in the flow of gases between air and the lung
alveoli, resulting in symptoms of wheeziness and
breathlessness. The condition can be triggered by 
a variety of environmental factors such as infection,
allergy, airborne chemicals and also exercise. The
degree of severity seen in the disease is broad. The
condition is the cause of considerable morbidity
and a rare cause of death.
Chronic asthma
Childhood asthma morbidity can be divided into:
• Infrequent episodic asthma: This constitutes up
to 75% of the childhood asthmatic population
and is associated with episodes occurring less
than once every 4–6 weeks, minor wheezing
after heavy exertion, no interval symptoms, 
and normal lung function between episodes.
Prophylactic therapy is not usually needed for
such patients.
• Frequent episodic asthma: This constitutes
about 20% of the childhood asthma population
and is associated with somewhat more frequent
attacks and wheezing on moderate exercise,
which can be prevented by predosing with 
β2-agonists. Symptoms occur less frequently 
than once a week, and there is normal or 
near normal lung function between episodes.
Prophylactic treatment is usually necessary.
• Persistent asthma: This affects roughly 5% of
children with asthma and is associated with
frequent acute episodes, wheezing on minor
exertion, and interval symptoms requiring 
β2-agonist drugs more than three times per 
week because of either night wakening or 
chest tightness in the morning. There is 
nearly always evidence of airflow limitation
between episodes. Prophylactic treatment 
is essential.1
Acute asthma
At any of these three levels of chronic morbidity 
a child may also suffer acute episodes of asthma,
which range from mild (in which there will be
coughing, audible wheezing, but peak expiratory
flow (PEF) or forced expiratory volume in the first
second of expiration (FEV
1
) will be above 75% of
predicted values, and patients can speak in normal
sentences between breaths), through to severe (in
which there will be severe distress, cyanosis, only
one to three words possible between breaths and
the patient will be chair or bed bound).1
The ability to use an inhaler correctly can be
affected during episodes of acute wheeze2 and in
some acute episodes there will be problems with
PEF and FEV
1
. However, in children with chronic
asthma who are not experiencing an acute episode,
actual lung function should not restrict the
effective use of breath-actuated inhaler devices.
Epidemiology
Mortality
Although deaths from asthma-related causes are rare
in children, there were 17 in England and Wales in
19993 in those aged 5–14 years, the majority of which
were likely to have been preventable.
Incidence and prevalence
The prevalence of doctor-diagnosed asthma in
children in Great Britain is around 10–23%. In 
8–9-year-olds in Sheffield, it was found to be 10%4
and in 11–16-year-olds in Nottingham it was 13%.5
A national survey across Great Britain of 12–14-year-
olds identified a prevalence of 21% in 1998,6 which
endorses the findings of the Health Survey for
England of 1995–1997.7 This survey reported a
prevalence of doctor-diagnosed asthma of around
18% in girls aged 5–15 years and 24% in boys aged
5–12 years, dropping to 22% in those aged 15.8
However, the condition is considerably undertreated,
as not all people who have asthma are currently
receiving therapy. Table 1 shows the number of those
treated for asthma per 1000 population for England
and Wales, subdivided by age and sex.9
In the UK, asthma treatment is strongly influ-
enced by the guidelines of the British Thoracic
Society (BTS),10 which currently promotes a step-
wise management to increasingly severe asthma
Chapter 1
Background 
Background 
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(appendix 1). The percentages of patients in each
of the five BTS steps have been derived from an
article by Hoskins and colleagues11 and are shown
in Table 2.
By applying these data to a district serving 
500,000 people, the numbers with asthma in 
each age range have been estimated. These are
shown in Figure 1.
Using the prevalence rate for patients treated 
for asthma and a standard population profile, 
in a district of 500,000 people,12 there would be
33,505 expected asthma sufferers, distributed by
age band and BTS step as shown in Table 3.
Significance in terms of ill health
Since there is no cure for asthma, these children
TABLE 1  Prevalence of patients treated for asthma 
per 1000 population (Office of National Statistics, 19969)
Age band (yr) M F
0–4 94.1 59.5
5–15 122.9 97.2
16–24 70.7 81.7
25–34 49.1 57.8
35–44 41.8 54.1
45–54 38.6 55.1
55–64 52.9 67.7
65–74 69.0 74.6
75–84 72.1 66.7
85≥ 54.6 42.4
All ages 66.2 67.7
M, male; F, female
TABLE 2  Estimated percentages of patients with asthma by
BTS step and age (derived from Hoskins et al., 200011)
% aged % aged % aged
<5 yr 5–15 yr ≥16 yr
Medication
below step 1 2 11 12
BTS step 1 47 20 18
BTS step 2 44 44 38
BTS step 3 7 19 22
BTS step 4 0 3 9
BTS step 5 0 3 1
Total 100 100 100
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FIGURE 1  Estimated number of people treated for asthma in a district serving a population of 500,000 (using an England and Wales
population profile) (Derived from Office of National Statistics, 19969; 199412)
TABLE 3  Expected number of people with asthma, by age
band and severity, in a district serving a population of 500,000
(Office of National Statistics, 199412)
0–4 yr 5–15 yr ≥16 yr
Medication
below step 1 57 845 2,790
BTS step 1 1,204 1,536 4,184
BTS step 2 1,147 3,379 8,834
BTS step 3 172 1,459 5,114
BTS step 4 0 230 2,092
BTS step 5 0 230 232
Total 2,580 7,679 23,246
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have a chronic persistent condition that manifests
with different degrees of severity and with occasional
episodes of acute symptoms. The degree of severity 
is assessed in terms of symptoms and reduction in
lung function. The goal of treatment is therefore to
achieve optimal control of the disease by preventing
chronic and troublesome symptoms, maintaining
near ‘normal’ lung function and normal activity
levels, and preventing recurrent exacerbations and
acute episodes, in order to maximise quality of life
for these individuals and satisfaction with their
care.13 The ability to provide an early, effective
treatment is also particularly important in children
because it may provide longer-term advantages, in
terms of both improved management and reduc-
tions in the social burden of disease caused through
lost school days and reduced activity levels.14–17
Current service provision
Pharmacological therapy is aimed at reversing and
preventing airway inflammation, managing acute
exacerbations and relieving symptoms. Drugs used
to treat respiratory airway disease can be adminis-
tered systemically or topically. The advantage of the
latter route is that the drug acts more quickly and
smaller amounts are required, thus reducing the
potential for adverse effects. Topically delivered
therapy is usually via the inhaled route using devices
delivering drugs such as β2-agonists, corticosteroids
and cromoglicate-like drugs in various doses. The
use of increasing doses of inhaled corticosteroids
used to be the mainstay of preventive therapy. How-
ever, the trend is now towards trying to minimise 
the dose of inhaled corticosteroids where possible,
through the use of additional therapies such as β2-
agonists or oral leukotriene antagonists, because of
persisting concerns regarding potential side-effects
associated with high doses of steroids. Currently
there are a number of different inhaler devices
available that can deliver a range of drugs for the
treatment of asthma in children aged 5–15 years.
Evidence and guidelines to inform
current service provision
A recent Cochrane systematic review examined the
effectiveness of pressurised metered dose inhalers
(pMDIs) with holding chambers compared with wet
chamber nebulisers to deliver β2-agonist medications
for acute asthma,18 and a recent HTA report con-
sidered the clinical and cost-effectiveness of inhaler
devices for children aged under 5 years with chronic
asthma.19 Finally, Brocklebank and co-workers20 have
looked at pMDI devices compared with alternative
inhaler delivery systems for managing asthma and
chronic obstructive pulmonary disease in patients 
of all ages. In their HTA systematic review, they
considered with respect to asthma:
• the relationship between in-vitro measurements
and in-vivo deposition measured by scintigraphy
• the relationship between in-vitro measurements
and clinical effect measured by lung function
• the delivery of corticosteroids by hand-held
inhalers for the treatment of stable asthma in
children and adults
• the delivery of short-acting β2-agonist broncho-
dilators by hand-held inhalers for the treatment
of stable asthma in children and adults
• the delivery of any short-acting bronchodilators
using a nebuliser compared with any hand-held
inhaler (usually a pMDI) in stable asthma in
children and adults
• inhaler technique with different inhaler devices.
Guidelines on asthma management
A number of guidelines have been developed 
with respect to asthma over the last few years. 
Of these, there are three of which clinicians and
other healthcare professionals working with
patients with asthma are most likely to be aware:
• BTS guidelines for the management of asthma.10
• Scottish Intercollegiate Guideline Network
(SIGN) guidelines,21 which contain information
on the primary care management of asthma.
They are currently developing a new guideline
on asthma in conjunction with the BTS. This 
is due to be published in summer 2002. The
National Institute for Clinical Excellence (NICE)
was considering the development of a guideline
on asthma, but instead will await publication 
of the SIGN guideline and will work with SIGN
and the BTS on any subsequent amendments.
• National Heart, Lung, and Blood Institute (USA)
guidelines for the diagnosis and management
of asthma.13
The BTS guidelines10 are those most commonly
used in UK practice.
BTS guidelines 1997
These were revised from guidelines published 
in 1993 and are not explicitly evidence based. 
The guidelines recommend a five-step approach to
the management of chronic asthma in adults and
children, starting with bronchodilators and intro-
ducing anti-inflammatory agents, with increased
doses of these if control is not maintained with the
previous drug and dose regimen. For most of the
recommendations, school children (aged 5 years
and over) and adults are considered to require a
similar therapeutic approach (see appendix 1).10
Background 
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National Heart, Lung and Blood Institute, USA 1997
These guidelines were produced by an expert
panel who revised and updated a set of previous
(1991) guidelines. They also take a four-step
approach for managing asthma in children older
than 5 years of age and adults. However, these
steps are defined in terms of symptoms, night-time
symptoms and lung function rather than on level
and type of medication required for control.13
Other evidence
Drug and Therapeutics Bulletin
These Bulletins are commissioned independent
reviews produced by the Consumers’ Association
for clinicians and pharmacists. They are widely
circulated to clinicians. The treatment of asthma 
in children by using inhaled steroids was addressed
in 1999;22 adults were considered in 2000.23 The
choice of inhaler devices for children was addres-
sed, but without any specific recommendations,
although inhaler devices themselves were also
reviewed in 200024 and age-specific recommenda-
tions were then made (presented in Table 4).
Third International Pediatric Consensus state-
ment on the management of childhood asthma
Paediatricians with a special interest in pulmonol-
ogy or allergy and clinical immunology met
together in 1995 to develop clinically sound 
and practical guidelines for the management 
of childhood asthma that could be implemented 
in different healthcare systems with a reasonable
chance of compliance. Their recommendations 
for management and treatment are based upon
symptom presence and frequency in children
(ages not stated). The report discusses the
different inhaler devices available but makes 
no recommendations on specific use.1
However, even with the published evidence and
guidelines, described above, available to inform
current service provision, Brocklebank and col-
leagues,20 in their recent HTA systematic review 
on inhaler devices for asthma, concluded that:
“There appears to be a lack of consensus and
guidance for an individual prescriber faced with 
a wide range of possible inhaler devices. The 
current guidelines are either vague, absent 
and where present, possibly contradictory” (p. 12).
Description of intervention
For use in a population of children aged 5–15 years
with chronic asthma, this review considers three
different inhaler device types: pressurised metered
dose (aerosol) inhalers, breath-actuated metered
dose (aerosol) inhalers, and breath-actuated dry
powder inhalers (DPIs). In addition, there is also
discussion on the combined devices of spacers 
or extension tubes used with either pressurised
metered dose or breath-actuated aerosol inhalers
and, finally, metered dose inhalers (MDIs)
pressurised with either chlorofluorocarbon 
(CFC) or hydrofluoroalkane (HFA) propellants.
CFCs have long been used as propellants in pMDIs
as they are non-inflammable and chemically inert.
However, the free chlorine radicals produced by
breakdown of CFCs in the stratosphere have been
associated with the catalytic conversion of ozone 
TABLE 4  Inhaler devices: age-specific recommendations (modified from Drug and Therapeutics Bulletin 2000;38(2):9–13.24)
Age (yr) First choice Second choice
0–2 pMDI + spacer + face mask Nebuliser
3–6 pMDI + spacer Nebuliser
6–12 bronchodilators pMDI + spacer or DPI or 
breath-actuated pMDI
6–12 corticosteroids pMDI + spacer DPI or breath-actuated
pMDI for low-dose corticosteroids only
>12 bronchodilators pMDI DPI or breath-actuated pMDI
>12 corticosteroids pMDI (+ spacer for DPI or breath-actuated pMDI
moderate or high doses) for low-dose corticosteroids only
All ages; acute asthma pMDI + spacer or nebuliser
pMDI, pressurised metered dose inhaler; DPI, dry powder inhaler
Health Technology Assessment 2002; Vol. 6: No. 5
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to molecular oxygen, with implications for
depletion of the ozone layer, although medical
aerosols use only 0.5% of worldwide consumption.
The Montreal protocol,25 signed by 27 nations 
in 1987, proposed a 50% reduction in CFC
production by 1999. This was subsequently
amended to achieve elimination of CFCs by 2000.
Potential costs to the NHS of this transition of
bronchodilators and corticosteroid inhalers from
CFC to non-CFC versions have been estimated to
be as high as £270 million. However, the transition
has also provided an opportunity to review pre-
scribing policies and develop strategies that offer
maximum benefit to both patients and the health
service, sometimes resulting in cost savings.26
Manufacturers and pharmaceutical companies
have been working over the past few years to
produce non-CFC propellant MDIs. Alternative
propellants now available include the HFAs.
There is some evidence that use of HFA propel-
lants with beclometasone has led to improved lung
deposition,27 and a reduction in dose may become
possible when changing a child with stable asthma
from a CFC to an HFA-propelled inhaler.
Inhaler devices
For the purpose of this review, the three different
inhaler device types have been compared between
and also within type. In the tables in the following
section on pMDIs, information is provided on all
the inhaler devices currently marketed in the UK,28
grouped by drug delivered (type and generics).
Furthermore, for the purpose of this report, all
comparisons reviewed have been limited to those
in which the same generic drug is delivered at an
equivalent dose level by all the inhaler types
included in the comparison. Even within these
constraints, there is some evidence that two
chemically equivalent inhalers (salbutamol 
pMDIs) can result in statistically significant
differences in therapeutic efficacy.29
Pressurised metered dose aerosol inhalers
A list of currently available pMDI devices (not
breath actuated) is given in Table 5.
In England in 1995, the majority of all prescriptions
for inhaler medication containing short-acting (β2-
agonists (83%) or inhaled steroids (78%) used a
pMDI delivery mechanism.30 Although, for children
aged 5–12 years living in the West Midlands, bron-
chodilator prescriptions for pMDIs accounted for
only 57%, with the other 43% being for DPIs.31 The
pMDI was initially introduced in 1956. It comprises
a small portable plastic case in which is located an
aerosol canister containing up to 200 metered
doses of the drug, propellants (traditionally CFCs)
to aerolise the drug for inhalation, and lubricants.
The inhaler is prepared by shaking it to re-suspend
the drug particles and, for optimal use, the user
takes a slow, deep inhalation to full capacity,
actuating the device fractionally after the
inhalation, and breath holding for 10 seconds.
A number of common local side-effects, such as
mild throat irritation, cough, mouth dryness and
paradoxical bronchospasm, have been reported 
to be associated with the CFC propellants and the
lubricants.32 However, after the decision taken at
Montreal in 1987,25 CFC propellants are now being
phased out and replaced with CFC-free alternatives.
A number of problems that limit the effective use
of pMDIs have been identified:
1. pMDIs generate many particles that are too
large to reach the lower airway and are
associated with significant oropharyngeal
deposition.
2. The cold freon effect can occur with a standard
MDI. When the propellant hits the back of the
oropharynx it causes the patient either to stop
breathing completely or at least to breathe
through the nose rather than the mouth. 
This is known to occur in 10% of patients.33
3. The effective delivery of a dose using a pMDI
requires coordination between actuation and
dose inhalation. A number of users have
problems in coordinating their inhalation with
their action to release the drug from the pMDI;
this can result in excessive deposition of the
drug in the oropharynx.32 Deposition of
corticosteroids in the oropharynx is associated
with local side-effects such as oral candidiasis32
and hoarseness due to muscle weakness. These
two complications are known to be relatively
rare in children, although they are more
common in adults.
Spacer systems were developed to surmount these
problems, while breath-actuated devices were
designed to overcome the third problem specif-
ically and also another problem that arises with 
the use of spacers, namely that of having to carry
the spacer around with the inhaler for use during
the day.
Spacers and tube extenders
Large-volume spacer devices were introduced in the
late 1980s to address some of the identified problems
associated with pMDIs. Currently, spacer devices are
available as large, medium or small volume with or
without a one-way valve, or as tube extenders.
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TABLE 5  PMDIs (excluding breath actuated) by drug type, for children aged 5–15 years for routine management of chronic asthma
Drug type Generic drug Device brand name Manufacturer Users
Adrenoceptors: Salbutamol Maxivent® aerosol (CFC) APS Children >2 yr
short-acting Asmaven® aerosol (CFC) Berk Children >2 yr
β2-agonists Salamol® aerosol (non-CFC) Baker Norton Children >2 yr
Airomir® aerosol (non-CFC) 3M Children >2 yr
Salbulin® aerosol (non-CFC) 3M Children >2 yr
Ventolin® Evohaler® (non-CFC) GlaxoSmithKlinea Children >2 yr
Terbutaline sulphate Bricanyl® aerosol (CFC) AstraZeneca Adults and children;
no age given
Reproterol Bronchodil® aerosol (CFC) ASTA Medica Adults and children
hydrochloride aged ≥6 yr
Adrenoceptors: Salmeterol Serevent® aerosol (CFC) GlaxoSmithKlinea Adults and children 
long-acting aged ≥4 yr
β2-agonists
Antimuscarinic Ipratropium bromide Atrovent® aerosol (CFC) Boehringer Adults and children
bronchodilators Ingelheim 1 month upwards
Atrovent Forte aerosol (CFC) Boehringer Adults and children
Ingelheim ≥6 yr
Oxitropium bromide Oxivent® aerosol (CFC) Boehringer Not recommended
Ingelheim for children; no age
given
Ipratropium and Duovent® aerosol (CFC) Boehringer Children aged >6 yr
fenoterol Ingelheim
Corticosteroids Beclometasone Beclazone® aerosol (50, 100, 200) Baker Norton Adults and children;
dipropionate (CFC) no age given
Beclazone aerosol (250) (CFC) Baker Norton Not recommended
for children; no age
given
Filair® aerosol (50, 100) (CFC) Generics and 3M Adults and children;
no age given
Filair Forte aerosol (250) (CFC) Generics and 3M Not recommended
for children; no age
given
Becotide® aerosol (50, 100) (CFC) GlaxoSmithKlinea Adults and children;
no age given
Becloforte® aerosol (250) (CFC) GlaxoSmithKlinea Not recommended
for children; no age
given
Qvar® aerosol (50, 100) (non-CFC) 3M Adults and children
aged ≥12 yr
Budesonide Pulmicort® aerosol (CFC) AstraZeneca Adults and children;
no age given
Fluticasone Flixotide® aerosol (CFC) GlaxoSmithKlinea Children aged ≥4 yr
propionate
Flixotide Evohaler (50) GlaxoSmithKlinea Children aged ≥4 yr
(non-CFC)
Flixotide Evohaler (125, 250) GlaxoSmithKlinea Not indicated for
(non-CFC) children; age
unknown
Compound Beclometasone Ventide® aerosol (CFC) GlaxoSmithKlinea Adults and children;
preparations dipropionate and no age given
salbutamol
Fluticasone and Seretide® Evohaler® (non-CFC) GlaxoSmithKlinea Children aged  
salmeterol >12 yr and adults
continued
Some spacers are integral to the pMDI and form 
a single unit, whereas others have a flexible
opening designed to accommodate either all or
most available pMDIs or only those of the same
manufacturer. Evidence on the efficacy and safety
of use of attached spacers versus integrated
modules appears to be lacking.
All spacers work on the same principle and with 
the same intended end-point and outcome. They
address some of the problems that occur with
pMDI use. However, there are a number of factors
that can reduce the effectiveness of the pMDI–
spacer combination. A list of spacer devices that are
not integral to specific inhalers is given in Table 6.
Electrostatic charge. Plastic spacers cause a rapid
loss of delivery to the lungs of drug aerosol
particles owing to their deposition, because of
electrostatic charge, on the walls of the spacer.
Elimination of the charge results in an increase 
in the aerosol half-life, thus reducing the require-
ments for good and swift coordination between
actuation of the inhaler and inhalation, which is 
a key problem for younger children.
It has been proposed that the electrostatic charge
on plastic spacers may be reduced in a number of
ways, such as, coating the inside surface with
antistatic paint, washing the spacer in detergent
but not drying it with a cloth, building up the
antistatic layer through repeated use of the pMDI,
or neutralising the electrostatic charge with
benzalkonium chloride.34 However, consideration
would also need to be given to the stability and
effectiveness of any coating used, the toxicity of
chemicals employed in the coating and any
interaction between drug delivered through the
spacer and the coating.34 The effectiveness of drug
delivery through metal spacers, which are non-
electrostatic, has been compared with that through
plastic. Currently, metal spacers are not available in
the UK, although the NebuChamber®, a stainless
steel spacer 250 ml device, is to be launched in 
the UK (AstraZeneca communication).35
Breath-actuated aerosol inhalers
Further development of pMDIs resulted in MDIs that
combined the actions of actuation and inhalation,
thus eliminating the need for hand–lung coordi-
nation. The drug is released from the inhaler device
when the user inhales through the mouthpiece, in
contrast to the user having to release the drug by
pressing with a finger a button on the top of the
device and having to synchronise inhalation with this
action. With the pressurised component retained,
little additional force is needed to trigger the device.
Although some recommend that a spacer is also
used with this inhaler type in order to minimise the
risk of oropharyngeal deposition, particularly with
corticosteroid delivery, in practice spacers are rarely
used with breath-actuated devices. The propellant
used in breath-actuated inhalers was originally CFC,
but this is now being replaced by alternatives. There
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TABLE 5 contd  PMDIs (excluding breath actuated) by drug type, for children aged 5–15 years for routine management of chronic asthma
Drug type Generic drug Device brand name Manufacturer Users
Cromoglicate Sodium Cromogen® aerosol Baker Norton Adults and children;
therapy cromoglicate no age given
Intal® aerosol (CFC) Rhône-Poulenc Adults and children;
Rorer no age given
Intal® Syncroner® (with Rhône-Poulenc Adults and children;
integral open-tube spacer) Rorer (Aventis no age given
(CFC and non-CFC) Pharma Ltd)
Nedocromil sodium Tilade® aerosol (CFC) Pantheon Children aged >6 yr
and adults
Tilade Syncroner (with integral Pantheon Children aged >6 yr
open-tube spacer) (CFC) and adults
Compound Sodium cromoglicate Aerocrom® aerosol (CFC) Castlemead Not recommended 
preparations and salbutamol for children; no age
given
Aerocrom aerosol Syncroner (CFC) Castlemead Not recommended
for children; no age
given
Items in normal typeface were found in the recent systematic review by Brocklebank and colleagues20 and the BNF (British
National Formulary);25 those in bold appear in the BNF now25 but not in the review20
aGlaxoSmithKline includes Allen and Hanburys
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are two breath-actuated CFC-free inhaler devices
currently licensed for use in the UK, although the
inhaler delivering a corticosteroid (beclometasone)
is licensed only for 12-year-olds and older.
There are currently two breath-actuated aerosol
devices licensed for use in the UK, the Autohaler®
and Easi-Breathe®. Details of the drugs delivered
by each are given in Table 7.
Autohaler
The Autohaler contains a manually-operated lever,
which, when lifted, primes the inhaler through 
a spring-loaded mechanism, allowing the aerosol 
to be dispensed. The drug is released when the
user breathes through the mouthpiece at a rate 
of 30 l/min or higher. The Autohaler is used to
deliver a number of different bronchodilators:
salbutamol, ipratropium bromide and oxitropium
bromide; and one anti-inflammatory cortico-
steroid, beclometasone dipropionate.
Easi-Breathe
This breath-actuated device consists of an alumini-
um canister with a breath-operated mechanism, 
an actuator and a dust cap. The device is primed
when the user opens the hinged cap and actuated
in response to inhalation. It can be used to deliver
salbutamol, a bronchodilator, and two anti-inflam-
matory drugs, the corticosteroid beclometasone
dipropionate, and sodium cromoglicate.
Dry powder inhalers
DPI devices contain the drug in the form of a dry
powder. They lack propellants and other potentially
harmful additives, but the micronised drug in most
DPI devices is mixed with a coarse carrier substance,
usually lactose, which has been shown to cause airway
irritation in some asthmatic patients.36 DPIs work on
the principle of mechanical inhalation driven by the
user’s own inspiratory efforts (i.e. they are breath acti-
vated by the user). The energy imparted to the system
by the user is used to disperse the drug particles. Dis-
persion is aided through the use of a carrier in many
of the devices, together with a variety of physical
forces, depending on the device, such as turbulence
and/or a grille. Individual DPIs have varying internal
resistance and require different minimum flow rates.
However, with all current DPIs, patients should inhale
forcefully because it is the inspiratory effort rather
than the resistance that is crucial to the effectiveness
of drug dispersal. In an acute asthma episode, the
level of inspiratory effort achieved may be insufficient
but, for children with a chronic stable condition, the
minimum flow rate required should be achievable.
The mechanism in a DPI eliminates the require-
ment for synchronisation between actuation and
inhalation, as required in pMDIs. Therefore, by
design, the problems of coordination associated
with pMDIs, although to some extent eliminated
with the additional use of a spacer device, are not
present in DPIs. In general, DPIs and pMDIs are
equally portable, although the inclusion of a spacer
device with a pMDI reduces its portability as a
delivery system.
A list of currently available DPIs is given in Table 8.
Rotahaler® and Spinhaler®
Two DPIs, Rotahaler and Spinhaler, were intro-
duced over 10 years ago. Both are unit-dose DPIs,
TABLE 6  Spacer devices available as units for attachment to inhaler devices
Name (manufacturer) Type Use with:
Able Spacer® (Clement Clarke) Small-volume device Any pressurised aerosol inhaler
AeroChamber® Medium-volume device, adult, Airomir, Salbulin, Qvar
(Trudell Medical; UK distributor 3M) child and infant models, 145 ml,
rigid plastic tube
Compatible with all shapes of pMDI
Babyhaler® (Allen and Hanburys) Paediatric device Becotide and Ventolin inhalers
E-Z Spacer® (Vitalograph) Large-volume device, collapsible Any pressurised aerosol inhaler
Nebuhaler® (AstraZeneca) Large-volume device, 750 ml, Bricanyl, Pulmicort
plastic pear-shaped cone
Volumatic® (GlaxoSmithKline) Large-volume device, 750 ml reservoir Compatible with all GlaxoSmithKline
corticosteroid and bronchodilator MDIs
Optimiser™ (Norton) Small-volume tubular attachment Easi-Breathe® steroid inhalers
Fisonair® (Aventis) Large-volume device Intal (sodium cromoglicate)
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with each dose of the drug blended with a carrier
substance, lactose, and contained in a gelatin
capsule. The drug is delivered when the gelatin
capsule is pierced or split in two. Users have to
carry a supply of capsules and load each one as
required, which may be a difficult feat in someone
experiencing an acute asthma attack or having
limited dexterity, as in younger children. The
Rotahaler, and its later derivative, the Diskhaler®,
which contains four or eight doses of individual
plastic and foil bubble blister packs of the drug
(depending on the drug), and the Spinhaler
operate under two different principles. The
Rotahaler and Diskhaler operate on the cyclone
principle, whereas Spinhaler capsules are attached
to a turbine that rotates on inhalation.36 Powder
becomes deposited on various parts of the inhaler
and regular cleaning with a brush or scraper is
advised. One problem with the older DPIs that 
use gelatin capsules is that the gelatin can soften 
at high temperatures and in high humidity, 
making it harder to pierce.
Rotahalers and Diskhalers deliver either salbutamol
(a short-acting β2-agonist, a bronchodilator) or
beclometasone dipropionate (an anti-inflammatory
corticosteroid). In addition, the Diskhaler can
deliver salmeterol (a long-acting β2-agonist, a
bronchodilator) and fluticasone. The Spinhaler
delivers sodium cromoglicate, a non-steroidal anti-
inflammatory drug.
More recently, other multidose DPIs incorporating
new design approaches have been introduced.
Diskus® (Accuhaler®)
The Diskus (alternative name Accuhaler) is another
multidose DPI. It is a disk-shaped plastic device
approximately 9 cm in diameter and 3 cm wide.
A built-in dose counter counts down the number 
of doses left from a 60-dose pack. Each unit dose is
packed in a foil blister and contains a mixture of dry
powdered drug and lactose. All 60 doses are provided
sequentially on a long coiled strip within the device.
Movement of a small lever coupled with an audible
and palpable click advances the strip and indicates
that the dose is loaded and the inhaler is ready for use.
In the priming, the next blister foil is aligned for use
and its lid is dislodged from the base foil and collected
on a contracting wheel. As the user inhales, which 
can be from any orientation, air is drawn in through
the device and aerolises the blister contents, releasing
the drug through the mouthpiece. The empty strip 
is stored in a further storage area. When not in use,
the mouthpiece is protected by an integral cover.36
The Diskus delivers salbutamol and salmeterol
(short- and long-acting β2-agonists respectively,
TABLE 7  Breath-actuated MDIs, by drug type, for children aged 5–15 years for routine management of chronic asthma
Drug type Generic drug Device brand name Manufacturer Users
Short-acting Salbutamol Aerolin® Autohaler® (CFC) 3M Children aged >2 yr
β
2
-agonists Airomir Autohaler (non-CFC) 3M Children aged >2 yr
Salamol Easi-Breathe (CFC) Baker Norton Children aged >2 yr
Antimuscarinic Ipratropium bromide Atrovent Autohaler (CFC) Boehringer Adults and children 
bronchodilators Ingelheim ≥1 months
Oxitropium bromide Oxivent Autohaler (CFC) Boehringer Not recommended
Ingelheim for children; no age
given
Combined therapy Ipratropium and Duovent Autohaler (CFC) Boehringer Children aged >6 yr
fenoterol Ingelheim
Corticosteroids Beclometasone AeroBec® Autohaler® (50, 100) (CFC) 3M Adults and children;
dipropionate age unknown
AeroBec Forte Autohaler (250) (CFC) 3M Not indicated for
children; age unknown
Beclazone Easi-Breathe Baker Norton Adults and children
Qvar Autohaler (50, 100) 3M Adults and children
(non-CFC) aged ≥12 yr
Cromoglicate Sodium cromoglicate Cromogen Easi-Breathe (CFC) Baker Norton Adults and children;
therapy age unknown
Items in normal typeface were found in the recent systematic review by Brocklebank and colleagues20 and the BNF;25 those in bold
appear in the BNF now25 but not in the review20
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TABLE 8  DPIs by drug type, for children aged 5–15 years for routine management of chronic asthma
Drug type Generic drug Device brand name Manufacturer Users
Short-acting Salbutamol Asmasal® Clickhaler® Medeva Children aged >2 yr
β
2
-agonists Ventodisks® Diskhaler® GlaxoSmithKline
Ventolin® Accuhaler® GlaxoSmithKline
Ventolin® Rotahaler® GlaxoSmithKline
Pulvinal® Trinity Children aged ≥6 yr
Terbutaline sulphate Bricanyl® Turbohaler® AstraZeneca
Long-acting Formoterol fumarate/ Foradil® Novartis Adults and children 
β
2
-agonists eformoterol fumarate aged >5 yr
Oxis® Turbohaler® AstraZeneca Adults and children
aged >12 yr
Salmeterol Serevent® Accuhaler® GlaxoSmithKline Adults and children
aged ≥4 yr
Serevent Diskhaler GlaxoSmithKline Adults and children
aged ≥4 yr
Antimuscarinic Ipratropium Atrovent® Aerocaps® Boehringer Adults and children
bronchodilators bromide (with Atrovent® Aerohaler®) Ingelheim aged ≥12 yr
Corticosteroids Beclometasone Asmabec Clickhaler® (50, 100) Medeva Adults and children;
dipropionate no age given
Asmabec Clickhaler (250) Medeva Not recommended
for children
Becodisks® Diskhaler® GlaxoSmithKline Adults and children;
age not given
Becotide® Rotacaps® GlaxoSmithKline Adults and children;
(100, 200, 400) (with Rotahaler) age not given
Becloforte (400) (with Diskhaler) GlaxoSmithKline Not recommended
for children; age
unknown
Pulvinal Trinity Children aged ≥6 yr
Budesonide Pulmicort Turbohaler AstraZeneca Adults and children;
age not given
Fluticasone Flixotide Accuhaler GlaxoSmithKline Children aged 
propionate 4–16 yr and adults
Flixotide Diskhaler GlaxoSmithKline Children aged ≥4 yr
Compound Beclometasone and Ventide Rotacaps (with Rotahaler) GlaxoSmithKline Adult and paediatric;
preparations salbutamol including Paediatric Rotacaps no age given
Fluticasone and Seretide (100) Accuhaler GlaxoSmithKline Children aged >4 yr
salmeterol and adults
Seretide (250 and 500) Accuhaler GlaxoSmithKline Children aged 
>12 yr and adults
Cromoglicate Sodium cromoglicate Intal® Spincaps® Rhône-Poulenc Adults and children;
therapies (with Spinhaler insufflator®) Rorer (Adventis no age given
Pharma Ltd 
submission)
Intal Syncroner Rhône-Poulenc
Rorer
Items in normal typeface were found in the recent systematic review by Brocklebank and colleagues20 and the BNF;25 those in bold
appear in the BNF now25 but not in the review20
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both bronchodilators), fluticasone propionate 
(an anti-inflammatory corticosteroid) and a
combined prescription of salmeterol and 
fluticasone propionate.
The Diskhaler and Accuhaler are both unit dose
devices, while the Turbohaler®* and Clickhaler®
are both reservoir devices.
Turbohaler
The Turbohaler is a multidose DPI that contains
50–200 metered doses of the drug, depending on
drug strength. Unlike other DPIs and pMDIs, it does
not contain any propellants, additives or lubricants
except lactose. The inhaler device assembly consists
of moulded plastic with a steel spring. There are two
compartments, one in which the dry powder is stored
and a dosing unit through which the dry powder is
delivered. A single dose is added (in the upright
position) by twisting the base of the device fully in
one direction and then back again. With each twist 
of the end of the unit, a dose of powder is shaved off
from a drug reservoir. Inhalation forces air through
the dosing holes, while spiral channels in the mouth-
piece create turbulence and agitate the dry-air
mixture, ensuring that a large proportion of the drug
is delivered as free particles. The device should not
be shaken after the dose is loaded and should not be
used with a spacer. The child should not exhale into
the inhaler. A red mark appears in the indicator
window to indicate when a limited number of doses
remain. The inhaler contains a desiccant that may
sound, when shaken, as though some drug is present
even when all doses have been used.37
The Turbohaler functions at an inspiratory flow
rate of 30 l/min, but ideally requires 60 l/min. 
This is a more powerful flow than that required
with the Rotahaler and the Diskhaler because of in-
built areas of resistance in the Turbohaler structure.
The Turbohaler is used to deliver terbutaline
sulphate and formoterol fumarate (short-acting
and long acting β2-agonists respectively, both
bronchodilators), and budesonide (an anti-
inflammatory corticosteroid).
Clickhaler
The Clickhaler is similar to a pMDI in appearance.
It contains 100 or 200 actuations, depending upon
the drug and the dose; it has a dose counter and
locks when empty. Children aged 7–16 years with
mild to moderate stable asthma have been shown
to generate inspiratory rates of 60 l/min or more
when using this device.38
The Clickhaler delivers salbutamol (a short-acting
β2-agonist bronchodilator) or beclometasone dipro-
pionate (an anti-inflammatory corticosteroid).
At least two other DPIs are under development.
(Yamanouchi provided confidential information,
which was included in the version of the report
that was sent to the Appraisals Committee, but 
this information has been removed from this
current document.)
Pulvinal®
Pulvinal is a new DPI recently launched in the 
UK. It is a multidose DPI comprising: a rotating 
mouthpiece with a dose-lock button to prevent
unintentional priming; a drug chamber, containing
the drug and a lactose carrier; and metering 
and distribution systems. The drug chamber is
transparent, thus enabling the user to see the
amount of drug remaining. Priming, activation 
and inspiration are independent steps, so precise
coordination is not required for successful
inhalation. Pulvinal delivers the anti-inflammatory
corticosteroid, beclometasone dipropionate and
the short-acting β2-agonist salbutamol.
Drugs
A person’s asthmatic condition can be managed by
using a number of therapeutic approaches. For the
purpose of this review a specific list of drugs has
been considered that are available for delivery in
one or more types of the inhaler devices described
above. The drugs included are bronchodilators
(short- and long-acting β2-agonists, other
adrenoceptors, antimuscarinic bronchodilators)
and anti-inflammatory drugs (corticosteroids,
cromoglicates) that are licensed for use in 
5–15-year-old children.
Main types
Bronchodilators (relievers)
The principal action of the β2-agonists is to 
relax the airway smooth muscle by stimulating 
the β2-receptors, which increases cyclic adenosine
monophosphate and produces functional antago-
nism to bronchoconstriction. They are used as an
adjunct to anti-inflammatory therapy for providing
short- or long-term control of symptoms, especially
nocturnal symptoms, and to prevent exercise-
induced bronchospasm. Short-acting β2-agonists
cause a prompt increase in airflow, peaking at
20–30 minutes and then fading rapidly, whereas
long-acting inhaled β2-agonists have a longer dura-
tion of bronchodilation of at least 12 hours after a
*“Turbuhaler” may occur as an alternative spelling for this product.
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single dose. With formoterol, the onset of action is
similar to that seen in short-acting β2-agonists, but
with salmeterol the onset of action is slower.
The prompt response seen after the inhalation of
most short-acting β2-agonists provides immediate
feedback to the patient that the device has deliv-
ered some drug to the relevant sites. Short-acting
β2-agonists are usually inhaled as required.
Anti-inflammatory agents (preventers)
Corticosteroids are the most potent anti-inflam-
matory agents currently used to treat asthma.
Three inhaled corticosteroid compounds are
currently licensed for use in the UK: fluticasone
propionate, budesonide and beclometasone dipro-
pionate, although not all are available through all
three of the inhaler delivery devices under review:
pressurised metered dose, breath-actuated metered
dose, and dry powder. Standard dose cortico-
steroids are usually inhaled twice daily (morning
and evening).
Differences in the relative potency and efficacy of
each compound have been reviewed.39 There is
substantial evidence to suggest that significant
variation in potency exists between the cortico-
steroid compounds, although this can be overcome
by giving equipotent doses. Although individual
laboratories report different relative potencies, 
the rank order of beclometasone dipropionate <
budesonide < fluticasone propionate has been
shown in a review to be consistent across
laboratories.39 With respect to efficacy, the same
review concluded that current evidence does not
support an efficacy difference among inhaled
corticosteroids.39 There have been concerns over
safety and health issues associated with steroid use.40
Sodium cromoglicate and nedocromil sodium also
provide effective non-steroidal anti-inflammatory
treatment for some children.41
Other
Combined therapies and compound drug prepara-
tions are also considered in this review if they are
currently delivered through one of the inhaler
devices described above and are licensed for use 
in 5–15-year-old children.
Drug delivery
This is currently believed to be achieved best by
delivering both symptom-relieving and preventative
anti-inflammatory medication as directly as possible
to the lungs. However, the effectiveness of such
drugs requires that the drug not only reaches its
target areas but is evenly dispersed across them.
The process of delivering drugs to the relevant sites
is influenced by a number of factors associated with
the drug, the delivery mechanism, and the patient.
In terms of the physical mode of delivery of asthma
drugs there are a number of counterbalancing
factors that need to be considered in the achieve-
ment of the goal of optimal drug delivery and
symptom control. For example, aerosol delivery
provides non-uniform drug deposition across the
lungs while, with systemic therapy, the distribution
is much more uniform. However, the speed of
onset of β2-agonists through aerosol delivery is
much more rapid than when the same drug is
delivered systemically. Similarly, for corticosteroids,
the improvement seen in the therapeutic index in
the last few years has been as the result of using
inhaled rather than systemic delivery of
corticosteroid therapy.
In terms of patient-related issues, there are also a
number of factors to be considered:
• Competence: Incompetent inhaler technique 
in children, due either to poor training in using
a device or a mis-suited device, can reduce
significantly the proportion of the dose of drug
molecules that is actually inhaled or delivered,
and also the amount of drug deposition in the
lungs. This can mean that much higher metered
doses of the drug will be needed to achieve the
same clinical effect, therefore impacting on the
cost-effectiveness of the drug/delivery system, or
it can simply result in poor clinical management
of the disease. Younger children in particular
have difficulties in achieving the coordination 
of actuation and inhalation. Poor inhalation can
also lead to increased side-effects from drugs,
particularly in the case of corticosteroids causing
oral mucosa-related problems. Again, this can
lead to additional treatment-related costs. How-
ever, in his review of inhaler use in children with
asthma, Pedersen concluded that most children
older than 5 years of age can be taught the
effective use of an inhaler. He also concluded
that, once the correct technique had been
learnt, it was rarely forgotten if the inhaler 
was used regularly.2
• Adherence: Poor adherence to medication, 
due to either physical or cognitive difficulties
experienced with a specific delivery device, can
strongly impair the effectiveness of treatment and
result in poorly managed asthma. Some children
can find certain devices much too difficult to
handle physically. Such problems of poor adher-
ence due to device-related difficulties can lead to
higher healthcare costs in the longer term.
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• Contrivance: Not using the device effectively 
or appropriately, such as using a pMDI without
the spacer, even when knowing how to do so,
can result in poor drug delivery and less than
optimum benefit from treatment.
• Preference: Inhaler users often express a prefer-
ence for a specific type of device or a particular
device. Although this may encourage better
adherence to treatment, in some patients it does
not automatically result in better compliance 
or more effective/efficient use of the device. 
A number of devices are now being launched
that record the date and time of actuation; this
may have an impact on patient adherence.42
Thus, as well as selecting the most appropriate
medication for children with asthma, in terms of
the actual clinical properties of the drug itself, it is
also vital that the selected delivery device system is
the one most appropriate to the child’s own life-
style and physical, cognitive and emotional needs.24
In terms of disease management, poorly controlled
asthma results in increased numbers of exacer-
bations, which are associated with increased health-
care costs. In one study it was found that 50% of
the total resource use costs were accounted for by
22% of the patients who had experienced asthma
attacks.11 One predictor of an attack was poor
inhalation technique, which would be due partly 
to the device, its design and its availability, and
partly due to the patient and the healthcare
professional who is promoting inhaler competence
in terms of adherence and ability to use. Thus, the
dose reaching the lungs of a person with asthma
has little to do with the prescribed dose and is 
influenced by the factors described above, such 
as choice of device, inhaler technique, and adher-
ence.41 This relationship is further compromised in
that variations occur in deposition of the drug in
the patient’s lungs with different types of inhalers,
with or without spacers. The drug delivery system is
a unique combination. A review of in-vitro evidence
concluded that data from one MDI spacer
combination should not be extrapolated to other
combinations. In one study, deliveries of beclo-
metasone dipropionate by MDI in combination
with a spacer, using the products of three different
manufacturers, ranged from 21% to 33%.39 Some
data demonstrating variation in drug deposition by
different inhaler devices are shown in Table 9.43
Although less in-vivo evidence is available, that
which exists also supports variations in pulmonary
delivery by inhaler device, although the results by
drug and device do not all move in the same
direction in all studies.39 The dose prescription
therefore needs to relate to the expected lung 
dose for a specific device–drug combination 
rather than to the factory-dispensed dose.
One review of drug delivery concluded that 
studies in children show that the percentage of 
the drug deposited in the lungs is smaller than in
adults, although the values are not a reflection of
the smaller lungs and body weight of children.44
Everard, in his review of asthma drug delivery
systems, identified three issues that should be
addressed when considering these systems in
children: the suitability of the device for the age 
of the user; a liking for or toleration of the device
by the user; and a device–drug combination that
minimises the systemic effects for a given clinical
benefit.41 With β2-agonists, because of their wide
therapeutic index, the first two factors and issues
of cost are important, whereas, for inhaled
steroids, the third issue becomes more significant.41
Scope of the review
The study question for this current review is to
appraise “the clinical and cost-effectiveness of the
use of inhalers in the routine management of
chronic asthma in children aged 5–15 years”.
For the purpose of this question, inhaler devices
are defined as pMDIs, breath-actuated pMDIs, and
DPIs, with the first two considered with or without
the use of a spacer and using CFC or non-CFC
propellants.
There is also a requirement to examine the relation-
ship between in-vivo and in-vitro evidence in terms of
the relationship between in-vitro measurements and:
• lung deposition measured by scintigraphy
• clinical effect measured by lung function.
TABLE 9  Pattern of drug deposition with different inhalers:
percentage total drug use (modified from Bandolier Drug Watch,
1994 (Feb)43)
DPI MDI MDI with
large-volume
spacer
Patient 95 95 35
Lung 10–15 10–15 20
Oropharynx 80 80 15
Device 5 5 65
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Methods for reviewing effectiveness
Search strategy
The search aimed to identify all articles relating to
childhood asthma inhalers and outcomes previously
addressed in the systematic review by Brocklebank
and colleagues20 and published subsequent to that
review. It also aimed to identify all articles that
addressed childhood asthma inhalers (e.g. compar-
isons between different powder devices) or out-
comes (e.g. patient preference/compliance, quality
of life, unwanted effects, etc.) that were not covered
in Brocklebank and co-workers’ review.20 An update
of these authors’20 search on in-vitro studies was also
undertaken. All literature searches were conducted
between April and July 2001.
Sources searched
Fifteen electronic bibliographic databases were
searched, covering biomedical, science, social
science, health economic and grey literature
(including current research). A list of databases 
is provided in appendix 2.
In addition, the reference lists of Brocklebank and
colleagues’20 review and other relevant articles were
checked. Various health services research-related
resources were consulted via the Internet. These
included health economics and health technology
assessment organisations, guideline producing
agencies, generic research and trials registers, and
specialist asthma sites. A list of these additional
sources is given in appendix 3. All sponsor
submissions to NICE were also handsearched.
Search terms
A combination of free-text and thesaurus terms 
was used. Asthma search terms were combined with
generic terms regarding asthma inhalers (e.g. admin-
istration, inhalation, aerosols, powders, meter(ed)
dose(s), mdi(s), pmdi(s), etc.) and limited to
children. Searches were also conducted on named
inhalers and spacers (e.g. Maxivent®, Nebuhaler®,
Accuhaler, etc.). The search strategies used for the
major databases are given in appendix 4.
Search restrictions
Where possible (e.g. in the smaller databases),
searches were not restricted by publication type 
or study design. However, methodological filters
aimed at identifying guidelines, systematic reviews,
clinical trials, economic evaluations, unwanted
effects, compliance and quality-of-life studies, 
were used in MEDLINE (refer to appendix 4 for
details of the filters used). Searches for reviews,
guidelines and clinical trials were limited to 1998
onwards because earlier studies had already been
identified by Brocklebank and co-authors’20
review. No language restrictions were used in 
the search strategy.
Inclusion and exclusion criteria
Inclusion criteria
• Participants: Human patients aged between 
5 and 15 years with chronic asthma or experi-
encing a mild to moderate exacerbation
(increased symptoms and reduced lung function
requiring usual treatment delivery but at an
increased frequency and/or dosage, not
requiring emergency treatment or addition of
oral steroids). For searches for in-vitro evidence,
the inclusion criteria omitted “subjects”.
• Intervention: Use of any one inhaler device to
deliver bronchodilators (short- and long-acting
β2-agonists, other adrenoceptor agonists, anti-
muscarinic bronchodilators), corticosteroids
(beclometasone dipropionate, budesonide and
fluticasone propionate), cromoglicate, nedo-
cromil, or combination therapy, for the routine
management of chronic asthma. This includes
any inhaler devices delivering drugs not licensed
for use in the UK but included within the
categories defined above (but such drug/device
combinations will be specifically identified in
the review). Inhaler devices to include:
– pressurised metered dose aerosols, using
either a CFC or an HFA propellant, with 
or without a spacer (all sizes)
– breath-actuated metered dose aerosols, 
using either a CFC or an HFA propellant
– breath-actuated dry powder devices
• Comparators: Alternative inhaler devices from
the list above, but delivering the same form of
medication, by generic drug, not by drug type,
and at the equivalent dose level.
Exclusion criteria
• Interventions: Any interventions on drug efficacy
in isolation from the device used to deliver it.
• Language: Any articles not available in the English
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language (this review was subject to a very short
timescale that precluded time for translation).
• Time: No date limits were imposed.
• Abstracts: Studies available only as abstracts were
also excluded.
Data extraction strategy
All abstracts, and the titles of those articles for
which abstracts were not available, were double
read and a consensus was reached on which articles
should be acquired for further consideration of the
evidence based upon the full text. All articles were
read and appraised by two reviewers, who extracted
relevant information, transferring it directly to an
extraction/evidence table. One reviewer worked
with the clinical effectiveness literature and the
other with the compliance/preference literature.
Quality assurance was monitored by double extrac-
tion of the first three and a random selection of
subsequent articles by a third reviewer, with
comparison for content and accuracy of the
material extracted.
Quality assessment strategy
Included articles were assessed according to 
the accepted hierarchy of evidence, whereby 
meta-analyses of randomised controlled trials 
are taken to be the most authoritative forms 
of evidence, with uncontrolled observational
studies the least authoritative.
• Randomised controlled trials were assessed with
respect to randomisation procedures, blinding,
and handling of withdrawals and drop-outs, by
using the Jadad scoring system.45
• Non-randomised studies using quantitative data,
such as case-control and cohort studies, case
series and case reports, were assessed with
respect to validity by using guidelines from the
Centre for Health Evidence based upon the
Users’ Guides to Evidence-Based Medicine.46
• Qualitative evidence was assessed using the
Critical Appraisal Skills Programme checklist 
for qualitative research.47
In most instances, the use of data from non-
randomised studies was considered only when
there was insufficient evidence from good-quality
randomised controlled trials. This was the case for
issues of ease of use, preference, compliance and
resource use. Qualitative evidence was specifically
included for issues on preference.
• The quality of the economic literature was
assessed according to the ‘Guidelines for
authors and peer reviewers of economic
submissions’ to the BMJ.48
Results
Quantity and quality of research
available
Number of references
A total of 7234 references were identified from 
all the searches carried out, of which 1731 were
unique. Twelve potentially useful foreign language
papers were excluded on the basis of language.
Table 10 provides a breakdown of the references
ordered and used in this review.
Exclusions
Details of all studies excluded and reasons for their
exclusion are given in appendix 5.29,38,49–214,272
Research registers
Three potentially useful research studies were
identified from searches of the research registers,
all of which were due for completion by 2000.
The lead researchers were contacted in each case
TABLE 10  Reference statistics
Topic No. identifieda No. ordered/ No. used
contacted Reviews RCTs Non-RCTs
In-vitro/in-vivo update 31 2 0 0 0
Clinical effectiveness, reviews, guidelines 375 17 1 0 0
Clinical effectiveness trials 5531 0 27 0
Patient preference, ease of use 183 287 0 10 20
Non-specific searches 605 0 0 0
Cost-effectiveness 369 16 0 0 0
Current research 140 4 0 0 0
Total 326 1 37 20
aIncludes duplicates
RCT, randomised controlled trial
Health Technology Assessment 2002; Vol. 6: No. 5
17
for further details. However, one has since retired, 
a second sent a further contact name and a third
has not replied. Given the anticipated completion
dates for this research, it is hoped that any pub-
lished results from these studies, if relevant, would
have been identified in the literature searches.
Clinical effectiveness
Review question
The study question for this current review was to
appraise “the clinical and cost-effectiveness of the
use of inhalers in the routine management of
chronic asthma in children aged 5–15 years”.
For clinical effectiveness, this review updates the
available information on the in-vitro questions
addressed by Brocklebank and colleagues in their
recent review:20
• Is there any relationship between in-vitro
measurements and lung deposition measured 
by scintigraphy?
• Is there any relationship between in-vitro
measurements and clinical effect measured 
by lung function?
Plus:
• Comparison between three hand-held inhaler
device types delivering bronchodilatory drugs,
corticosteroids, or cromoglicate compounds, 
for the routine treatment of chronic asthma in
children aged between 5 and 15 years (building
on Brocklebank and co-workers’ findings20
where available).
The three inhaler device types are pressurised
metered dose aerosol inhalers, breath-actuated
metered dose aerosol inhalers, and DPIs, with the
first two considered with or without the use of a
spacer and using a CFC or non-CFC propellant.
In-vitro evidence
Information on this aspect was taken from the
recently published review20 and updated with new
published evidence. Brocklebank and co-authors20
identified three studies that met their review 
criteria; from these they concluded that:
“Recent studies with modified in vitro techniques
suggest that there is a relationship between in vitro
measurements and lung deposition. This relation-
ship is specific to the set (inhaler device and drug
combination) for which the in vitro/in vivo parameters
were conducted. Studies have also shown that there 
is a relationship between in vitro measurements and
clinical effect measured by lung function (FEV
1
and
PEFR [peak expiratory flow rate]). However, there is 
still an incomplete understanding of the relationship
between in vitro techniques, particle size, aerodynamic
diameter and drug mass (µg)” (p. 5).20
Our search update identified no further studies
published in the previous two years.
Delivery of drugs for children with chronic asthma
Although the recent systematic review of inhaler
devices for asthma and chronic obstructive
pulmonary disease20 will be used to inform this
review, it did not address all of the issues defined
for this report. Two of the five key areas addressed
by Brocklebank and co-workers20 are of relevance
to this review:
• the delivery of corticosteroids by hand-held
inhalers for the treatment of stable asthma
in children
• the delivery of bronchodilators in the same
manner and to the same patient group.
In both of the above areas, Brocklebank and co-
workers considered only studies that compared a
standard pMDI inhaler, with or without a spacer
device, versus one of the other types of inhaler
device (DPI, CFC-free or breath actuated).
The scope of this review is broader than that of
Brocklebank and colleagues20 in terms of:
• Inhaler device comparisons: We have included
comparisons between and within each of the
three inhaler types.
• The range of drugs to be considered that 
can be delivered by these inhaler devices: 
In addition to corticosteroids, the current 
review includes other anti-inflammatory drugs,
the cromoglicates. For bronchodilators, the
specification is also broader. Brocklebank and
colleagues20 included the β2-agonists, and, of
these, the short-acting ones only. This review
includes inhaler devices delivering long-acting
β2-agonists, other bronchodilators and the
antimuscarinic drugs, as well as short-acting 
β2-agonists.
A summary of the comparisons made and number
of articles identified within each comparison is
provided in Table 11.
Only one study215 was found relating to any 
inhaler device comparisons with the same
propellant delivering cromoglicates, and only
one215 on comparisons of other inhaler types 
with breath-actuated inhaler devices. The same
study addressed both of these areas.
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In presenting the findings from Brocklebank and
co-workers’ systematic review20 we have chosen,
with permission from the authors, to show their
relevant extraction tables of evidence. The reason
for this is that, because very little evidence was
found with respect to children, they presented
information as narrative with conclusions, rather
than combined in a meta-analysis with an overall
measure of clinical effectiveness for each inhaler
device type. This form of presentation of our
findings alongside those of Brocklebank and
colleagues enables the reader to compare all the
evidence for comparisons of each set of inhaler
devices rather than adding small pieces of
additional evidence to previous summaries.
Indeed, we found little further evidence for those
comparisons of inhaler types that Brocklebank’s
team had already addressed. We did however
identify a number of articles that examined some
other comparisons, such as those between different
DPIs, which had not been covered in the previous
review. We also took the decision not to carry out
any meta-analyses, given the limited amount of
evidence available within each comparison group.
Delivery of β
2
-agonist bronchodilators by hand-
held inhaler devices using the same propellants
Nine studies117,216–223 were found in total by
Brocklebank and colleagues20 that compared
inhaler devices using the same propellant and
delivering bronchodilating drugs. An additional 
14 studies that fulfilled the inclusion criteria were
identified for the current review. Details of all
studies are given in appendices 6–8 (Tables 12–15).
• Comparisons of pMDIs with/without a spacer vs
other pMDIs with/without a spacer (appendix 6,
Table 12)
This comparison was not included in Brocklebank
and co-authors’ review.20
Seven articles were identified for the current
review.224–230
In a randomised trial Kerac and colleagues224
compared a pMDI against two other pMDI 
spacer combinations (Volumatic®, plastic bottle,) 
all delivering salbutamol, and a pMDI placebo, 
in 48 children and adults. However, with an age
range of 10–75 years, few of the patients were 
likely to be within the 5–15-year age eligibility
criteria for this review. Significant differences in
PEFR (p < 0.05) were found between both the 
pMDI spacer combinations and the pMDI placebo 
at 30 minutes after inhalation, but there were no
significant differences between the two spacerless
pMDIs (salbutamol and placebo). A second study225
using salbutamol, in which a pMDI was compared
with a pMDI spacer combination (Volumatic) in 
TABLE 11  Evidence for systematic review
Comparison                                                                      No. studies
Inhalers Drug Brocklebank This 
et al. 200120 review
pMDI with/without spacer vs pMDI with/ β
2
-agonists Not included 7
without spacer, same propellants
pMDI with/without spacer vs breath-actuated MDI β
2
-agonists 0 0
pMDI with/without spacer vs DPI β
2
-agonists 9 4
DPI vs DPI β
2
-agonists Not included 3
pMDI with/without spacer vs pMDI with/ Corticosteroids Not included 1
without spacer, same propellants
pMDI with/without spacer vs breath-actuated MDI Corticosteroids 0 0
pMDI with/without spacer vs DPI Corticosteroids 3 2
DPI vs DPI Corticosteroids Not included 2
pMDI with/without spacer vs breath-actuated MDI Cromoglicates Not included 1
pMDI with/without spacer vs pMDI with/ β
2
-agonists 1 4
without spacer, different propellants
pMDI with/without spacer vs pMDI with/ Corticosteroids 0 1
without spacer, different propellants
Breath-actuated vs breath-actuated, different propellants Corticosteroids 0 1
pMDI with/without spacer vs pMDI with/ Cromoglicates 0 1
without spacer, different propellants
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ten children aged 8 to 14 years, demonstrated no
difference between inhaler devices over a 30-minute
period after inhalation. In Lee and Evans’229 cross-
over study, the four treatment arms were compar-
isons of albuterol (US term for salbutamol)
delivered by a pMDI compared with three other
pMDI–spacer combinations in 23 children (of
whom 20 completed the study) aged 8–15 years.
These authors reported no differences, either
overall or for 14 children who had the correct
inhaler technique, in the increase in FEV1 after
treatment between any of the delivery systems.
However, for the six children identified as having an
incorrect pMDI technique, there was a significantly
greater FEV1 response in the three pMDI–spacer
combinations compared with the pMDI alone 
(p < 0.05). In one further study,227 in 16 children
aged 5–12 years randomised to pMDI or pMDI 
plus spacer, both delivering the bronchodilator
metaproterenol sulphate, or to a pMDI or pMDI
plus spacer, both delivering a placebo, no differ-
ences were found in FEV1 or the forced expiratory
flow over 25% to 75% of expiration (FEF25–75%)
between the two drug-delivering inhaler combi-
nations. Metaproterenol sulphate is not available 
in the UK. The final three studies,226,228,230 all in
children, looked at a pMDI compared with a 
pMDI plus spacer delivering terbutaline sulphate. 
Becker and co-workers226 found that the pMDI and
spacer, and pMDI alone, were equally effective for
improving pulmonary function. However, in both 
of the other two studies228,230 the pMDI–spacer
combination was significantly better for PEFR 
in the 60 minutes after inhalation. All study
participants were aged between 4 and 14 years; 
18 were between 4.9 and 13.7 years,228 and 
12 were between 7 and 11 years.230
In summary, the evidence from a small number 
of studies, with small numbers of participants,
mainly carried out in children, showed no clear
evidence in favour of either delivery system 
(a pMDI or pMDI–spacer combination delivering
bronchodilating drugs) to support better lung
function performance.
• pMDIs with/without a spacer vs DPIs 
(appendix 7, Tables 13 and 14)
Nine studies117,216–223 were identified by Brockle-
bank and co-workers.20 In two the DPI used was 
a Rotahaler and salbutamol was delivered; in the
other seven, the DPI was a Turbohaler and turbu-
taline was delivered, except for one study that used
salbutamol. All except one were based on a cross-
over design. The main outcomes reported were
lung function variables and, overall, no significant
differences were found in FEV1, FEF25–75%, forced
vital capacity (FVC) or PEFR between the pMDI
and the DPI. The conclusions of the reviewers20
were that they were not able to demonstrate any
difference in the clinical bronchodilator effect of
short-term β2-agonists delivered by pMDI or DPI.
However, they also highlighted the fact that, in the
studies appraised, a dosing schedule of 1:1 was
used, whereas the prescribing recommendations
for salbutamol suggest doses of 100–200 µg by
pMDI and 200–400 µg by Rotahaler, and for
terbutaline, they indicate the use of 250–500 µg 
by pMDI and 500 µg by Turbohaler. The authors
stated that these 1:1 dosing studies would tend 
to favour the Turbohaler and disadvantage the
Rotahaler when compared with the pMDI.
Four additional studies were published between
1999 and 2001; two used a cross-over design231,232
while the other two were based around parallel
groups.233,234 The Spiros® DPI was used in two of 
the studies,231,233 an Easyhaler® in the third,232 and 
a Diskus in the fourth.234 Three studies231–233 used
salbutamol or albuterol, while the fourth234 used 
a long-acting β2-agonist, salmeterol. As with the
nine earlier studies, no significant differences were
found in FEV1, in the area under the FEV curve, or
in PEF. Although two studies had small numbers of
participants (<32), the other two were much larger
than many seen in this research area, with 283 and
498 recruited (240 and 395 completing the study)
respectively.233,234 However, the problems with all
four of these studies as a source of evidence for this
review were that the populations studied ranged in
age from 7 to 79 years, with only a small proportion
of children aged under 15 years included in each,
and no subgroup analysis by age was available.
The Spiros DPI and Easyhaler devices are not
currently available in the UK.
• DPIs vs DPIs (appendix 8, Table 15)
This comparison was not part of Brocklebank and
colleagues’ review.20
Two studies were identified235,236 that compared the
Diskus DPI with the Diskhaler DPI, both delivering
salmeterol. One was a three-way cross-over study235
while the second used parallel groups.236 In neither
study was any significant difference found between
the percentage predicted FEV1
235 or PEFR and
symptoms.236 However, Bronsky and co-workers235
studied only 24 patients (mean age 9 years, stan-
dard deviation 2.1) and, although Boulet’s group236
had included 380 participants by the end of their
study, their mean age was 39 years (range 12–70),
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making it unlikely that many of them were within
the age range of interest for this review. A third
study237 compared the single-dose Rotahaler with
the multidose Pulvinal, both delivering salbutamol
to 13 children aged 8–12 years. No differences
were found between the two devices with 
respect to FEV1 or PEFR.
Delivery of corticosteroids by hand-held inhaler
devices, using the same propellants
Three studies238–240 were identified by Brockle-
bank and colleagues20 and a further five in this
review. Details of all the studies are given in
appendices 9–11 (Tables 16–19).
• pMDIs with/without spacer vs pMDIs
with/without spacer (appendix 9, Table 16)
This comparison was not included in Brocklebank
and co-authors’ review.20
One study was identified241 that compared two
pMDI spacer combinations delivering budesonide.
Drug delivery was measured as the amount of drug
deposited on a filter placed between the spacer
outlet and the patient’s mouth. Significantly higher
(p < 0.0001) drug dose deposits were recorded on
filters attached to the metal NebuChamber than on
those attached to a Volumatic. However, there were
only 16 patients aged 5–8 years in this randomised
cross-over trial. The metal spacer, which, at 250 ml,
is one-third the size of the plastic spacer (750 ml) 
is currently not available in the UK, although its
introduction into the UK marketplace is proposed.
• pMDIs with/without spacer vs DPIs (appendix 10,
Tables 17 and 18)
Brocklebank and colleagues20 identified three
randomised controlled trials comparing pMDIs
(two with spacers) with DPIs.238–240 In two studies
beclometasone dipropionate was used and in the
third budesonide. The review authors’ summary 
of one study239 was:
“… this large and well-designed study does support
the equivalence of the pMDI + Nebuhaler versus
Turbuhaler (sic) at half of the pMDI dose. However, 
it does not present any evidence for advantages over 
the accepted place of the pMDI + large volume 
spacer as the device of choice in childhood asthma
management (p. 17).”
The other two studies were basically dismissed by
the authors. One was in abstract form only.238 In
the other, inappropriate or unsuitable devices 
were used with children, such as no spacer and a
Rotahaler DPI; the study was also underpowered.240
Two further studies were identified during the
current review. In a study by Agertoft and co-
workers,242 the amount of drug deposited on a
filter was compared when using either a pMDI–
Nebuhaler combination or a Turbohaler DPI, 
both delivering budesonide. Drug deposition was
significantly higher from the DPI Turbohaler in
children aged 6–15 years but, for younger children
aged 4 and 5 years, there were no differences
between the two inhaler devices. Bateman and
colleagues243 compared an HFA pMDI versus a 
DPI (Diskus), both delivering a combination of
fluticasone dipropionate and salmeterol. The
patients were aged 11–79 years and no differences
in lung function and symptoms were found.
• DPIs vs DPIs (appendix 11, Table 19)
Two studies were identified,244,245 both of which
compared the Diskus with the Diskhaler, with
fluticasone propionate as the medication. In
neither study were any differences found between
the two inhaler devices for FEV1, symptom scores,
albuterol use, or night-time wakenings. Both studies
had sufficient power according to the details given
in each article. In one,244 the number of patients
within the age range of relevance for this review 
was low, as the 229 studied ranged from 12 to 
76 years of age. However, in the second study,245
the 437 children recruited were aged 4–11 years.
Delivery of cromoglicates by hand-held inhaler
devices using the same propellant (appendix 12,
Table 20)
One study was identified215 that compared a pMDI
with a breath-actuated inhaler device (Autohaler)
in children aged 4–18 years (with one person 
aged 39). The drug used was sodium cromoglicate.
No differences were found between the devices for
a number of lung function parameters. However,
the study was underpowered, with 181 people
recruited, 166 completing the 8-week follow-up,
compared with the 150 participants per group
required in the authors’ power calculation.
Delivery of bronchodilators or anti-inflammatory
drugs by hand-held inhaler devices using 
different propellants
The Montreal Protocol of 198725 proposed the 
phasing out of CFC propellants over the following
few years. The UK Government became committed
to the removal of CFCs from all medicinal products
by 2000. Because of this, manufacturers have been
working on the development of pMDIs using alter-
native propellants to deliver bronchodilating and
anti-inflammatory drugs for asthma management.
There have been problems but the first non-CFC
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short-acting β2-agonist inhaler became available in
1995 and further products have now been launched.
Although there is some evidence that beclometa-
sone dipropionate pMDIs with HFA give better drug
deposition and that drug doses may be reduced
compared with those given through pMDI CFC
inhalers,246 in this review our brief was not to exam-
ine the evidence for effectiveness of different drug
doses. Therefore we have looked only at studies that
compared inhaler devices that have delivered the
same drug in equivalent doses. In this section the
same approach has been applied.
Given the timescale for and the difficulties in the
development of non-CFC inhalers, Brocklebank
and co-authors20 identified only one study exam-
ining this issue, while a further seven have been
published in the last 2 years. Details of all these
studies are to be found in appendices 13–16
(Tables 21–25).
• Delivery of β2-agonist bronchodilators by 
pMDI using different propellants (appendix 13,
Tables 21 and 22)
Brocklebank and colleagues20 identified one study
in their review,247 which looked at lung function in
children with asthma using either a CFC or non-
CFC inhaler delivering a short-acting β2-agonist. 
No differences in FEV1 were found.
A further four studies248–251 have been identified, 
all of which compared pMDI CFC-propelled
albuterol with a pMDI HFA-propelled equivalent
dose of albuterol. In one study251 the patients
recruited were over 12 years of age and, with 
an average age around 30 years, few of the 
313 total would be within the age range for this
review. However, in the other three studies the
patients were aged 4–11248,249 and 6–11 years.250
No significant differences were found between 
CFC and HFA use with respect to mean percent-
age predicted FEV1 or the mean percentage 
predicted PEF.248,249 Colice and co-workers250
examined the impact of the two pMDI devices 
in children with exercise-induced asthma and 
also found no significant differences in the 
percentage change in FEV1 postexercise 
between the two groups.
A similar pattern of evidence was also seen in 
the study on older patients,251 with no changes in
pulmonary function, morning or night-time PEFR
values, symptom scores, night-time awakenings, 
or use of back-up short-acting β2-agonists, when
patients switched from inhalers containing CFC 
to those containing HFA propellants.
• Delivery of corticosteroids by pMDI using
different propellants (appendix 14, Table 23)
One study examined the impact on lung function
of CFC versus non-CFC pMDIs delivering a cortico-
steroid, triamcinolone acetonide (not currently
available in the UK), via a pMDI spacer.252 The
participants were aged 6–13 years. Pearlman 
and colleagues examined the effect of three
different dose regimens (150 µg/day, 300 µg/day,
600 µg/day) each delivered by both a CFC- and 
an HFA-propelled pMDI, and found no differences 
in morning and evening PEFR, FEV1, symptom
scores, night-time wakening, or albuterol use.252
• Delivery of corticosteroid therapy by breath-
actuated inhalers using different propellants
(appendix 15, Table 24)
Of all the evidence found, only one study compared
breath-actuated inhaler devices. Farmer and 
colleagues253 looked at differences between two
breath-actuated inhalers delivering beclometasone
dipropionate to children aged 7 to 12 years,
one of which used CFC and the second, an HFA 
propellant. The study may have been slightly
underpowered based on their 90% power calcu-
lation for participant numbers in that 105 patients
were required for each arm of the study and 
only 199 participated completely. No significant
differences were reported for PEF, FEV1, symptom
scores, and relief medication use.
• Delivery of cromoglicate therapy by pMDIs using
different propellants (appendix 16, Table 25)
Only one study from all the evidence found compar-
ed inhaler devices delivering sodium cromoglicate,254
using pMDIs and CFC compared with HFA propel-
lants. The authors found no differences in symptom
scores, the use of albuterol, and morning and
evening PEF in 280 participants aged 12–79 years.
The patients rated the effective-ness of their treat-
ment similarly in the two treatment groups (73% for
CFC, 77% for HFA, p = 0.989). However, the clini-
cians rated the CFC inhaler as more effective (63%)
for patients than the HFA one (56%) (p = 0.042).
Discussion
The evidence on the clinical effectiveness of
different inhaler devices delivering a range of
bronchodilating and anti-inflammatory medication
in vivo is patchy. In terms of devices, while pMDIs
and DPIs have been compared both against each
other and within type, only two studies have con-
cerned breath-actuated inhalers,215,253 one of which
was not a comparison of device types but of the
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propellants used.253 Similarly, in terms of drugs,
although short-acting β2-agonists and cortico-
steroids are well represented in the evidence, only
two studies215,254 related to the difference between
inhalers delivering sodium cromoglicate; one of
these was a comparison of propellants.254 Few
studies have addressed the question of long-acting
β2-agonists alone234 or in combination therapy.243
In general, from the evidence available, the impact
of different asthma medication inhaler devices 
on lung function and symptoms in children with
chronic asthma aged 5–15 years, and being treated
in a randomised controlled trial situation, suggests
that there are no obvious benefits to asthma
symptom control when using one specific inhaler
type over another, or even one inhaler device over
another within type. With the exception that there
is some very limited evidence to support the use 
of spacers with pMDIs224,228,230 and a suggestion that
those made of metal may be more effective than
those currently available in the UK, which are
made of plastic.241 There may also, however, be 
cost implications with this latter option.
The evidence from the earlier systematic review 
of Brocklebank and co-authors,20 although not so
comprehensive in scope as the current review, led
to a similar conclusion that there was no evidence
of an advantage for any one type of inhaler device
over another.
Being unable to identify any significant differences
when they may actually exist may be due to the
studies being underpowered (Type 2 error). In 
most instances, no power calculations were reported
and patient numbers were usually low (<50 per
treatment arm). Where power calculations were
reported, sample sizes were in the order of 70+ 
with one exception.255 It would be illogical if, with
most of the authors looking at the same primary
outcomes, FEV1, PEF, PEFR, presumably with similar
levels of effect, in similar populations of children
with a similar condition (mild to moderate asthma),
the studies did not all require similar patient
numbers to be sufficiently powered.
In a systematic review of studies of CFC MDIs
compared with non-CFC MDIs delivering short-
acting β2-agonists, Hughes and co-authors256
pointed out that many of the trials reviewed were
underpowered. A second point made related to 
the ability of studies to demonstrate equivalence.
That issue is relevant for this review also.
In 43% of the studies identified, the sample popu-
lations lay entirely within the age range of interest
for this review.225–230,235,237,241,250,252,253 However, 
16 studies covered a much greater age range
distribution, with the age band of interest lying 
in one tail of the distribution, so it is possible 
that any variation in response in children may be
masked because of this wider age range. Subgroup
analysis by age band was not available for any 
of the studies that concerned adolescents and 
adults; indeed, the studies may not have had
sufficient power for such analyses. The exclusion
from the review of all the studies in which the 
age range was not totally within the review criteria
would have more than halved the amount of
evidence available.
It is also possible that the populations studied do
not represent the population profile for childhood
asthma. For 50% of the studies, patients with mild
to moderate asthma were recruited specifically; 
a number of them expressly excluded those with
more severe disease. Yet, children with moderate 
to severe disease would also be taking inhaled
medication, albeit at a higher dose (step 4 of the
BTS guidelines).10 It is not necessarily appropriate
to assume that children with more severe asthma
would have shown similar lung function responses
with the various inhaler types to those seen in the
children surveyed and reported in this evidence.
In terms of therapeutic benefit associated with 
the different inhaler devices, those studies that
considered adverse effects reported few or
none;227–229,231–237,231 there also appeared to be 
no obvious differences in these by inhaler type
irrespective of drug delivered, with one exception.243
The cost of replacing CFC with HFA inhalers was
predicted to be high26 but, in 2001, with most of
these costs being non-recurring and the number 
of HFA devices in the marketplace increasing, any
major potential impact of this transfer on clinical
effectiveness should be declining.
One way of biasing trial results would be to have
dissimilar treatment arms. An example could be
that, in one arm, a patient would be required to
take a dose more times per day than a patient in
another arm, although the final dose would be
equivalent. This could encourage possible non-
compliance in those having to take a drug more
frequently and patient preference for the lower
dose-number regimen, independently of the
research question. In the studies considered in 
this review, treatments in each arm were taken 
at similar frequencies, although there were 
some instances in which one puff was required
compared with two in a second treatment arm.
Health Technology Assessment 2002; Vol. 6: No. 5
23
Summary
To summarise, the clinical evidence suggests that,
for children with chronic asthma aged between 
5 and 15 years, for routine maintenance:
• There is no difference in benefit between
pMDIs using either CFC or HFA propellants,
between pMDIs and DPIs, or between DPIs,
delivering either short-acting β2-agonists or
corticosteroids.
• There is some evidence of benefit from using a
pMDI spacer combination rather than a pMDI
alone, specifically a metal spacer.
• There is no evidence on the clinical advantages
or disadvantages of breath-actuated inhalers
compared with either pMDIs or DPIs.
Recommendations
Further properly designed equivalence trials,
adequately powered, could produce some non-
equivalent evidence. However, the patient numbers
required would be very large. It would seem more
useful to explore patient issues surrounding
inhaler use.
Given the lack of evidence on clinical effectiveness,
it is opportune to revisit the three issues raised by
Everard41 when considering asthma drug delivery
systems in children: suitability for age of the user;
liking or tolerance of the device by the user; and 
a device–drug combination that minimises the
systemic effects for a given clinical benefit. This
review has demonstrated that there appear to be
no differences between device–drug combinations
for given clinical benefit with minimal systemic
effect; therefore the other two issues become more
important. In the next section, the evidence on
factors relating to patient adherence to inhaled
asthma medication associated with different
inhaler devices in children aged 5–15 years and
their carers is considered. Adherence will be
affected by the suitability of the device and the
user’s liking of it.
Ease of use, patient/carer preference for
and compliance with inhaler devices
Review question
In this section of the review, the impact of ease 
of use, preference for and adherence to different
inhaler types on their clinical effectiveness in
children aged 5–15 years is considered.
Quantity and quality of the evidence
The quantity and particularly the quality of the
evidence to inform this section of the review are
poor. Of the 29 articles included in the review, plus
one industry submission study (data summarised in
appendix 17, Table 26), 12 studies (including an
extension study)197,215,218,226,236,237,240,257–261 amounted
to randomised controlled trials, of which five(plus 
the extension study) were blinded.226,236,240,257–259
(Yamanouchi provided confidential information,
which was included in the version of the report
that was sent to the Appraisals Committee, but 
this information has been removed from this
current document.)
The remainder included large and small open,
non-controlled studies concerned with various
perceived adherence factors in addition to the
choice and ease of use of the inhaler device 
or ability to use it after a training programme.
Fourteen of the studies did not involve com-
parisons between two or more inhaler device
types.257,262–271,273–275 Five studies on instruction
giving have been included because of their impact
upon use, although not directly upon ease of
use.263,274,276–278 In 12 of the studies selected, lung
function and symptom variables were the primary
outcome measures used, together with patient
compliance and use in some studies but not
all.197,215,218,226,236,237,240,262,267,269,274,275 In the other 
18 studies the primary outcomes related to
adherence factors only.
With respect to the age of participants, in eight
studies the age range selected was within the 5–15-
year age band of relevance to this review.226,237,262,265,
266,268,269,271 Patients much older than 15 years 
were included in seven studies218,236,259,260,270,274,276
and much younger than 5 years in a further
three.263,267,279 In 11 studies the age ranges were
between 4 and 18 years.197,215,240,257,258,264,273,275,277,278,280
Patient numbers for all studies, with the exception
of three, ranged between 13237 and 463.236 For 
the three exceptions, participant numbers were
considerably higher at 1133,275 2056268 and 4529.270
Seventeen groups studied less than 100 patients.
The majority of studies were observational, with
small numbers of participants who were older 
than 15 years, and they did not directly or robustly
address the issues of interest, namely the impact 
of ease of use, preference for, and adherence to
different inhaler device types on clinical effective-
ness in the management of routine asthma in
children aged between 5 and 15 years.
Use
The most general finding was that adequate,
individual (verbal) instruction was the key to
correct inhaler technique263,269,270,275,276 and
improvement in lung function and symptoms,269,274
Effectiveness
24
regardless of the choice of inhaler device.263,276
Choice of inhaler device did not appear to repre-
sent a barrier to effective use in children over the
age of 5 years, with the proviso that adequate
(verbal) instruction and supervision were provided.
Deciding upon an inhaler device in combination
with lung function testing appeared to produce
better outcomes in terms of efficiency of use.278
A range of problems have been identified associ-
ated with poor technique273 that is not necessarily
specific to the inhaler device.226,260 Age may have 
an impact on ability to use, with younger children
(4–6 years of age) having a less efficient tech-
nique than those somewhat older (7–16 years),278
although, in a second study, improvements in
ability to use after a training intervention were
independent of age.276
In terms of ease of use, Ng and colleagues279
reported that 22 of 31 adolescents rated the DPI
(Diskus (Accuhaler)) as easiest to use, compared
with three in favour of the DPI (Turbohaler) 
(p = 0.002) and six the breath-actuated Autohaler
(p = 0.0311). In a comparison study of two other
DPIs, patients (n = 463) rated the Diskus (85%)
and Diskhaler (45%) as very easy to use.236 The
authors of a further study reported the investiga-
tors’ assessment of their 13 patients. Ease of use
was recorded as excellent in ten and good in three
when using the DPI Pulvinal, compared with three
excellent, eight good, and two fair when using the
DPI Rotahaler.237 One specific factor that impacts 
upon ease of use is the ability to load the device
correctly; significant differences were found
between the percentage of errors made when
loading the DPI Turbohaler compared with the
DPI Diskus (p = 0.045).260
(Yamanouchi provided confidential information,
which was included in the version of the report
that was sent to the Appraisals Committee, but 
this information has been removed from this
current document.)
Adherence
When examining adherence, measuring it in 
some way was consistently a far more accurate
reflection than self-reporting methods. Self-
reported adherence by patients to drug-dose
schedules has been overestimated by as much 
as 100% when compared with records of actual
use,257,262,266 although correlation between self-
reported and estimated actual use is often poor 
or non-existent.264,265 Some discordance was also
seen between parent/child and parent/physician
reports of asthma medication use.271
Factors such as age,258,270 socio-economic status,266
and ethnicity266,268 were also found to interplay with
measured adherence, with adherence appearing 
to decline with progress into adolescence.258 The
current authors suggest that even greater attention
needs to be paid to adherence factors in this
patient group. Finally, there was little correlation
between symptom scores and measures of
adherence. This is probably confounded by the
inclusion of children with mild to moderate
asthma only in most study designs, the relatively
short duration of study periods, and the small
numbers of patients involved.
Preference
Patient preference, where expressed, tended to
favour DPIs over MDIs, but comparative outcome
data were sparse. In a comparison of a pMDI with a
DPI (Rotahaler) the younger children in a study of
4–15-year-olds preferred the Rotahaler, but this was
not one of the listed outcomes of the study and no
data were reported.240 The DPI Diskhaler was also
preferred over the pMDI by the majority of the
children in the Kesten and co-workers’ study 
(p < 0.001).270
Most of the evidence found related to comparisons
of different DPI devices. In Sharma and co-
authors’ report,280 the DPI Diskus scored more
highly than the DPI Turbohaler in terms of a list 
of features, including attractiveness, dose indicator,
shape, ease of use and ease of carrying, but not
size. Overall, design was the key factor that guided
preference among 10–14-year-olds and ease of use
among those aged 4–9.280 The DPI Diskus was rated
more favourably than the DPI Turbohaler in
another study on similar features, that is, dose
indicator and ease of correct use.197 In this parallel
group study, more children in the Diskus group
(85%) compared with the Turbohaler group
(58%) said that they would be happy to receive 
the same device again, while 8% and 25% in the
same two groups would not.197 Patient preference
was significantly in favour of the Diskus over the
Turbohaler in the study by Ng and colleagues.279
However, van der Palen and colleagues260 noted 
the reverse finding, with more people preferring
the Turbohaler (25) to the Diskus (17) (eight 
had no preference). These differences were not
significant and the participants were an older
group (15–74 years), but significant differences
were found in favour of the Turbohaler with
respect to ease of carrying, size, inconspicuousness
and dose counter (p < 0.001). Some variation in
preference relating to the features listed earlier 
was also seen between Diskus and Diskhaler
DPIs.259 In a study by Boulet and co-workers,236
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73% preferred the Diskus and 15% the Diskhaler,
while 12% expressed no preference. Another DPI
comparison between the Pulvinal and the Rotahaler
showed 11 of 13 patients preferring the Pulvinal,
one preferring the Rotahaler, and two with no
preference (data as presented by authors).237
(Yamanouchi provided confidential information,
which was included in the version of the report
that was sent to the Appraisals Committee, but 
this information has been removed from this
current document.)
The pMDI has also been compared with the
breath-actuated Autohaler. Ninety of 181 children
and adolescents found the Autohaler to be more
acceptable that the pMDI, 24 opted for the reverse
opinion, and 43 found both devices equally
acceptable (p < 0.001).215
Summary
Overall, the evidence on patient preference, ease
of use and adherence is limited in quantity with
respect to covering all the different inhaler devices
and appropriate outcomes, and the data available
are of a less than robust quality.
Recommendations
Well-designed qualitative studies, or qualitative
data collected during a randomised controlled
trial, would provide a greater understanding of
the factors that underlie children’s relationships
with their asthma inhaler devices. Given apparent
equivalence in clinical effectiveness between
inhaler types and the importance of patient
factors, such studies would contribute greatly
to our understanding and therefore to the
management of children and adolescents with
chronic asthma.
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Methods for economic analysis
Economic analysis was undertaken in the form of a
review of existing cost-effective evidence, including
evidence submitted to NICE by companies produc-
ing asthma inhalers, followed by further economic
modelling undertaken by the review team.
Review of the economic sub-
missions and published literature
No published studies analysing the cost-
effectiveness of different inhaler types with 
the same drug in the required population were
found. The reason for exclusion in the majority 
of the articles request-ed and reviewed was either
that different drugs were being used in addition 
to different devices, or that the study population 
did not match the 5–15-year age range specified 
in the review inclusion criteria.
Sponsors of inhaler devices were invited by NICE
to submit evidence on effectiveness. The following
is an appraisal of the economic evidence submitted
to NICE by companies producing inhaler devices.
Each submission was documented according to the
following categories:
• sponsor name
• number of sponsor products in the submission.
For each product the following categories were
used where applicable:
• product name
• product device type
• drug delivered
• comparator device(s) for economic analyses.
Economic analyses were appraised according to 
the following categories:
• analytical approach taken
• time horizon considered
• discounting rates used where applicable
• source of drug and device costs
• assumptions made for the economic analysis 
of each product
• conclusion reached for each product
• budgetary impact model presented 
where applicable.
Each submission was assessed on the appro-
priateness and accuracy of the economic 
analyses presented.
Overview of economic analyses
in submissions
Six of the eight submissions adopted a standard
cost-minimisation approach, citing that no
significant clinical differences between devices
have been proved. Therefore, the cheapest option
with which the patient is both compliant and
proficient in using should be chosen.
The submission by Norton Healthcare281
used a cost–consequence approach, using a
retrospective observational database to look at
resource usage between patients who had changed
to their product (Easi-Breathe) and patients 
who had changed to pMDIs. The resulting data
showed that there were significantly fewer GP
consultations for Easi-Breathe and that the overall
direct NHS costs were less. It was hypothesised 
that there would also be allied quality-adjusted 
life-year (QALY) increases owing to Easi-Breathe
treatment, however these were not quantified 
to provide a cost-effectiveness ratio.
The submission by GlaxoSmithKline282 argued
that, although no evidence was found to prove
that the inhaler devices were significantly 
different, this did not mean that they were
necessarily equivalent because the published 
trials may not have had enough power to detect
small differences.
The review team concurs that there is no
statistically significant evidence of equivalence.
However, if a pragmatic consensus of clinicians 
is that the devices are equivalent, then a cost-
minimisation approach should be taken.
Review of the economic analysis
presented in submission 1283
• company name: 3M
• number of products detailed in the
submission: two.
Chapter 3
Economic analysis 
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Product 1:
• name: Autohaler
• device type: breath-actuated pMDI
• drugs delivered: salbutamol (HFA and CFC),
beclometasone dipropionate (HFA and CFC)
• comparators for economic analyses: pMDIs
and DPIs.
Product 2:
• name: AeroChamber®
• device type: medium-volume spacer
• compatible with: all pMDIs
• comparator for economic analyses: 
other spacers.
Appraisal of economic analysis:
• analytical approach taken: cost-minimisation
• time horizon: 1 year
• discounting: none taken
• source for drug and device costs: British 
National Formulary (BNF) March 2001284 or
Monthly Index of Medical Specialities (MIMS) 
June 2001.285
Product 1 (Autohaler)
Assumptions made
All devices have the same clinical efficacy and an
equal adherence rate.
Submission conclusion
pMDIs are the cheapest device based on
acquisition cost but, when patients are unable to
adhere to the pMDI technique, Autohaler devices
are the next cheapest option.
Budgetary impact model presented
A typical district of 500,000 people was used as 
the population base. If all patients were prescribed
pMDIs (a relatively inexpensive device) then the
estimated inhaler cost would be £919,000. This
figure would be £1,477,000 if all patients used
Diskhalers. The figure would be £1,065,000 if all
patients were to be prescribed Autohalers. Scaling
these data to the population of England and Wales,
the figures are £96 million, £154 million and 
£112 million respectively.
Reviewer comment
The cost methodology used is potentially flawed 
in that it allows for non-integer doses to be taken
per day. For example, the cost of the drug is
calculated to per microgram and then multiplied 
to calculate the daily cost. This presents a problem
when the daily requirement is 400 µg per day and a
puff contains 250 µg. Clearly, two puffs would be
needed, not 1.6 as has been calculated.
Nevertheless, this does not influence the main
conclusion that the Qvar® Autohaler is the
cheapest non-pMDI device. It is noted however
that the Qvar Autohaler is not recommended 
for children aged under 12 years, and that the
AeroBec® Autohaler is more expensive than a
number of competitor devices.
The impact of the equivalence assumptions made
with regard to the QALY improvement necessary
for the device to be cost-effective has been explored
in the model presented by the review team.
Product 2 (AeroChamber)
Assumptions made
All spacers have the same clinical efficacy and an
equal adherence rate.
Submission conclusion
Based on the manufacturer’s recommended
lifespan for each spacer, the cheapest option is the
AeroChamber, at a cost saving of £1.22 per patient
per year compared with the next cheapest device.
Budgetary impact model presented
An estimate of 125,000 spacers prescribed per 
year was made. If this figure were correct then the
savings compared with the next cheapest spacer
would be estimated at £153,000, although it is not
explicitly stated whether this figure applies to the
UK or to England and Wales.
Reviewer comment
The mathematics behind the calculations appear
to be robust.
The impact of the equivalence assumptions made
with regard to the QALY improvement necessary
for the device to be cost-effective has been explored
in the model presented by the review team.
Review of the economic analysis
presented in submission 2286
• company name: Aventis
• number of products detailed in the 
submission: three.
Product 1:
• name: Fisonair®
• device type: large-volume spacer
• compatible with: Intal® pMDI (sodium cromo-
glicate)
• comparator for economic analyses: Intal pMDI.
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Product 2:
• name: Syncroner®
• device type: pMDI with an integral open 
tube spacer.
• drug delivered: Intal (sodium cromoglicate) 
or Tilade® (nedocromil sodium)
• comparator for economic analyses: Intal pMDI
or Tilade pMDI.
Product 3:
• name: Spinhaler
• device type: DPI
• drug delivered: Intal (sodium cromoglicate)
• comparator for economic analyses: Intal pMDI.
Appraisal of economic analysis:
• analytical approach taken: cost-minimisation
• time horizon: 1 year
• discounting: none taken
• source for drug and device costs: not stated,
although equal to those in the BNF March
2001284 or MIMS June 2001.285
Product 1 (Fisonair)
Submission conclusion
The additional cost of using a Fisonair device is
£5.94 per annum. Were a GP consultation avoided,
at a minimum cost of £15, then the device would
be cost saving.
Budgetary impact model presented
None.
Reviewer comment
The mathematics regarding one GP consultation,
or indeed one GP consultation per two patients,
becoming cost saving are correct. However, no
evidence has been presented that GP consultations
are reduced by the use of a Fisonair device.
The impact of the equivalence assumptions made
with regard to the QALY improvement necessary
for the device to be cost-effective has been explored
in the model presented by the review team.
Product 2 (Syncroner)
Assumptions made
The Syncroner has the same clinical efficacy and
an equal adherence rate as the comparative (i.e.
Intal or Tilade) pMDI.
Submission conclusion
Assuming a daily regimen equal to the normal
maximum dose, the Intal Syncroner is £0.19 per
patient cheaper per 28 days’ therapy. This is
approximately £1.14 per patient per year.
The costs of the Tilade Syncroner and the Tilade
Inhaler are very similar, a difference of £0.01 per
patient per 28 days, in favour of the Syncroner.
It is concluded that the Syncroner is cost saving
compared with the comparative pMDIs.
Budgetary impact model presented
None.
Reviewer comment
The cost difference between the Intal pMDI and
the Intal Syncroner appears to be £0.21 per patient
per 28 days, which would result in an approximate
£1.26 saving per patient per year.
It is agreed that the Syncroner is cost saving, given
the assumptions made.
The impact of the equivalence assumptions made
with regard to the QALY improvement necessary
for the device to be cost-effective has been explored
in the model presented by the review team.
Product 3 (Spinhaler)
Assumptions made
The Spinhaler has the same clinical efficacy and an
equal adherence rate as the Intal pMDI.
Submission conclusion
The cost of the Spinhaler and Intal Spincaps® is
calculated to be £28.30 less per year than the cost
of Intal pMDIs.
Budgetary impact model presented
None.
Reviewer comment
It is agreed that the Spinhaler is cost saving, given
the assumptions made.
The impact of the equivalence assumptions made
with regard to the QALY improvement necessary
for the device to be cost-effective has been explored
in the model presented by the review team.
Review of the economic analysis
presented in submission 3
There is no submission 3.
Review of the economic analysis
presented in submission 4287
• company name: Celltech
• number of products detailed in the submission: one.
Economic analysis
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Product 1:
• name: Clickhaler
• device type: DPI
• drug delivered: salbutamol or beclometasone
dipropionate
• comparator for economic analyses: other DPIs.
Appraisal of economic analysis:
• analytical approach taken: cost-minimisation
• time horizon: 1 year
• discounting: none taken
• source for drug and device costs: MIMS March
2000.288
Product 1 (Clickhaler)
Assumptions made
All devices have the same clinical efficacy and an
equal adherence rate.
Only HFA devices would be considered.
Submission conclusion
The Clickhaler is the cheapest DPI device.
Budgetary impact model presented
Changing all DPI users to a Clickhaler could 
have saved the NHS up to £14 million in 1999. 
Up to a further £39 million could have been saved
were all patients on beclometasone dipropionate,
fluticasone or budesonide switched to a Clickhaler
delivering beclometasone dipropionate.
Reviewer comment
The focus on HFA-only devices means that some
types with HFA licences pending, such as Easi-
Breathe, have been omitted from the analyses. 
The explicit budgetary impact calculations have
not been given. It is noted that the cost saving
from switching patients on fluticasone or budes-
onide has been calculated, although the Clickhaler
does not deliver these drugs. It is also noted that
the costs of the drugs used in this submission were
over 1 year old compared with the costs used in 
the other submissions and the review team model.
Review of the economic analysis
presented in submission 5282
• company name: GlaxoSmithKline
• number of products detailed in the submission:
six.
Product 1:
• name: inhaler
• device type: pMDI (CFC)
• drugs delivered: beclometasone dipropionate,
salmeterol dipropionate, beclometasone
+ salbutamol
• comparator for economic analyses: none.
Product 2:
• name: Evohaler®
• device type: pMDI (HFA)
• drugs delivered: salbutamol, fluticasone
propionate, fluticasone propionate + salmeterol
• comparator for economic analyses: none.
Product 3:
• name: Diskhaler
• device type: DPI
• drugs delivered: beclometasone dipropionate,
salmeterol, salbutamol, fluticasone
• comparator for economic analyses: none.
Product 4:
• name: Accuhaler
• device type: DPI
• drugs delivered: salbutamol, fluticasone
propionate, salmeterol, fluticasone propionate 
+ salmeterol
• comparator for economic analyses: none.
Product 5:
• name: Rotahaler
• device type: DPI
• drugs delivered: beclometasone dipropionate,
beclometasone dipropionate + salbutamol
• comparator for economic analyses: none.
Product 6:
• name: Volumatic
• device type: large-volume spacer
• compatible with: all GlaxoSmithKline pMDIs
• comparator for economic analyses: none.
Appraisal of economic analysis:
• analytical approach taken: budgetary impact
model only
• time horizon: 1 year
• discounting: none taken
• source for drug and device costs: BNF March
2001284 or MIMS June 2001.285
GlaxoSmithKline did not undertake any economic
analysis other than a budgetary impact model,
citing that there are no trials that have proved
equivalence between different inhaler devices. 
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As such it is claimed that cost-effectiveness or cost-
minimisation analyses are inappropriate.
Budgetary impact model presented
If all patients using a pMDI also used a spacer, 
the total cost of asthma treatment would increase
by £0.33 million per annum.
If 20% of all of those patients on GlaxoSmithKline
pMDIs were prescribed Accuhalers (DPIs), there
would be an increase in total costs of £0.43 million
per annum.
If 100% of all of those patients on GlaxoSmithKline
pMDIs were prescribed Accuhalers (DPIs), there
would be an increase in total costs of £1.3 million
per annum.
The submission rates these increases as not impos-
ing a large extra burden on the NHS resources in
England and Wales.
Reviewer comment
There is no conclusive evidence that inhaler types
are equivalent. The model produced by the review
team allows some indication of the QALY gains
needed for more expensive inhaler devices to be
cost-effective compared with cheaper devices.
However, if a pragmatic consensus was that the
devices were equivalent, then a cost-minimisation
approach should be taken.
Review of the economic analysis
presented in submission 6281 and
supplementary requested information289
• company name: Norton Healthcare
• number of products detailed in the submission: one.
Product 1:
• name: Easi-Breathe
• device type: breath-actuated inhaler
• drug delivered: salbutamol or beclometasone
dipropionate
• comparator for economic analyses: pMDIs.
Appraisal of economic analysis:
• analytical approach taken: cost consequence
• time horizon: 5 years
• discounting: none taken
• source for drug and device costs: MIMS June 2001.285
Product 1 (Easi-Breathe)
Assumptions made
The retrospective observational data from the
Asthma Resource Use Study were representative
of the true difference between the resources
consumed when comparing pMDI and Easi-Breathe.
Submission conclusion
Total costs are reduced by £17.46 per patient per
annum when using Easi-Breathe compared with a
pMDI, made up of reduced GP consultations for
asthma-related illnesses. In a supplementary
analysis, the difference in total costs between pMDI
users and Easi-Breathe users was reported as
£17.94, with a p-value of 0.014.
A sensitivity analysis drawing random observations
from the 95% confidence intervals for inhaled
steroids, β
2
--agonists, oral steroids, antibiotics and
GP consultations gave results that showed Easi-
Breathe to be cheaper on 99.11% occasions
compared with a pMDI.
Budgetary impact model presented
If all patients using a beclometasone or salbutamol
pMDI were switched to Easi-Breathe, an extra
device cost of £2.17 million per annum would be
expected for an estimated 674,000 users. It was
postulated that these patients would accrue a saving
of £13.94 million per annum, resulting in a net
saving of £11.77 million per annum. An analysis
phasing in Easi-Breathe by 20% of pMDI use over
the forthcoming 5 years was also presented.
Reviewer comment
This is divided into two sections: study design and
the data presented.
• Asthma Resource Use Study design
The Asthma Resource Use Study was a retrospective
observational analysis of the resource use of two
cohorts of asthma sufferers over a 12-month period,
using the Doctors’ Independent Network-Link
database (DIN-Link). DIN-Link is a large longi-
tudinal database from 100 practices, equating with
approximately 360 geographically representative
GPs and 900,000 patients.
These cohorts were divided into a group of patients
in whom all asthma medication (beclometasone
dipropionate and salbutamol) was given via a pMDI
and a second group in whom such medication was
delivered by Easi-Breathe. Each group was then
subdivided into whether patients were existing
medication users or new sufferers. It appears that
only the results for existing patients were presented
in the submission.
It is shown that the baseline dose of beclometasone
dipropionate was higher for the group on Easi-
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Breathe than for those using a pMDI. The sponsors
report that this suggests that Easi-Breathe users
may have had more severe symptoms, or that they
were switched to Easi-Breathe in order that control
of the asthma was achieved. This is plausible,
although not categorically conclusive. It could be
that those GPs with a keener interest in asthma
were more likely to use Easi-Breathe and more
likely to have previously controlled their patients’
asthma with the use of higher doses. Alternatively,
the demographics and social status of the patients
using Easi-Breathe may be more conducive to
better adherence rates than those using a pMDI.
The reported reduction in combined resource
usage may be accounted for more by the variation
in adherence rates than by the different inhaler
devices used. The extent of this bias was examined
using the ACORN (A Classification Of Residential
Neighbourhoods) socio-economic groups devel-
oped by CACI Limited,290 presented by the
sponsor.289 There are six categories, with the last
one divided into five groups: (1) older people, 
less prosperous areas; (2) council estate residents,
better-off homes; (3) council estate residents, 
high unemployment; (4) council estate residents,
greatest hardship; and (5) people in multi-ethnic,
low-income areas. In the study, 38% of the pMDI
cohort of patients with socio-economic data were
in this group. This figure was only 12% for those 
in the Easi-Breathe group. This is countered by 
the higher proportions using Easi-Breathe in the
higher socio-economic groups, but it could be 
a factor were deprivation (i.e. category F) to
influence device usage, while those in categories
A–E could use a device correctly. Anecdotal
evidence (Everard M, Sheffield Children’s Hospital
NHS Trust, Sheffield: personal communication,
2001) and evidence from the current review
contained in the discussion of results in chapter 2
suggest that this may be a factor.
After further analysis289 it was shown that patients
who had remained either on a pMDI device or on
the Easi-Breathe device were not counted in the
analysis. This may introduce bias if the act of
switching pMDI device, or changing to a pMDI
device, is related to lack of control of the asthma.
Patients who did not switch pMDI device may be
happy and suffering fewer attacks than those who
do change their device. Although this may also be
true for Easi-Breathe users, if both cohorts had
similar resource usage then pMDIs would be
cheaper owing to the lower acquisition costs.
Thus, the conclusions drawn in the submission
regarding cost offsets are relevant only to those
patients who changed to a pMDI device and those
who changed to Easi-Breathe. No conclusions can
be drawn comparing resource use between patients
who remained on the same pMDI and those who
remained on Easi-Breathe.
• Data presented
If only those cost vectors that were individually
significant (β
2
-agonist prescriptions, antibiotic
prescriptions and GP consultations) are 
summated, the cost saving is reduced to 
£10.58 per patient per annum. This would 
reduce the total projected cost savings, were all
patients on a beclometasone dipropionate or
salbutamol pMDI switched to Easi-Breathe, to
£6.28m per annum.
The sensitivity analysis presented needed further
explanation. There was no discussion on the
distribution assumed between the 95% confidence
intervals of each vector (e.g. normal, uniform) 
or on the correlation between vectors. It is
probable that those in the upper distribution for
antibiotics would also be in the upper distribution
for GP consultations. The assumption of no
correlation between vectors is likely to constrain
the higher differences, as in the above example;
patients would have to fall randomly into upper
distributions of both GP consultations and
antibiotic use.
There appears to be a discrepancy between the
cost savings given (£17.46) and those from the
addition of the individual vectors in Table 30 in 
the industry submission (£15.86) that is not
accounted for by the excluded outpatient atten-
dance figures. The reason for this discrepancy is
not given. Similarly, there seems to be an error 
in the number of GP consultations prevented. 
Results shown in Table 10 of the submission show
an average of 2.504 GP consultations, but also
shows an average of 2.179 consultations for lower
respiratory tract infections and 0.965 consultations
for upper respiratory tract infections. These
summated equal 3.144 consultations, which is
greater than the total number reported.
If the Asthma Resource Use Study results are valid,
then Easi-Breathe produces cost savings. Analyses
with and without such savings are presented in the
review team’s model. It is stressed, however, that
the cost offset could be taken as valid only under
the conditions of the study (i.e. patients who switch
to a pMDI or switch to Easi-Breathe) and assuming
that there was no bias in socio-economic status of
the cohorts.
Health Technology Assessment 2002; Vol. 6: No. 5
33
No conclusion can be drawn from the evidence
presented in the submission for new sufferers of
asthma, or for patients who do not switch to a
pMDI or who remain on the same pMDI.
Review of the economic analysis
presented in submission 7
(Yamanouchi provided confidential information,
which was included in the version of the report
that was sent to the Appraisals Committee, but 
this information has been removed from this
current document.)
Review of the economic analysis
presented in submission 835
• company name: AstraZeneca
• number of products detailed in the submission:
one.
Product 1:
• name: Turbohaler
• device type: DPI
• drugs delivered: budesonide, terbutaline
sulphate, eformoterol fumarate, budesonide 
+ eformoterol fumarate
• comparator for economic analysis: none.
Appraisal of economic analysis:
• analytical approach taken: no quantified analysis
• time horizon: none
• discounting: none taken
• source for drug and device costs: MIMS June
2001.285
Product 1 (Turbohaler)
Submission conclusion
Turbohaler significantly reduces hospitalisation
compared with a pMDI.
Budesonide Turbohaler reduces hospitalisation
and increases the number of symptom-free days.
Eformoterol fumarate Turbohaler increases the
number of symptom-free days.
Compliance is a key driver and patient preference
should be a key factor in determining the 
device selected.
Budgetary impact model presented
No quantitative data were presented. A relation-
ship between poor compliance and associated
increased costs is hypothesised, with the claim that
were more patients to be compliant on Turbohaler
then direct costs could be reduced.
Reviewer comment
The efficacy results presented unfortunately do 
not meet the scope of the review, either through
participants being older than the required age
range or because different drugs and different
devices were being compared.
The model presented by the review team investi-
gates the increase in QALYs needed in order for
more expensive devices to become cost-effective.
Estimations of increased QALYs owing to better
compliance, together with the review team model,
allows a more informed decision to be made on
device selection.
Review of the economic analysis
presented in submission 9
There is no submission 9.
Review of the economic analysis
presented in submission 10291
• company name: Trinity Pharmaceuticals
• number of products detailed in the submission:
three.
Product 1:
• name: Pulvinal
• device type: DPI
• drugs delivered: beclometasone dipropionate
and salbutamol
• comparators for economic analyses: other DPIs.
Product 2:
• name: inhaler
• device type: pMDI
• drugs delivered: ipratropium bromide,
ipratropium bromide + fenoterol hydro-
bromide
• comparators for economic analyses: none.
Product 3:
• name: Autohaler
• device type: breath-actuated inhaler
• drugs delivered: ipratropium bromide,
ipratropium bromide + fenoterol hydrobromide
• comparators for economic analyses: none.
Appraisal of economic analysis – Product 1:
• analytical approach taken: cost-minimisation
• time horizon: 1 year
• discounting: none taken
• source for drug and device costs: MIMS January
2001.292
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Appraisal of economic analysis – Products 2 and 3:
• analytical approach taken: none
• time horizon: none
• discounting: none taken
• source for drug and device costs: MIMS 
April 2001.293
Product 1 (Pulvinal)
Assumptions made
All devices have the same clinical efficacy and an
equal adherence rate.
Submission conclusion
Pulvinal will be the cheapest DPI on the market,
saving between £1.90 and £121.11 per patient 
per annum on beclometasone dipropionate and
between £4.56 and £19.96 per patient per annum
on salbutamol.
Budgetary impact model presented
None, except individual patient data.
Reviewer comment
The Pulvinal device has recently been licensed in
the UK, but the submission predicted its launch, 
so it is noted that the price quoted is a projected
price only.
Products 2 and 3 (pMDI and Accuhaler)
Submission conclusion
The Drug and Therapeutics Bulletin22
recommendations for ages 6–12 years are also
applicable for the age group 5–15 years.
Budgetary impact model presented
None, except individual patient data.
Reviewer comment
No additional calculations have been conducted.
Review group model
Methodology
Little evidence has been presented showing that
the clinical outcomes are different between 
inhaler devices. The review group has therefore
undertaken a simple cost-minimisation approach,
but also a QALY threshold approach.
The QALY is a more sophisticated measure of
health benefit than the more traditionally used 
life-year gained (LYG) because it gives an
indication of a patient’s health in the LYG to be
considered, allowing distinctions to be made
between those enjoying full health and those who
are severely disabled. In this subject area there 
are very few quality-of-life data, with none specifi-
cally provided by the sponsors. In addition, this 
is a disease area with a low mortality rate and 
little evidence to suggest that any treatment can 
improve this rate. Explicit cost per QALY values
have therefore not been calculated. The QALY
threshold approach allows calculation of the mar-
ginal gain in QALYs needed for a more expensive
device to be purchased.
For both methodologies, all unit costs have been
taken from the BNF 41 March 2001284 and MIMS
May 2001.294 These have been multiplied by the
appropriate daily doses and are comparable with
the prices in the submissions.35,261,281–283,286,287,291 For
devices that can be refilled, it has been assumed
that two devices will be bought per annum, with
refills bought for the remaining doses. For spacer
devices, apart from where specifically stated in 
the manufacturer’s guidance, it has been assumed
that two spacers per annum are required. It has
also been assumed that the spacers will be used
without a mask and, further, that, where a pMDI
manufacturer does not also manufacture a spacer,
a spacer made by a company that does not manu-
facture pMDIs would be added.
The cost-minimisation approach simply chooses the
cheapest method of delivering the required daily
dose assuming all devices are equivalent. Therefore,
only drug and device costs are considered.
The QALY threshold approach uses a relatively low
default direct medical cost per QALY purchasing
limit of £5000, at which price it is assumed that 
the intervention would be purchased. Additional
analyses have been undertaken assuming a 
£20,000 cost per QALY threshold, which is
assumed to be the maximum price at which the
intervention would be purchased. This form of
analysis is preferable to that of cost-minimisation 
as it allows a more informed decision to be made
if there is an expectation of different QALYs
between devices.
For example, a clinician may believe that an
individual patient would be more adherent on
device A, and that this would lead to an increase
in that patient’s quality of life. If the estimations 
of the marginal QALYs were above the threshold
values presented for device A in Tables 27–38
in appendix 18, then that device should be pur-
chased at the relevant cost per QALY threshold.
Alternative sources of increased QALYs may occur
by reducing the deposit of drug in the oropharynx
or by the patient suffering fewer asthma symptoms.
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If, conversely, the clinician believes that, for an
individual patient, all devices are equivalent in
terms of the QALYs accrued, then all marginal
QALYs are zero, and the cheapest device should 
be selected. In this instance, this approach
replicates the results of a cost-minimisation analysis.
Examples are given in the tables in appendix 18.
The scope of the project was the cost-effectiveness
of the devices themselves, not of the drug pre-
scribed. The analysis has therefore focused on
which device should be given if the clinician has
decided that a certain drug is required; thus, there
is a separate table for each drug considered.
For each table it has been assumed that the costs
incurred by the NHS are independent of device
type. That is, there will be no changes in the
amount of asthma medication prescribed, out-
patient visits or GP consultations required that 
are dependent on the device. On clinical advice
the high-strength beclometasones (250 µg and
above) and equivalent strengths for budesonide
and fluticasone propionate have not been costed
owing to their unsuitability for children.
The exception is for Easi-Breathe products 
that deliver beclometasone dipropionate and
salbutamol, for which the Norton Healthcare
submission has provided some evidence that
resources can be saved. Beclometasone dipro-
pionate Easi-Breathe devices have therefore been
modelled twice, once at their acquisition cost and
once at a cost set to be a conservative £10 per
patient per annum below the cheapest pMDI. 
The value of £10 is the approximate summation 
of differences for only those vectors with a statis-
tically significantly different value and includes 
the reduction in costs due to reduced GP consult-
ations. It has been assumed that the cost offsets
seen in this submission were due to the beclo-
metasone dipropionate device solely, not to the
salbutamol device. It is stressed that the cost offset
attributed to the Easi-Breathe device is valid only 
in comparisons with patients who change to a 
new pMDI device and assuming that there was 
no bias introduced by the socio-economic 
status of the patients studied.
Results
Sample results are presented in Tables 27–38 in
appendix 18, with an example detailed in this
section. In each table the devices have been ranked
in ascending cost order. This allows the cost-
minimisation analysis to consist solely of selecting
the first device on the list. Where this is an Easi-
Breathe beclometasone dipropionate device, the
second device could be selected if the cost offset
was not to be believed.
Although not presented, the results for terbutaline
sulphate, reproterol hydrochloride, nedocromil
sodium, beclometasone dipropionate + salbutamol,
fluticasone propionate + salmeterol, ipratropium
bromide + salbutamol, ipratropium bromide +
fenoterol hydrobromide, salmeterol, eformoterol
fumarate, and ipratropium bromide are similar to
those presented in Tables 27–30 in appendix 18.
The results presented are for relatively low dosage
levels. Tables 31 and 32 assume that a high dose of
beclometasone dipropionate is given.
An example of using the tables to determine 
the device for cost minimisation
For Tables 27, 28, 33–38, the cheapest devices are
those at the top of the vertical column. For example,
in Table 27, the cheapest devices are Maxivent at
£3.14 per annum, and Asmaven at the same price.
For beclometasone (Tables 29–32), the issue is not
so clear, owing to evidence of resource savings
presented by Norton Healthcare. Using acquisition
prices alone, the cheapest devices are Qvar (50),
Qvar Autohaler (50) and Filair (100), at £28.73 
per annum. If, however, resource savings are
produced by the use of Beclazone Easi-Breathe
(100) that effectively price it at £10 less than the
cheapest alternative device, Easi-Breathe would 
be the cheapest at £18.73.
Owing to uncertainty concerning the validity of the
resource savings results, Beclazone Easi-Breathe
has been included in Tables 29–32 at both £18.73
and its true acquisition price of £30.08.
An example of using the tables to determine the
incremental QALY thresholds between devices
It is assumed that a daily dose of 200 µg of
beclometasone dipropionate (100 µg for Qvar 
as per manufacturer’s dosage levels) is required.
(Table 29 in appendix 18).
The QALY threshold approach allows some
indication of the incremental QALYs that more
expensive devices would need to achieve to be 
cost-effective at the £5000 cost per QALY level.
As an example, Filair® 100 would cost £28.73 per
annum to provide the dose, assuming two puffs daily
of 100 µg Filair. With the addition of an AeroCham-
ber the cost is £33.01 per annum, an incremental cost
of £4.28. In order for the AeroChamber device to
have a cost per QALY of £5000, 0.00086 extra QALYs
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per annum would be required. (This is equivalent 
to less than 8 hours of perfect health per annum.)
The value of 0.00086 can be found in the 
Filair 100 row, moving rightwards until the 
Filair 100 + AeroChamber column is reached.
Thus, were it believed that the additional Aero-
Chamber produced more QALYs than this figure,
it would be deemed cost-effective at the £5000
level, whereas, conversely, if it were believed that
fewer QALYs would be produced then the device
would not be cost-effective at this level.
Although beyond the initial scope of the project,
different dosages of the drugs (e.g. Beclazone 
100 µg and 200 µg) to achieve the same daily dose
have been included in order that some indication 
is given of the QALYs needed to be obtained by
giving two smaller strength doses rather than a
single large dose, as sometimes occurs in clinical
practice (Tables 31 and 32).
Calculating QALY threshold results
QALY threshold results for those drugs that are not
presented can be calculated by the following formula,
assuming that no cost offsets are considered:
(device cost A – device cost B)/cost per QALY
threshold selected
Therefore if device A cost £65 per annum 
and device B cost £60 per annum, the QALY
threshold value at £5000 cost per QALY would 
be (65–60)/5000 = 0.001.
Further research
The trial size needed to detect a QALY difference of
0.00807 at a 95% significance level and 80% power,
assuming a general population QALY standard
deviation of 0.1295–297 has been calculated.
The approximate number needed can be
calculated using the following formula:298
16/[(effect size needed to detect/population
standard deviation)]2
Substituting in the numbers from the example:
16/[0.00807/0.1]2
which equals just under 2500 in each arm.
As the detection level approaches 0.0025 and
0.0001, the number of patients required would rise
to 25,600 and 160,000 respectively in each arm.
Such trials are likely to prove impractical,
especially given the large numbers of potential
combinations that exist.
Conclusions
It is seen in Table 29 in appendix 18 that the 
largest QALY needed, assuming no Easi-Breathe
cost offsets, for a cost per QALY ratio of £5000 at
the 200 µg of beclometasone dipropionate dose
per day is 0.01007. (This equates to an additional 
88 hours of perfect health per annum.) It is clear
that, with the small QALY increase required, no
intervention can be categorically dismissed as 
not being cost-effective. Using a cost per QALY
threshold of £20,000, the largest incremental
QALY gain needed, assuming no Easi-Breathe cost
offset, is 0.00202 (Table 30 in appendix 18); many
QALY increments required less than 0.001. (This
latter figure is equivalent to less than 9 hours of
perfect health per annum.)
It is noted that the maximum incremental QALYs
needed for different devices delivering salbutamol
(Tables 27 and 28 in appendix 18) and budesonide,
fluticasone and cromoglicate (Tables 33–38 in
appendix 18) have the same order of magnitude 
as the results for low-dose beclometasone 
(Tables 29 and 30 in appendix 18).
To put such QALY increments into perspective,
suffering a wrist fracture has a QALY loss of 0.01,299
and suffering a vertebral fracture has a QALY loss
of 0.092.300
It is stressed that these tables assume clinical
equivalence. Were a device to prevent a hospital-
isation when compared with another device 
delivering the same medication, due, for example,
to a patient’s reluctance to use a device, the cost-
effectiveness would be significantly altered. The
cost of an average hospitalisation for a patient aged
over 5 years was calculated to be £857 per patient
per stay at 1996 prices,301 which is far in excess 
of the marginal costs presented. However, no
submission, with the exception of that of Norton
Healthcare, made any claim for a reduction in
resources used according to device type.
The tables presented in this analysis allow health
providers to estimate, taking into consideration
patient preferences, the device that is most likely 
to be cost-effective for an individual. In cases 
where the patient and the clinician believe that
devices produce equivalent QALYs then the
cheapest device should be selected but, in cases
where there are estimations of different QALYs,
the most appropriate device can be selected.
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No implications for other parties were identified.
Chapter 4
Implications for other parties 
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W ith respect to CFC and HFA propellants,although, for a number of products, we 
are in the transition phase at present, with dual
availability of both CFC and CFC-free versions 
of the same product, this phase is coming to an
end as the second pMDI non-CFC corticosteroid 
is launched. From the evidence available there
appear to be no differences in respiratory
outcomes between the old CFC and new HFA
devices delivering equivalent therapeutic doses 
of either reliever or anti-inflammatory asthma
medication. The enforced change, although 
costly, is also providing an opportunity for the 
NHS to review its prescribing practices. The
evidence from this review should help to inform
that debate.
Chapter 5
Factors relevant to the NHS 
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O verall, there is no evidence to suggest, on thegrounds of relative clinical efficacy, that any
one hand-held inhaler device is either better or
worse than any other when used by children in the
routine management of chronic asthma. There is
some evidence to support an additional benefit of
using a spacer with a pMDI rather than a pMDI 
on its own. Limited evidence, predominantly 
from observational studies, suggests that patient
preference tends to favour one DPI over another,
but good comparative data are sparse. It would
appear that the choice of an inhaler device does
not represent a barrier to effective use in children
over 5 years of age if adequate instruction and
supervision are provided.
In terms of cost-effectiveness, the largest QALY
needed at a dose of 200 µg of beclometasone
dipropionate per day was calculated to be 0.00807,
assuming no cost offsets from a breath-actuated
device (Easi-Breathe). Thus, with such a small
QALY increase required, no intervention can be
categorically dismissed as not being cost-effective.
Further research, using double-blind randomised
studies with adequate power are needed, together
with participants representing the full profile of
the condition, from the mild to moderate to those
at the severe end of the disease spectrum. Such
studies also need a qualitative component to try 
to understand the factors that underlie children’s
relationships with their condition and the manage-
ment thereof. The third dimension to any future
studies is to ensure that they are sufficiently
powered to examine health resource differences
and asthma symptoms between devices.
Chapter 6
Discussion
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O nly one submission
281 provided data support-
ing that a device produces direct medical cost
offsets compared with an alternative device for the
defined population.
None of the submissions provided quantitative data
on any quality-of-life benefits associated with one
specific device compared with another.
The yearly costs of each device and drug type were
calculated. Assuming cost per QALY threshold levels
of £5000 or £20,000, it was seen that the marginal
QALYs needed to be deemed cost-effective were
very small.
No device type could be categorically rated as not
cost-effective. Tables 27–38 in appendix 18 provide
indications of the marginal QALYs needed when
comparing between devices.
If a clinician and a patient decide that a device
would improve the patient’s quality of life by 
more than the marginal QALY then the more
expensive device should be selected. However, 
if the clinician and the patient concur that the
patient’s quality of life is not affected by device
type, then the cheapest device should be selected.
Chapter 7
Conclusions
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T he authors of this report conclude that noneof the products considered could be deemed
categorically not cost-effective. The QALY gains
(from potential sources such as improved chronic
quality of life or reduced side-effects) required to
make a more expensive inhaler device cost-effec-
tive are very small. Given that no clear recommen-
dations could be given on which inhaler device
should be used it was deemed inappropriate to
conduct a budgetary impact analysis.
Chapter 8
Budgetary impact modelling
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Best Evidence
Biological Abstracts
CCTR (Cochrane Controlled Trials Register)
CDSR (Cochrane Database of Systematic Reviews)
EMBASE
HEED
HMIC (Health Information Management Consortium – 
comprising DH-Data, the King’s Fund Database, and HELMIS)
MEDLINE
NHS DARE
NHS EED
NHS HTA
PsycINFO
PubMed (previous 90 days)
Science Citation Index
Social Sciences Citation Index
Appendix 2
Electronic bibliographic databases searched 
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ABPI (Association of the British Pharmaceutical Industry)
AHRQ (Agency for Healthcare Research and Quality)
Alberta Clinical Guidelines Programme
American Thoracic Society
ARIF (Aggressive Research Intelligence Facility)
Bandolier
British Thoracic Society
CCOHTA (Canadian Co-ordinating Centre for Health Technology Assessment)
CCT (Current Controlled Trials)
CenterWatch Trials Register
Centre for Clinical Effectiveness, Monash University
Centre for Health Economics, University of York
ClinicalTrials.gov, National Institutes of Health Clinical Trials Database
CRiB (Current Research in Britain)
eMC (Electronic Medicines Compendium)
EMEA (European Agency for the Evaluation of Medicinal Products)
eGuidelines
HSTAT (Health Services/Technology Assessment Text, US National Library of Medicine)
INAHTA (International Network of Agencies for Health Technology Assessment) Clearinghouse
MCA (Medicines Control Agency)
MRC (Medical Research Council) Funded Projects Database
National Guideline Clearinghouse
National Heart, Lung and Blood Institute
National Research Register
NCCHTA (National Co-ordinating Centre for Health Technology Assessment)
NHS CRD (Centre for Reviews and Dissemination), University of York
NHS R&D Programmes
NIH (National Institutes of Health) Consensus Development Program
North of England Guidelines, University of Newcastle
OMNI (Organising Medical Networked Information)
ReFeR (Research Findings Register)
SBU (Swedish Council for Health Technology Assessment)
ScHARR (School of Health and Related Research) Library Catalogue
SIGN (Scottish Intercollegiate Guidelines Network)
SumSearch
Trent Working Group on Acute Purchasing
TRIP (Turning Research into Practice) Database
Health Evidence Bulletins, Wales
Wessex DEC (Development and Evaluation Committee) Reports
West Midlands DES (Development and Evaluation Services) Reports
Appendix 3
Other sources searched
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Best Evidence (Ovid Biomed
1991 – April 2001)
1 asthma$.mp. [mp=title, abstract, full text,
keywords, caption text]
2 inhal$.mp. [mp=title, abstract, full text,
keywords, caption text]
3 aerosol$.mp. [mp=title, abstract, full text,
keywords, caption text]
4 meter$ dose$.mp. [mp=title, abstract, full text,
keywords, caption text]
5 mdi.mp. [mp=title, abstract, full text, keywords,
caption text]
6 mdis.mp. [mp=title, abstract, full text,
keywords, caption text]
7 pmdi$.mp. [mp=title, abstract, full text,
keywords, caption text]
8 spacer$.mp. [mp=title, abstract, full text,
keywords, caption text]
9 or/2–8
10 1 and 9
11 child$.mp. [mp=title, abstract, full text,
keywords, caption text]
12 infant$.mp. [mp=title, abstract, full text,
keywords, caption text]
13 adolescent$.mp. [mp=title, abstract, full text,
keywords, caption text]
14 teenager$.mp. [mp=title, abstract, full text,
keywords, caption text]
15 paediat$.mp. [mp=title, abstract, full text,
keywords, caption text]
16 pediat$.mp. [mp=title, abstract, full text,
keywords, caption text]
17 or/11–16
18 10 and 17
Biological Abstracts (SilverPlatter
WebSPIRS 1985 – May 2001)
#5 #1 and #2 and #3 and #4
#4 trial*
#3 (child* or infant* or adolescent* or teenager*
or paediat* or pediat*)
#2 (inhal* or haler* or aerosol* or meter* dose*
or mdi or mdis or pmdi* or spacer*)
#1 asthma*
CDSR and CCTR (The Cochrane
Library 2001 Issue 2)
#1 asthma*:me
#2 asthma*
#3 #1 or #2
#4 administration-inhalation*:me
#5 nebulizers-and vaporizers*:me
#6 aerosols*:me
#7 aerosol*
#8 inhaler*
#9 nebuliz*
#10 nebulis*
#11 meter* near dose*
#12 mdi or mdis
#13 pmdi*
#14 #4 or #5 or #6 or #7 or #8 or #9 or #10 
or #11 or #12 or #13
#15 child*:me
#16 #3 and #14
#17 #16 and #15
CINAHL (Ovid Biomed 1982 –
May 2001)
1 exp asthma/
2 asthma$.tw
3 or/1–2
4 “nebulizers and vaporizers”/
5 aerosols/
6 inhal$.tw
7 aerosol$.tw
8 powder$.tw
9 meter$ dose$.tw
10 (mdi or mdis).tw
11 pmdi$.tw
12 spacer$.tw
13 or/4–12
14 3 and 13
15 exp child/
16 child$.tw
17 infant$.tw
18 adolescent$.tw
19 teenager$.tw
20 paediat$.tw
21 pediat$.tw
22 or/15–21
23 14 and 22
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Citation Indexes (Science and
Social Sciences) (Web of Science
1981 – April 2001)
Topic=asthma* and (inhal* or aerosol* or meter*
dose* or mdi or mdis or pmdi* or spacer*) and
(child* or infant* or teenager* or adolescent* or
paediat* or pediat*) and trial*; DocType=All
document types; Language=All languages;
Databases=SCI-EXPANDED, SSCI; Timespan=All
Years (sorted by latest date)
CRD Databases (NHS DARE,
EED, HTA) (CRD Web site –
complete databases)
asthma*/All fields AND (inhal* or aerosol* or
meter* dose* or mdi or mdis or pmdi* or
spacer*)/All fields AND (child* or infant* or
teenager* or adolescent* or paediat* or
pediat*)/All fields
EMBASE (SilverPlatter WebSPIRS
1980 – May 2001)
#37 #23 or #30 or #34 or #36
#36 #22 and #35
#35 spacer* or holding chamber* or aerochamber
or babyhaler or haleraid or nebuhaler
#34 #22 and #33
#33 #31 or #32
#32 integra or fisonair or nebuhaler or aeroscopic
or syncroner or nebuchamber or volumatic or
rotahaler or spinhaler or turbuhaler or diskus
or sidestream or ventstream or lc plus or lc
star or halo lite or aerobec or aerolizer or
pari baby
#31 maxivent or spacehaler or asmaven or salamol
or autohaler or airomir or salbulin or
easibreathe or easi-breathe or evohaler or
ventolin or bricanyl or berotec or bronchodil
or serevent or alupent or atrovent or oxivent
or combivent or duovent or beclazone or
filair or becotide or becloforte or qvar or
pulmicort or flixotide or ventide or seretide
or cromogen or intal or tilade or aerocrom or
aerobec or asmasal or clickhaler or ventodisk*
or diskhaler or Rotahaler or turbohaler or
foradil or aerocap* or asmabec or rotacap* or
accuhaler or steri-nab or ipratropium or
respontin
#30 #22 and #29
#29 #24 or #25 or #26 or #27 or #28
#28 inhal* suspen*
#27 powder inhal*
#26 pmdi* in ti, ab
#25 (mdi or mdis) in ti, ab
#24 meter* dose*
#23 #22 and #13
#22 #3 and #21
#21 #14 or #15 or #16 or #17 or #18 or #19 or #20
#20 pediat*
#19 paediat*
#18 teenager*
#17 adolescent*
#16 infant*
#15 child*
#14 explode ‘child-’ / all subheadings
#13 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
or #12
#12 nebulis*
#11 nebuliz*
#10 powder*
#9 aerosol*
#8 explode ‘nebulizer-’ / all subheadings
#7 ‘aerosol-’ / all subheadings
#6 ‘inhalational-drug-administration’ / all
subheadings
#5 ‘inhalation-’ / all subheadings
#4 explode ‘inhaler-’ / all subheadings
#3 #1 or #2
#2 asthma* in ti, ab
#1 explode ‘asthma-’ / all subheadings
HEED (OHE HEED CD-ROM –
complete database)
Search terms
• asthma*
• inhal* or haler* or aerosol* or meter* dose* or
mdi or mdis or pmdi* or spacer*
• child* or infant* or adolescent* or teenager* or
paediat* or pediat*
Fields searched
• Abstract
• All data
• Article title
• Book title
• Keywords
• Technology assessed
HMIC (SilverPlatter WinSPIRS
1983 – May 2001)
#1 asthma*
#2 inhal*
#3 haler*
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#4 aerosol*
#5 meter* dose*
#6 mdi or mdis
#7 pmdi*
#8 spacer*
#9 #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 #1 and #9
#11 child*
#12 infant*
#13 adolescent*
#14 teenager*
#15 paediat*
#16 pediat*
#17 #11 or #12 or #13 or #14 or #15 or #16
#18 #9 and #17
MEDLINE (Ovid Biomed 1966 –
May 2001)
1 exp asthma/
2 asthma$.tw
3 or/1–2
4 administration, inhalation/
5 “nebulizers and vaporizers”/
6 exp aerosols/
7 is.fs
8 aerosols.rw
9 powders.rw
10 nebuliz$.tw
11 nebulis$.tw
12 or/4–11
13 3 and 12
14 meter$ dose$.tw
15 (mdi or mdis).tw
16 pmdi$.tw
17 powder inhal$.tw
18 inhal$ suspens$.tw
19 or/14–18
20 3 and 19
21 maxivent.af
22 spacehaler.af
23 asmaven.af
24 salamol.af
25 autohaler.af
26 airomir.af
27 salbulin.af
28 easibreathe.af
29 easi-breathe.af
30 evohaler.af
31 ventolin.af
32 bricanyl.af
33 berotec.af
34 bronchodil.af
35 serevent.af
36 alupent.af
37 atrovent.af
38 oxivent.af
39 combivent.af
40 douvent.af
41 beclazone.af
42 filair.af
43 becotide.af
44 becloforte.af
45 qvar.af
46 pulmicort.af
47 flixotide.af
48 ventide.af
49 seretide.af
50 cromogen.af
51 intal.af
52 tilade.af
53 aerocrom.af
54 aerobec.af
55 asmasal.af
56 clickhaler.af
57 ventodisk$.af
58 diskhaler.af
59 Rotahaler.af
60 turbohaler.af
61 foradil.af
62 aerocap$.af
63 asmabec.af
64 rotacap$.af
65 accuhaler.af
66 steri-nab.af
67 ipratropium.af
68 respontin.af
69 or/21–68
70 3 and 69
71 integra.af
72 fisonair.af
73 nebuhaler.af
74 aeroscopic.af
75 syncroner.af
76 nebuchamber.af
77 volumatic.af
78 rotahaler.af
79 spinhaler.af
80 turbuhaler.af
81 diskus.af
82 sidestream.af
83 ventstream.af
84 lc plus.af
85 lc star.af
86 halo lite.af
87 aerobec.af
88 aerolizer.af
89 pari baby.af
90 or/71–89
91 3 and 90
92 spacer$.tw
93 holding chamber$.tw
94 aerochamber.tw
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95 babyhaler.af
96 haleraid.af
97 nebuhaler.af
98 or/92–97
99 3 and 98
100 13 or 20 or 70 or 91 or 99
101 exp child/
102 child$.tw
103 infant$.tw
104 adolescent$.tw
105 teenager$.tw
106 paediat$.tw
107 pediat$.tw
108 or/101–107
109 100 and 108
PsycINFO (SilverPlatter
WebSPIRS 1967 – May 2001)
#19 #18 and #17
#18 #3 and #11
#17 #12 or #13 or #14 or #15 or #16
#16 paediat* or pediat*
#15 teenager*
#14 adolescent*
#13 infant*
#12 child*
#11 #4 or #5 or #6 or #7 or #8 or #9 or #10
#10 spacer*
#9 powder*
#8 pmdi*
#7 mdi or mdis
#6 meter* dose*
#5 inhal*
#4 aerosol*
#3 #1 or #2
#2 asthma*
#1 ‘asthma-’ in de
PubMed (last 90 days from
18 May 2001)
#26 Search #16 AND #24 Limits: 90 days
#25 Search #16 AND #24
#24 Search #17 OR #18 OR #19 OR #20 OR #21
OR #22 OR #23
#23 Search pediat* [tw]
#22 Search paediat* [tw]
#21 Search teenager* [tw]
#20 Search adolescent* [tw]
#19 Search infant* [tw]
#18 Search child* [tw]
#17 Search child [mh]
#16 Search #3 AND #15
#15 Search #4 OR #5 OR #6 OR #7 OR #8 OR #9
OR #10 OR #11 OR #12 OR #13 OR #14
#14 Search spacer* [tw]
#13 Search pmdi* [tw]
#12 Search mdis [tw]
#11 Search mdi [tw]
#10 Search meter* dose* [tw]
#9 Search powder* [tw]
#8 Search inhaler* [tw]
#7 Search aerosol* [tw]
#6 Search aerosols [mh]
#5 Search “nebulizers and vaporizers” [mh]
#4 Search administration, inhalation [mh]
#3 Search #1 and #2
#2 Search asthma* [tw]
#1 Search asthma [mh]
In-vitro search strategies
(2000 – July 2001)
EMBASE (SilverPlatter WebSPIRS
2000 – July 2001)
#12 #11 and (PY=2000-2001)
#11 #3 and #10
#10 #4 or #5 or #6 or #7 or #8 or #9
#9 random* near5 trial*
#8 ‘randomized-controlled-trial’ / all
subheadings
#7 single blind procedure / all subheadings
#6 double blind procedure / all subheadings
#5 crossover procedure / all subheadings
#4 randomization / all subheadings
#3 #1 and #2
#2 asthma*
#1 ‘in vitro’
MEDLINE (Ovid Biomed 2000 – 
July 2001)
1 in vitro.af
2 exp asthma/
3 asthma$.tw
4 or/2–3
5 clinical trial.pt
6 4 and 5
7 limit 7 to yr=2000–2001
Methodological search filters used
in Ovid MEDLINE
Guidelines
1 guideline.pt
2 practice guideline.pt
3 exp guidelines/
4 health planning guidelines/
5 or/1–4
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Systematic reviews
1 meta-analysis/
2 exp review literature/
3 (meta-analy$ or meta analy$ or metaanaly$).tw
4 meta analysis.pt
5 review academic.pt
6 review literature.pt
7 letter.pt
8 review of reported cases.pt
9 historical article.pt
10 review multicase.pt
11 or/1–6
12 or/7–10
13 11 not 12
Randomized controlled trials
1 randomized controlled trial.pt
2 controlled clinical trial.pt
3 randomized controlled trials/
4 random allocation/
5 double blind method/
6 or/1–5
7 clinical trial.pt
8 exp clinical trials/
9 ((clin$ adj25 trial$)).ti, ab
10 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).ti, ab
11 placebos/
12 placebos.ti, ab
13 random.ti, ab
14 research design/
15 or/7–14
16 comparative study/
17 exp evaluation studies/
18 follow up studies/
19 (control$ or prospectiv$ or volunteer$)).ti, ab
20 prospective studies/
21 or/16–20
22 6 or 15 or 21
Economic evaluations
1 economics/
2 exp “costs and cost analysis”/
3 economic value of life/
4 exp economics, hospital/
5 exp economics, medical/
6 economics, nursing/
7 economics, pharmaceutical/
8 exp models, economic/
9 exp “fees and charges”/
10 exp budgets/
11 ec.fs
12 (cost or costs or costed or costly or costing$).tw
13 (economic$ or pharmacoeconomic$ or price$
or pricing).tw
14 or/1–13
Unwanted effects
1 ae.fs
2 ct.fs
3 co.fs
4 ((side or adverse or unintended or unwanted)
adj2 (effect$ or event$)).tw
5 harm$.tw
6 complication$.tw
7 contraindication$.tw
8 or/1–7
Patient preference/compliance
1 exp patient acceptance of health care/
2 patient$ complian$.tw
3 patient$ preference$.tw
4 or/1–3
Quality of life (asthma)
1 exp quality of life/
2 quality of life.tw
3 life quality.tw
4 qaly$.tw
5 quality adjusted life year$.tw
6 (sf36 or sf 36 or short form 36).tw
7 (eq5d or eq 5d or euroqol).tw
8 asthma self-efficacy scale.tw
9 juniper.tw
10 asthma quality of life questionnaire.tw
11 aqlq.tw
12 living with asthma questionnaire.tw
13 asthma bother profile.tw
14 asthma symptom checklist.tw
15 childhood asthma questionnaire.tw
16 paediatric asthma quality of life
questionnaire.tw
17 child asthma short form.tw
18 children$ health survey for asthma.tw
19 about my asthma.tw
20 or/1–19
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Study Reason for exclusion
Agertoft and Pedersen, 199449 Patients aged <5 years
Agertoft and Pedersen, 199850 Inhaler technique training intervention
Ahonen et al., 200051 Some included articles in abstract form only
Ahrens et al., 199552 In vitro, wrong research question
Anhoj et al., 200053 Inappropriate study design
Argenti et al., 200054 Patients aged >15 years
Ayres et al., 200055 Patients aged >15 years
Barry and O’Callaghan, 199456 In vitro, but wrong research question
Barry and O’Callaghan, 199657 In-vitro drug delivery from 7 spacers – not in the criteria
Barry and O’Callaghan, 199758 In-vitro drug delivery and spacer – not in the criteria
Barry and O’Callaghan, 199959 In vitro, spacer devices – not in the criteria
Baumgarten et al., 200060 Patients aged >15 years
Berg et al., 199863 Patients aged >15 years
Bisgaard et al., 199465 No comparison device
Bisgaard et al., 199866 Different drugs used
Bloomfield et al., 197967 Patients aged >15 years
Boccuti et al., 199668 Assessment of technique
Boccuzzi et al., 200069 Cohort study
Böllert et al., 199770 Adults
Borgström et al., 199671 Patients aged >15 years
Bourne, 199672 Not available from the British Library
Bousquet et al., 200073 Drug intervention
Brand et al., 200174 Patients aged <5 years
Brannan et al., 199864 In vitro, spacer and pMDI – not in the criteria
Burgess, 199375 Abstract only
Busse et al., 199976 Patients aged >15 years
Cavagni et al., 199377 Spacer device (Jet disposable – Chiesi Farmaceutici SpA,
Parma, Italy) not in criteria
Chan and DeBruyne, 200078 Study population was parents
Chang et al., 200079 Asthma management
aChapman and Brubaker, 199380 Patients aged >15 year
Chapman, 199581 Review
Chhabra, 198729 Drug intervention
Chipps et al., 199282 Inappropriate study design
Chuffart et al., 200183 In vitro, spacers – not in the criteria
Clark and Lipworth, 199684 Healthy volunteers
Conroy et al., 200085 Drug intervention
Corris, 199286 Drug intervention
Crompton, 1982272
Cunningham and Crain, 199487 Patients with episodic emergency department visits for acute
asthma attack
Dahl et al., 199788 Patients aged >15 years
Davies et al., 199889 Patients aged >15 years
Dawson et al., 198590 Different drug doses
de Benedictus et al., 199462 Drug intervention
Deenstra et al., 198891 Adults
Demedts et al., 199992 Patients mostly >15 years
aDiggory et al., 199193 Patients aged >15 years
Dinh Xuan et al., 1989198 Drug not device
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Dubus and Dolvich, 200094 In vitro, wrong research question
Emeryk et al., 199995 Abstract only
Engel et al., 199096 Patients aged >15 years
Everard et al., 199297 In vitro, spacers – not in the criteria
Finlay and Zuberbuhler, 199898 Patients aged <5 years
Finlay and Zuberbuhler, 199999 Patients aged <5 years
Fuller, 1986100 Adults
Geoffroy et al., 1999101 Patients aged >15 years
Giannini et al., 2000102 Patients aged >15 years
Gillies, 1997103 Discussion article
Goh et al., 1998104 Survey of CFC awareness
Goldberg et al., 1996105 Inappropriate study design
Gross et al., 1999107 Patients aged >15 years
aGrossman et al., 1997108 Patients aged >15 years
Gunawardena et al., 1997109 Adults
Gurwitz et al., 1983110 Non-randomised controlled trial, acute and chronic asthma
Haahtela et al., 1994111 Adults
aHampson and Mueller, 1994112 Non-asthmatic participants
Haughney, 1995113 Discussion article
aHendry et al., 1995114 Patients aged >15 years
Hidinger and Dorow, 1984115 Adults
Hilton, 1990116 Study on technique
Jacobson et al., 1999118 Patients aged >15 years
Jones et al., 1992119 Asthma morbidity in primary care
Juntunen-Backman et al., 1996120 Abstract only
Kassirer, 1994121 Editorial
aKelloway and Wyatt, 1997122 Wrong age group
LaForce et al., 1993123 Healthy volunteers
Langaker and Hidinger, 1982124 Patients aged >15 years
aLangley 1999125 Wrong age group
Laurikainen et al., 1997126 Adults
Lees, 1988127 Drug device combination no longer available
aLenney et al., 2000128 Patients aged >15 years
Liam and Lim, 1998129 Included children with acute asthma
Liljas et al., 1997130 Patients aged >15 years
Lipworth and Clark, 1997131 Healthy volunteers
Lipworth and Clark, 1997132 Abstract only
Lipworth et al., 1998133 Drugs
Löfdahl et al., 1994134 Abstract only
Magnussen, 2000135 Patients aged >15 years
Mahadewsingh et al., 1996136 Adults
Mash et al., 2002137 Patients aged >15 years
Mawhinney et al., 1991138 Patients aged >15 years
Milanowski et al., 1999139 Adult patients, comparing different drug doses
Mitchell and Nagel, 1997140 In-vitro testing of three spacers – not in the criteria
Muittari and Ahonen, 1979141 Patients aged >15 years
Nankani et al., 1990142 Drug, not inhaler device intervention
Nantel and Newhouse, 199938 No comparison device
Nantel et al., 1996143 Device unknown, no drug delivered
Nelson and Loffert, 1994144 Adults
Newman et al., 1991145 Adults
Newman et al., 1982146 Patients had chronic obstructive pulmonary disease
Newman et al., 1989147 Patients aged 21–76 years
Nielsen et al., 1998148 Not comparing devices
O’Gorman et al., 1990106 Drug intervention
O’Reilly et al., 1986149 Adults
aOldaeus et al., 1994150 Drug intervention
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Oliver et al., 1982151 Non-randomised controlled trial, cross-over study
Pedersen and Hansen, 1990152 Abstract only
Pedersen and Hansen, 1995153 Drug intervention
Pedersen and Mortensen, 1990154 Non-asthmatic children
Pedersen, 1983155 Acute asthma
Pedersen, 1992156 Abstract only
Pederson, 1986157 No comparison group
Pederson et al., 1990158 No comparison group
Perruchoud et al., 2000159 Patients aged >15 years
Petrie et al., 1990160 Adults only
Pierart et al., 1999161 In vitro, participants were healthy adult volunteers
Price and Kemp, 1999162 On oral tablet therapy
Quezada et al., 1999163 Comparing effects of different drugs
Quittner et al., 2000164 Patients with cystic fibrosis
Repper et al., 1994165 Drug intervention
Rivlin et al., 1983166 Study of technique
Ruggins et al., 1993167 Patients with acute asthma
Rutten-van Mölken et al., 1992168 Review
aRydman et al., 1999169 Teaching technique
Salat et al., 2000170 Patients aged >15 years
Samaranayake and Perera, 1998171 Acute asthma
Santanello et al., 1999172 Patients aged >15 years
Schecker et al., 1993173 Drug not available in UK
Schlaeppi et al., 1996174 Patients aged >15 years
Seale and Harrison, 1998175 Patients aged >15 years
Shapiro et al., 1998176 Different drug doses
Smith et al., 1998177 Comparing different drugs
Solé et al., 1993178 Acute asthma
Spector, 2000179 Review article on oral therapy
Ståhl et al., 1996180 Drug, not device
Stenius-Aarniala et al., 1993181 Adults
Tal et al., 1996182 No comparison group
Terzano and Mannino, 1996183 In vitro, wrong research question
Thompson et al., 1998184 Patients aged >15 years
Thorsson et al., 1994185 Patients aged >15 years
Tonnel et al., 2000186 Patients aged >15 years
Turgeon et al., 1996187 Training intervention
Turpeinen et al., 1999188 Patients aged <5 years
van Beerendonk et al., 199861 Patients aged >15 years
Vidgren et al., 1988189 Healthy volunteers
Weinstein, 2000190 Discussion article
Wettengel et al., 1998191 Patients aged >15 years
Wildhaber et al., 1996192 In vitro, spacer device – not in the criteria
Wildhaber et al., 1998193 Inappropriate study design
Wildhaber et al., 2000194 No comparison group
Wildhaber et al., 2000195 Patients aged >17 years
Wildhaber, et al., 1996196 Patients aged <4 years
Williams and Richards, 1997197 Comparing different drugs and doses
(400 µg budesonide vs 200 µg fluticasone propionate)
Yuksel and Greenough, 1994199 Patients aged <5 years
Zainudin et al., 1990200 Adults
Zar et al., 1999201 Acute asthma
Zar et al., 1998202 Inappropriate study design
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Foreign language articles – not extracted
Aceves-Vazquez-Guadalupa-De La Luz et al., 1995203
Aguilar and Mallol, 2000204
Carrion et al., 2000206
Chinet, 2000207
Dubus et al., 1997209
Dubus, 2001210
Garcia-Marcos et al., 2001205
Garde Garde and Medina Pomares, 1999211
Rufin et al., 2000212
Sanchez-Jimenez et al., 1998213
Vazquez Cordero et al., 1987208
aZureik and Delacourt, 1999214
aIdentified from industry submissions
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Appendix 6
pMDIs with or without spacer vs pMDIs
with or without spacer, with the
same propellants, delivering bronchodilating
drugs (randomised controlled trials,
physiological and clinical outcomes)
A
p
p
en
d
ix 6
7
8
TABLE 12  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Kerac et al.,
1998
224
T1: MDI
T2: MDI + spacer (Volumatic)
T3: MDI + plastic 1-litre soft-
drink bottle spacer
T4: MDI
Drug: Salbutamol (2 puffs)
T1,T2,T3
Placebo T4
Design: Randomised, double-
blind, placebo-controlled
Jadad = 3
1 site, Calcutta, India.
In: Chronic stable
asthmatic outpatients
Out: None
Power calculation:
No
PP analysis:Assumed
At beginning:
n = 48
At end: n = 48
Age: 43.8
± 3.5
(10–75)
M/F: 25/23
Run-in: Salbutamol 4 mg
+ deriphyllin
(bronchodilator) 100 mg
taken orally t.d.s.,
withheld overnight
Morning baseline PEFR
<80% of predicted for
age and height
FU: Patients attended
on 4 occasions, each 2
weeks apart.All devices
used on each occasion
but only one contained
active drug
Primary: PEFR
measured 15 and 30
minutes after MDI
administration
Mean ± SE baseline PEFR, 156.9 ± 8.4. No significant
differences among the 4 groups (p > 0.1)
Significant % improvement in PEFR over baseline in
T2 and T3 compared with T4, 30 minutes after
inhalation, and in T2 vs T4 at 15 minutes after
inhalation (both p < 0.05)
No differences between T1 and T4
Mostly adult patients
Plastic bottle spacer
was as effective as
commercial spacer
Green and
Price, 1991
225
T1: MDI + spacer (Volumatic)
and placebo via MDI
T2: MDI and placebo via MDI
+ spacer
T3: Placebo via both devices
Drug: Salbutamol, 200 µg
Design: Randomised, single-
blind (patient), placebo-
controlled
Jadad = 1
1 site, London, UK
In:Asymptomatic at the
time of study, proficient
in FEV
1
manoeuvres
Power calculation:
No
PP analysis:Assumed
At beginning:
n = 10
At end: n = 10
Age: 11 (8–14)
M/F: Not
stated
Run-in: Stopped
medication 24 h before
study
FU: 3 occasions, 2–7
days apart and within 14
days
Primary: Baseline FEV
1
,
FEV
1
after 15 minutes,
FEV
1
after a further 15
minutes
No significant difference in baseline FEV
1
for the
study days (p > 0.05)
From baseline to 15 minutes, standardised FEV
1
rose
significantly in T1 (mean +8.1%, 95% CI ±4.2%,
p = 0.0005) and T2 (mean +5.9%, 95% CI ±1.8%,
p = 0.0005) vs T3 (mean +0.25%, 95% CI ±2.5%,
paired t-test)
No significant
difference in
bronchodilation
between MDI +
spacer and MDI
Retrospective power
calculation,
75 patients needed
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TABLE 12 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Lee and Evans,
1987
229
T1: MDI
T2: MDI + spacer
(InspirEase
®
)
T3: MDI + spacer
(AeroChamber)
T4: MDI + spacer
(aerosol bag)
Drug:Albuterol, 2 puffs,
180 µg
All operations were assisted
by the examiner to ensure
correct use of aids
Design: Randomised, double-
blind, cross-over, placebo
Jadad = 3
1 centre, New York
In: Stable asthma,
correct inhalation
technique from a MDI,
receiving β
2
-agonist
aerosol from MDI
Power calculation:
No
PP analysis:Assumed
At beginning:
n =23
At end: n = 20
Age: 12.5
(8–15)
M/F: Not
stated
Run-in:Taught proper
use of 3 inhalation aids
(InspirEase,
AeroChamber, aerosol
bag) in laboratory
FU: 3 subsequent days
Primary: Pulmonary
function (FEV
1
) correct
MDI technique
14 children had correct inhalation technique while
6 had errors
Incorrect technique: 1 with MDI, 3 with InspirEase,
2 with InspirEase and AeroChamber, 0 for aerosol bag
Overall and for 14 children with correct technique,
no significant differences in FEV
1
% increase from
baseline over 3 h after inhalation in all treatment
groups
For 6 children with incorrect MDI technique,
significant difference (p < 0.05) in FEV
1
% increase
from baseline, over 3 h after inhalation between T2,
T3 and T4 compared with T1
Also, at 15 and 30 minutes only,T2 and T4 > T3 
(p < 0.05)
Side-effects similar for all treatments
No additional benefits
from T2,T3 and T4 
for those with correct
MDI technique,
but benefit of spacer
with incorrect 
MDI technique
AeroChamber
requires slightly
greater skill in its use
than InspirEase and
aerosol bag: the latter
two aids allow re-
breathing of aerosol
while AeroChamber
does not
All aids require some
skill in use; teaching 
is important for
effective use
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Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
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continued
Rachelefsky 
et al., 1986
227
T1: MDI placebo
T2: MDI
T3: MDI + spacer placebo
T4: MDI + spacer
(AeroChamber)
Drug:T2 and T4 broncho-
dilator metaproterenol
sulphate 130 µg, 2 puffs
Design: Randomised, double-
blind, placebo-controlled
Jadad = 2
1 site, USA
In: Moderate asthma,
fulfilled the American
Thoracic Society
criteria for reversible
airway disease
Power calculation:
No
PP analysis:Assumed
At beginning:
n = 16
At end: n = 16
Age: 9 ± 2
(5–12)
M/F: Not
stated
Run-in: Instruction
given on proper closed-
mouth technique at each
visit, including 3-minute
videotape viewing
All bronchodilators were
stopped 12 h before and
long-acting theophylline
24 h before time of
study
FU: 4 separate days
Primary: FEV
1
, FVC,
mid-maximal expiratory
volume (FEF
25–75%
)
before, and 5, 14, 30
minutes and hourly for
6 h after drug
administration
Secondary: Side-effects
No significant difference between T2 and T4 for FEV1
and FEF25–75%
Both T2 and T4 significantly different from placebo
(T1,T3)*
% ± SD increases from baseline after 4
treatments over a 6-h period:
FEV
1
FEF25–75%
Time T2 T4 T2 T4
15 minutes 26 ± 2* 18 ± 12* 56 ± 16* 44 ± 45*
30 minutes 25 ± 10* 20 ± 14* 56 ± 17* 47 ± 54*
1 h 32 ± 12* 20 ± 18* 74 ± 29* 53 ± 63*
2 h 27 ± 9* 23 ± 23* 62 ± 29* 49 ± 74*
3 h 17 ± 7 15 ± 22 37 ± 35* 36 ± 51*
4 h 14 ± 13 6 ± 15 34 ± 29* 29 ± 38*
5 h 9 ± 13 4 ± 21 21 ± 33 9 ± 21
6 h 3 ± 10 1 ± 19 3 ± 21 6 ± 36
No obvious side-effects were noted
The pMDI tube
spacer (Aero-
Chamber) was as
effective as the stan-
dard MDI device in
administering meta-
proterenol to asth-
matic children who,
ideally, have been
taught to use both
correctly
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Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Becker et al.,
1985
226
T1: MDI + spacer (tube 80 ml
10 × 3.2 cm) and placebo via
MDI
T2: MDI and placebo via MDI
+ spacer
T3: Placebo via both devices
Drug:Terbutaline, 250 µg/
actuation, given in a total dose
of 500 µg
Placebo was the CFC
propellant–surfactant mixture
used in the active inhaler
Design: Randomised, double-
blind, placebo-controlled
Jadad = 2
1 hospital, Canada
In:A history of asthma,
documented
reversibility of
obstruction to airflow
previously (increase
FEV
1
>20% after a
bronchodilator aerosol),
FEF
25–75%
<70%
predicted normal
Out: Severe acute
asthma on study day
Power calculation:
No
PP analysis:Assumed
At beginning:
n = 34
T1: 12
T2: 12
T3: 10
At end: n = 34
Age:
T1: 11.7 ± 0.8
T2: 10.2 ± 0.6
T3: 10.5 ± 0.6
M/F: Unknown
Run-in: Stopped oral
medication for 12 h or
inhaled bronchodilator
aerosol for 6 h before
study
Demonstration and
supervision given by
investigator
FU: 3 occasions, 2–7
days apart and within 14
days
Primary: Pulmonary
function
Pulmonary function (mean ± SE % predicted normal
for age, sex and height except for FEV
1
/FVC, which is
an absolute value)
T3 placebo results omitted from this table
Test Pre- Hours 
treatment post-treatment
0.5 1.0 1.5 2.0
FEV
1
T1 78.3 ± 6.1* 93.3 ± 6.6 92.7 ± 6.4 90.8 ± 6.7 89.7 ± 6.2
T2 87.0 ± 6.8 103.3 ± 8.3* 101.8 ± 8.3* 101.3 ± 8.1* 100.4 ± 8.3*
FEV
1
/FVC
T1 66.8 ± 3.4 77.2 ± 3.8 77.3 ± 4.1 76.0 ± 4.0 74.5 ± 3.9
T2 69.5 ± 2.2 78.4 ± 3.1 78.6 ± 3.1 77.8 ± 3.3 75.4 ± 2.8
FEF25–75
T1 38.3 ± 5.5 57.8 ± 8.4 62.1 ± 9.1 60.9 ± 10.4 58.7 ± 9.7
T2 40.6 ± 4.8 63.8 ± 8.1 63.5 ± 8.4 64.4 ± 8.1 63.3 ± 8.1
V
25
T1 60.4 ± 7.4 83.1 ± 9.3 82.5 ± 9.0 85.8 ± 10.2 86.3 ± 8.1
T2 70.8 ± 7.6 92.2 ± 9.3 83.0 ± 9.0 85.8 ± 10.2 79.4 ± 10.2
V
50
T1 41.7 ± 5.0 60.2 ± 8.4 64.2 ± 8.4 63.4 ± 9.0 61.2 ± 10.1
T2 48.7 ± 5.0 71.0 ± 7.7* 68.1 ± 7.8 71.2 ± 8.4 71.5 ± 8.6
V
75
T1 26.0 ± 4.9 41.5 ± 7.6 47.2 ± 8.0 44.0 ± 9.8 43.1 ± 9.0
T2 24.4 ± 4.9 42.3 ± 6.7 43.1 ± 7.6 50.3 ± 9.9 40.8 ± 7.1
*T1 vs T2 p < 0.05
Both MDI + spacer
and pMDI were
equally effective in
improving pulmonary
function from the
baseline state
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TABLE 12 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
T, treatment; PP, per protocol; M, male; F, female; SD, standard deviation; SE, standard error; FU, follow-up; CI, confidence interval;V
25(50)(75)
, flow at 25%(50%)(75%) of vital capacity; mean max
5–60
, mean maximum value
during 5–60 minutes
Hidinger and
Kjellman,
1984
228
T1: pMDI
T2: pMDI + spacer (750 ml
collapsible spacer)
Drug:Terbutaline sulphate, 1
puff, 0.24 mg
Design: Randomised, open,
cross-over
Jadad = 1
1 paediatric outpatient
department, Sweden
In: Bronchial asthma.All
children were regular
users of β
2
-receptor
agonists
All children had used
pMDI prior to study
Out: Not stated
Power calculation:
No
PP analysis
At beginning:
n = 18
At end: n = 18
Age: 8.0
(4.9–13.7)
M/F: 12/6
Run in: β2-agonists
withheld ≤10 h prior to
study; theophyllines also
excluded for >24 h
Tea/coffee not allowed
on the morning of study
FU: 2 days, 2–14 days
apart
Primary: PEFR at 0, 5,
20 and 60 minutes after
inhalation of the aerosol
5 minutes after inhalation there was a significant
increase over basal values in PEFR for T1 and T2 
(p < 0.001) and the response persisted throughout
the observation period (60 minutes)
Mean PEFR for T2 was significantly greater vs T1 at 5,
20 and 60 minutes after administering the aerosol 
(p < 0.05)
Mean max
5–60
for T2 was significantly greater vs T1
(p < 0.01)
PEFR (mean ± SD) l/min:
Minutes after T1 T2 p-value
inhalation
0 182 ± 69.4 194 ± 71.5 Not sig.
5 216 ± 64.0 232 ± 68.7 <0.05
20 217 ± 68.4 234 ± 69.5 <0.05
60 219 ± 65.2 235 ± 62.5 <0.05
Mean max
5–60
227 ± 65.5 243 ± 64.9 <0.01
There were no differences in effects related to age
The use of a spacer
attached to the usual
actuator improved
efficacy when patients
inhaled 1 puff of
terbutaline sulphate
Ellul-Micallef,
1980
230
T1: pMDI
T2: pMDI + spacer (750 ml
collapsible spacer)
Drug:Terbutaline sulphate,
1 puff, 0.25 mg
Design: Randomised, cross-
over
Jadad = 1
1 site, Sweden
In: Moderate bronchial
asthma
Out: Not stated
Power calculation:
No
PP analysis
At beginning:
n = 12
Age: 7–11
M/F: 8/4
Run in: On 1st and 2nd
visits, patients famil-
iarised themselves 
with a peak flow meter
FU: 4 separate
occasions at
approximately weekly
intervals
Primary: PEFR at 0, 5,
20 and 60 minutes after
inhalation of the aerosol
PEFR was 181 ± 6 l/min (mean ± SE) for T1 vs T2
206 ± 6 l/min
The values obtained when the spacer was attached
were significantly greater when measured at 20
minutes (p < 0.001) and 60 minutes (p < 0.01) after
therapy but not at 5 minutes
Adding the spacer to
a pMDI resulted in
significantly better
pulmonary function
Health Technology Assessment 2002; Vol. 6: No. 5
83
Appendix 7
pMDIs with or without spacer vs DPIs,
delivering bronchodilating drugs (randomised
controlled trials, physiological and 
clinical outcomes)
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TABLE 13  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
continued
Kemp et al.,
1989
216
Design: 2 separate studies reported:
(a) randomised double-blind double-
dummy cross-over study using 2 doses:
100 and 200 µg on separate days
(b) a parallel run study using 
200 µg q.d.s. for 12 weeks
Used computer-coded treatment
Device: Rotahaler vs pMDI alone
Drug: Salbutamol
Dose:
(a) 90–100 and 180–200 µg
(b) 180–200 µg
Duration:
(a) 360 minutes
(b) 12 weeks
Participants:
(a) 30 children, mean age 9.4 yr; lung
function measured from 5 to 360 minutes
post-dose
(b) 204 (164 F) children, age range 4–11 yr,
mean age 8.2 yr; lung function measured
from 5 to 480 minutes post-dose
Study quality:
(a) Cochrane-A
(b) Cochrane-A
(a) No significant differences in: FEV
1
,
HR or BP
(b) No significant differences in: FEV
1
,
FEF
25–75%
, FVC, PEFR, drop-out rate or
symptom scores
(b) Significant difference in: No. acute
exacerbations (requiring intervention): 26
(25%) in pMDI group vs 13 (13%) in
Rotahaler group (p < 0.05)
Analyses of baseline mean FEV
1
(using
unpaired two-tailed t-test) showed that the
pMDI group had significantly lower FEV1 when
compared with the Rotahaler group
This may explain the higher rate of acute
exacerbations seen in the pMDI group
Bronsky et al.,
1995
217
Design: Randomised double-blind
double-dummy cross-over study using
Latin-square treatment schedule
Exercise challenge used
Device: Rotahaler vs pMDI alone
Drug: Salbutamol
Dose: pMDI 180 µg vs Rotahaler 200 µg
Duration: 51 minutes
Participants: 44 children, age range 4–11 yr,
mean age 8 yr
Pulmonary function test performed up to 51
minutes after taking the drug and running on
a treadmill for 6 minutes at predetermined
target rates (85% of HR
max
)
Study also reported 15-minute post-dose
FEV
1
(i.e. pre-exercise)
Study quality: Cochrane-B
No significant differences in:
Pre- and post-exercise FEV
1
after drug
administration
Study used exercise challenge to show that
the two devices are equally effective against
EIA
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TABLE 13 contd  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
continued
Ahlström et al.,
1989
218
Design: Open randomised cross-over
study
Device:Turbuhaler® vs MDI +
Nebuhaler
Drug:Terbutaline
Dose: 0.5 mg q.d.s. (both devices)
Duration: 14 days
Participants: 21 children (7 F), age range
2–5 yr, mean age 3.9 yr
PEFR measured 15 minutes after drug
administration
Study quality: Cochrane-B
No significant differences in: Day or
night symptom scores, day or night side-
effects or additional use of beta-2
medication
Significant difference in: Morning PEFR
favouring Turbuhaler over pMDI +
Nebuhaler (p = 0.046)
PEFR result to be treated with caution as
evening baseline PEFR was significantly 
(p = 0.03) higher in the Turbuhaler group
Fuglsang and
Pedersen,
1989
219
Design: Single-blinded double-dummy,
cross-over study
Used computer-generated schedule
Device:Turbuhaler vs pMDI alone
Drug:Terbutaline
Dose: 2.0 mg (both devices)
Duration: Cumulative dosing study,
giving a total dose of 2.0 mg within 
80 minutes
Participants: 13 children (3 F), age range
7–15 yr, mean age 10.5 yr
Pulmonary function testing at 15 minutes
post-dose
Study quality: Cochrane-B
No significant differences in: FEV
1
,
FEF
25–75%
, PEFR or FVC
Significant differences in: HR when
using pMDI but not with Turbuhaler
More children complained of tremor in
the pMDI (7) group than in the
Turbuhaler group (0)
Hultquist et al.,
1989220
Design: Randomised double-blind
double-dummy cross-over study
Device:Turbuhaler vs pMDI alone
Drug:Terbutaline
Dose: 0.5 mg + p.r.n. (both devices)
Duration: 2 weeks
Participants: 57 children, age range 6–18 yr,
mean age 11 yr; PEFR was measured 10
minutes post-dose
Study quality: Cochrane-B
No significant differences in: PEFR
(morning and evening) and symptom
scores
Significant differences in: Preference
for device; more children preferred the
Turbuhaler (49%) than the pMDI (23%)
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TABLE 13 contd  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
continued
Laberge et al.,
1994
221
Design: Randomised double-blind
double-dummy cross-over study
Used random numbers
Device:Turbuhaler vs pMDI +
Nebuhaler
Drug:Terbutaline
Dose: Cumulative dosing study, giving a
total dose of 2.0 mg within 80 minutes,
then followed by nebulised salbutamol 
5 mg
Participants: 10 children, age range 3–6 yr,
mean age 4.6 yr
Lung function measured 15 minutes after
each dose of medication
Study quality: Cochrane-A
No significant differences in: HR, BP,
tremor or airway resistance
Svenonius et al.,
1994
222
Design: Randomised double-blind
double-dummy cross-over study
Exercise challenge used
Device:Turbuhaler vs pMDI alone
Drug:Terbutaline
Dose: 1 mg (both devices)
Duration: 15 minutes
Participants: 12 children (2 F), age range
9–17 yr, mean age 13.8 yr
Lung function measured before exercise then
given the drug and measured again up to 15
minutes post-dose to observe reversibility of
EIA
Study quality: Cochrane-B
No significant differences in: FEV
1
and
VTG
Hirsch et al.,
1997
117
Design: Randomised double-blind
double-dummy parallel study
Used drawing lots
Device:Turbuhaler vs pMDI alone
Drug:Terbutaline
Dose: 0.5 mg (both devices)
Duration: 10 minutes
Participants: 118 children, age range 
8–15 yr, mean age 11.3 yr
Pulmonary function testing done during 10
minutes post-dose
Study quality: Cochrane-A
No significant differences in: Change
from baseline FEV
1
and FVC
Significant differences in:V
50
favouring
pMDI
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TABLE 13 contd  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
HR, heart rate; EIA, exercise-induced asthma; BP, blood pressure;VTG, volume of trapped gas (a measure of small airways obstruction)
Razzouk et al.,
1999
223
Design: Randomised double-blind
double-dummy cross-over study
Device:Turbuhaler vs pMDI alone
Drug: Salbutamol
Dose: 100 µg (both devices)
Duration: 240 minutes
Participants: 40 children (9 F), age range
6–12 yr, mean age 9 yr
Pulmonary function testing performed from
15 to 240 minutes post-dose
Study quality: Cochrane-B
No significant differences in:
Geometric means of FEV
1
and FEV
1max
Study also used Turbuhaler 50 µg vs
Turbuhaler 100 µg and pMDI 100 µg,
showing no significant differences
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TABLE 14  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Koskela et al.,
2000
232
T1: DPI (Easyhaler
®
)
(Buventol® Easyhaler
®
)
T2: pMDI + spacer
(Volumatic)
T3: Easyhaler
T4: pMDI + spacer
Drug: Salbutamol 100 µg T1,
T2
Placebo T3,T4
Design: Randomised, cross-
over, double-blind, double-
dummy
Jadad = 2
1 hospital, Finland
In: Mild to moderate
asthma, 7–65 yr old, no
smoking during 6
months to study;
4 weeks to study FEV
1
or PEF ≥15%
Power calculation:
Yes, 90%, p = 0.05
Analysis: ITT and PP
At beginning:
n = 22
At end: n = 21
Age: 19 (7–65)
<16 yr: n = 12
M/F: 10/12
Run in:Abstained from
controlled-release
theophylline preparation
≥48 h, and from oral 
and inhaled long-acting
sympathomimetics ≥6 h
No caffeine-containing
drinks 4 h before lung
function tests
Correct inhalation
technique taught
FU: 2 study days –
interval ≥24 h
Primary: FEV
1max
Secondary:AUC FEV
1
before and at 15, 30 and
60 minutes; FEV
1max
as %
of predicted value at
baseline (during the first
study day); FVCmax;
PEFmax
No significant differences in primary or secondary
efficacy variables between T1 and T2
Mean (SD) ITT analysis:
T1 T2
Baseline 60 minutes Baseline 60 minutes
FEV1max(l) 2.44 (0.9) 2.69 (0.93) 2.43 (0.9) 2.67 (0.97)
FEV1 80.9 (10.9) 89.5 (10.7) 80 (12.3) 88 (11.7)
predicted (%)
AUC FEV1 – 10.2 (9.1) – 10.1 (9.0)
(l/min)
FVC (l) 3.26 (1.17) 3.35 (1.19) 3.25 (1.17) 3.31 (1.18)
No correlation with age, or PIFR and relative
treatment effect of the 2 devices
Even a PIFR as low as 23 l/min via Easyhaler was
sufficient to obtain a similar treatment effect to
normal inhalation from a pMDI + spacer
No adverse effects
A reasonably low
inspiratory flow rate
(30 l/min) via
Easyhaler produced
an equivalent
improvement in lung
function to a
correctly used pMDI
+ spacer
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TABLE 14 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Ahrens et al.,
1999
231
T1,T2: DPI (Spiros
®
)
T3,T4: MDI
Drug:
T1,T2 albuterol sulphate 
(108 µg = 90 µg of albuterol
base/actuation);T1 1,
T2 3 actuations
T3,T4 Ventolin (90 µg
albuterol base/actuation);
T3 1,T4 3 actuations
Design: Randomised, double-
blind, cross-over, double-
dummy
Jadad = 3
USA
In: Mild to moderate
asthma; age ≥12 years;
FEV1 ≥65% and PD20
≤4 mg/ml; PD20 to
increase 8-fold after 
2 actuations of Ventolin
At subsequent visits,
FEV1 ≥65% and PD20 to
be within 2-fold of
screening value
Non-smokers
Out: Used ≥ an average
of 1 β2-agonist
inhaler/month,
respiratory tract
infection within last 30
days, oral corticosteroid
within last 3 months of
screening, history of
life-threatening asthma,
other significant illness,
clinically significant
respiratory disorders,
current/ex smokers,
seasonal allergic asthma,
use of other named
medication within
specific time-frame of
visit 1 (ICS, oral or
parenteral steroid,
theophylline,
ipratropium bromide,
At beginning:
n = 31
At end: n = 24
Age: 26.2
(12–46)
M/F: 15/9
FU: 4 study days
Primary: PD20
measured by
methacholine challenge
Secondary:Adverse
events
No significant differences in PD20 FEV1
dose–response curves between all treatments
Adverse events profiles were similar for the two
inhalers
4 aged ≤15 yr 
(3 = 13 yr; 1 = 12 yr)
In this patient group,
the dose delivered by
Spiros DPI was
comparable with that
delivered by Ventolin
MDI 
Each actuation of
Spiros = 1.12
actuations of Ventolin
in the delivery of
albuterol (90% CI
0.68 to 1.94)
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TABLE 14 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
continued
Ahrens et al.,
1999
231
oral or nebulised β2-
agonists, salmeterol,
nedocromil sodium)
Power calculation: No
Analysis:
PP for efficacy
ITT for safety analysis
Nelson et al.,
1999
233
T1: DPI (Spiros) + pMDI
placebo
T2: pMDI + DPI (Spiros)
placebo
T3: DPI (Spiros) + MDI
Drug:Albuterol sulphate,
T1 (108 µg/actuation = 
90 µg/actuation)
Albuterol, T2 (90 µg/
actuation)
2 actuations q.d.s. for each
inhaler
T3, lactose placebo
Design: Randomised, double-
blind, double-dummy, placebo-
controlled 3-way-parallel
group, Phase III
Jadad = 3
20 centres, USA
In: Non-smokers, mild
to moderate asthma,
age ≥12 years, minimum
1 yr of asthma
documentation, healthy
(medical history,
physical examination,
12-lead ECG, clinical
laboratory test), no
hospital admission
within 4 weeks prior to
study, FEV1 40–80%
predicted normal on
restricted asthma
medication, FEV1 ≥12%
30 minutes after 
2 inhalations from
albuterol MDI
Out: Administration of
oral steroid
Power calculation:
No
PP analysis:Assumed
At beginning:
n = 283
T1: 97
T2: 92
T3: 94
At end:
n = 238
T1: 81
T2: 80 (79 AUC
above baseline)
T3: 77 (76 AUC
above baseline)
Age:
T1: 34.2 (±13.4)
T2: 34.6 (±15.4)
T3: 32.4 (±14.2)
M/F:
T1: 37/60
T2: 47/45
T3: 42/52
Run-in: 7–14 days,
instruction and training
to use and record PEF
on diary card
Training with Spiros
inhalation system and
MDI
FU: 12 weeks
Primary: FEV1max;AUC
FEV1 above baseline
Secondary: Rescue
albuterol use; episodes
of exacerbation; daily
PEF; nocturnal asthma
symptom scores from
self-recorded diary cards
The Spiros and MDI groups were comparable in all
FEV1 parameters and superior over the placebo
group (p = 0.0001)
With exception of treatment week 0 for the maximum
% change in FEV1, the duration of effect and the AUC
above baseline, no statistically significant differences
between T1 and T2 for any FEV1 parameters
Week 0, mean change:
T1 T2
Baseline FEV1 (%) 37.71 31.29
AUC above baseline (l/min) 141.50 181.73
Duration of effect (minutes) 192.0 162.7
Week 12, mean change, p = 0.0001:
T1 T2
Baseline FEV1 (%) 30 29
AUC above baseline (l/min) 126.29 126.85
Duration of effect (minutes) 150 144
Statistically significant differences for a.m. and p.m.
PEF values among all groups but they were small and
not considered to be clinically important
No statistically significant differences among groups
for asthma exacerbation, daily use of rescue albuterol
or asthma symptom scores
No difference in
clinical benefit for
Spiros DPI and
albuterol MDI with
same medication and
same dose
5 withdrawals for
treatment-related
adverse effects (T1 3,
T2 1,T3 1); the
incidence pattern is
consistent with that
expected in a
generally healthy
asthmatic population
over a period of time
Asthma exacerbation
due to change in
medication:T1 6,T2 4,
T3 7
H
ea
lth
 Tech
n
ology A
ssessm
en
t 2
0
0
2
;V
o
l.6
:N
o
.5
9
1
TABLE 14 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Wolfe et al.,
2000
234
T1: DPI (Diskus®) + MDI
placebo
T2: MDI + DPI (Diskus)
placebo
T3: DPI (Diskus) + MDI
Drug: Salmeterol
T1: 50 µg, twice daily
T2: 42 µg, twice daily
T3: Placebo
Design: Randomised,
multicentre, double-blind,
double-dummy, placebo-
controlled parallel group
Jadad = 3
27 centres, USA
In:
Screening:Age ≥12
years; ≥6-month history
of mild to moderate
asthma that required
pharmacotherapy;
baseline FEV1 50–85%
predicted normal value
after abstaining from
asthma medications,
≥15% reversibility of
airway obstruction
within 30 minutes after
2 actuations of albuterol
aerosol (180 µg)
Treatment day 1:
About 2 weeks after
screening visit,
reproducible lung
function within 15% of
the best screening visit
pre-albuterol FEV1 and
within 50–85% of the
predicted normal value
Patients with stable
regimen of inhaled or
intranasal
corticosteroids,
cromolyn (sodium
cromoglicate) or
nedocromil started at
least 1 month before
screening and regimen
At beginning:
n = 498
T1: 165
T2: 166
T3: 167
At end:
n = 395
T1: 134
T2: 139
T3: 122
Age:
T1: 33 (12–74)
T2: 35 (12–79)
T3: 34 (12–74)
M/F:
T1: 79/86
T2: 78/88
T3: 78/89
Ethnic:
White/Black/
Hispanic/other:
T1: 131/18/15/1
T2: 135/12/18/1
T3: 128/19/19/1
Baseline period:
2-week period
All patients received
both a Diskus and a MDI
device
Instruction given on use
Supplement aerosol MDI
given to all patients
FU: 12 weeks
Primary: 12-h serial
measurements at day 1,
and weeks 4 and 12, of
FEV1, PEF, self-rated
asthma symptom scores,
night-time awakenings
and supplemental
albuterol use
Secondary:Adverse
events
No significant differences between T1 and T2 in
improvement in pulmonary function
Compared with T3 placebo, significant decreases
demonstrated in T1 and T2 in albuterol use, night-
time awakenings and increases in % days with no
asthma symptoms for the entire study period
Mean change from week 1 to week 12 (±SE):
T1 T2 T3
FEV1(%) 23 22 9
PEF a.m. (l/min) 17–31 22–30 7–17
Albuterol use –2.1 ± 0.2 –1.9 ± 0.2 –0.7 ± 0.2
(puffs/day)
Nights without 12 ± 2 16 ± 2 4 ± 2
awakenings (%)
Symptom scores –0.4 ± 0.1 –0.4 ± 0.1 –0.2 ± 0.1
(no.)
No significant differences in adverse events related to
study drug among the groups. (T1 11 (7%),T2 9 (5%),
T3 6 (4%))
No difference shown
in clinical benefit for
Diskus vs. MDI with
same dose and drug
No differences
between gender,
ethnicity, or patients
with ICS vs those
without
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TABLE 14 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
ITT, intention-to-treat; AUC, area under the curve; PIFR, peak inspiratory flow rate; PD20, 20% decrease in FEV1; ICS, inhaled corticosteroids
continued
Wolfe et al.,
2000
234
constant throughout
study
Out: Upper or lower
respiratory tract or
middle ear infections
within 6 weeks of study
entry; evidence of
pulmonary abnormal-
ities unrelated to
asthma; > a 10-pack
year history of smoking;
smoking within 1 yr
prior to study entry;
exposure to secondary
tobacco smoke (≥4
h/day); and presenting
clinically significant
concurrent disease
Power calculation:
Yes, 90% power,
p < 0.05
Analysis: ITT
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Appendix 8
DPIs vs DPIs, delivering bronchodilating
drugs (randomised controlled trials,
physiological and clinical outcomes)
A
p
p
en
d
ix 8
9
4
TABLE 15  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Dal Col et al.,
1995
237
T1: DPI (Pulvinal, multidose)
T2: DPI (Rotahaler, single
dose)
T3: Placebo via Pulvinal
T4: Placebo via Rotahaler
Drug: Salbutamol powder,
single dose, 200 µg
Design: Randomised, cross-
over
Jadad = 1
1 site, USA
In: Stable asthma
At screening visit: FEV
1
and PEFR >75%
predicted normal;
history of EIA and
reversible airway
obstruction
On day 1 of study, with
no treatment, patients
had to have ≥15% max
fall in FEV
1
vs baseline
values to continue trial
Out: In case of possible
exposure to sensitising
agents during the
course of the study:
acute attacks of asthma
in prior 2 months;
presence of concomi-
tant disease, or of
cardiac, hepatic, renal 
or endocrine disorders;
use of oral steroids
during previous 2
months; and impos-
sibility of discontinuing
concomitant treatments
24 h before testing
Power calculation:
No
PP analysis
At beginning:
n = 13
Age: 10.9
(8–12)
M/F: 9/4
Run in: Standard
exercise performed at
the same time on each
trial day – 6 minutes on
a treadmill with a 10°
slope
Use of sodium
cromoglicate,
nedocromil sodium,
bronchodilators and
antihistamines stopped
for ≥24h before each
test
Inhaled steroid use
permitted, but dose to
remain constant
throughout study
Instructions on inhaler
use with drawings to
illustrate correct
inhalation technique
FU: 4 consecutive days,
15 minutes before stan-
dardised exercise test
Primary: FEV
1
and
PEFR before and
between treatment and
exercise challenge test,
and after exercise
challenge test; ease of
use and correct handling
technique
No significant difference between T1 and T2 
(p ≥ 0.05)
Investigator’s opinion on ease of use for T1 was
excellent for 10 patients and good for the other 3
Opinion for T2 was excellent for 3 patients, good for
8 and fair for 2
No patient reported a verdict of “poor” for ease of
use for either T1 or T2
11 patients preferred T1; 1 patient preferred T2; 2
patients had no preference (data as presented 
by authors)
No adverse events reported throughout study
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TABLE 15 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Bronsky et al.,
1999
235
T1: DPI (Diskus)
T2: DPI (Diskhaler)
T3: DPI (Diskhaler)
Drug:T1,T2 salmeterol 50 µg
T3 placebo
Design: Randomised, double-
blind, double-dummy, placebo-
controlled, single-dose, three-
way cross-over
Jadad = 3
2 sites
In: Mild to moderate asth-
ma; presence of EIA; aged
4–11 yr; FEV
1
≥70% pre-
dicted; asthma triggers other
than exercise (cold, air,
allergens, tobacco smoke)
Out: Received any short-
acting β
2
-agonists at ≤8 h of
screening visit, oral short-
acting β
2
-agonists at ≤12 h,
oral extended-release β
2
-
agonists or inhaled long-
acting β
2
-agonists at ≤24 h;
or required β
2
-agonists
other than study drug and
supplemental albuterol
during trial
Upper/lower respiratory
tract/middle ear infections
at ≤6 weeks of study entry;
clinically significant concur-
rent disease; abnormalities
in complete blood count,
or renal or hepatic profiles;
abnormal 12-lead ECG;
pulmonary abnormalities
unrelated to asthma; or
secondary exposure to
tobacco for ≥8 h/day
Power calculation: No
Analysis: ITT
At beginning:
n = 24
At end: n = 24
Age: 9 (±2.1)
M/F: 14/10
Ethnicity:
White/Black
22/2
FU: 3 treatment visits
+ post-treatment FU
visit, 2–14 days apart
Primary: Serial FEV
1
at 1, 6, and 12 h after
study drug
administration
Secondary:Adverse
events
No significant differences found between T1 and T2
in mean % predicted FEV
1
after EIB at 1, 6 and 12 h
No difference in the magnitude of bronchoprotection
provided by salmeterol from the two devices
Mean % predicted FEV
1
:
T1 T2 T3
Baseline (1 h 85.2 85.2 83.2
pre-exercise)
Mean % predicted FEV
1
fall after exercise challenge at:
1 h 1.4 ± 2.6 0.0 ± 3.0 10.5 ± 2.6
(p = 0.002 vs T3) (p < 0.001 vs T3)
6 h 5.4 ± 1.4 5.7 ± 1.3 11.1 ± 2.0
(p = 0.03 vs T3) (p = 0.07 vs T3)
12 h 5.6 ± 2.1 4.0 ± 1.3 12.1 ± 3.2
(p < 0.02 vs T3) (p = 0.01 vs T3)
3 adverse events but not study drug related
Salmeterol powder
delivered via Diskus
and Diskhaler gave
equivalent and long-
lasting broncho-
protection against 
EIB in children
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TABLE 15 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
EIB, exercise-induced bronchoconstriction
Boulet et al.,
1995
236
T1: Diskus + placebo via
Diskhaler
T2: Diskhaler + placebo via
Diskus
Drug: Salmeterol, 50 µg b.d.
Design: Randomised, double-
blind, double-dummy, parallel-
group, multicentre
Jadad = 3
16 sites, USA
In:Age ≥12 yr; FEV
1
between 60% and 90%
predicted normal;
receiving adequate anti-
inflammatory and
inhaled β
2
-agonist
Last 7 days of baseline
period: mean morning
PEFR 60–80% 15
minutes after inhalation
of 800 µg albuterol
No methylxanthines,
anti-cholinergics,
oral/parenteral
corticosteroids/other
routine β
2
-agonist
during study
Power calculation:
99%, 150/group
PP analysis:Assumed
At beginning:
n = 463
At end: n = 380
T1: 190
T2: 190
Age:
T1: 39 (12–70)
T2: 39 (12–69)
M/F:
T1: 77/113
T2: 78/112
Run-in: 2 weeks;
instruction leaflet and
taught by physician on
the use of study devices
FU: 4 weeks;
questionnaires
completed on 4 visits
(screening visit, after
run-in period, 6th and
12th weeks of study)
Primary: Self-filled daily
record of a.m. and p.m.
PEFR, a.m. and p.m.
asthma symptom scores,
and use of albuterol
Clinic-recorded
pulmonary function tests
and adverse effects
Increase in mean a.m. PEFR during treatment,T1 = T2
No significant differences observed for p.m. PEFR,
a.m. and p.m. symptoms, and albuterol back-up use
No unexpected adverse events
Majority aged >15 yr
Diskus and Diskhaler,
both with salmeterol,
produced similar
clinical effects
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Appendix 9
pMDIs with or without spacer vs pMDIs 
with or without spacer, with the same 
propellants, delivering corticosteroids 
(randomised controlled trials, physiological 
and clinical outcomes)
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TABLE 16  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Janssens et al.,
1999
241
T1: pMDI + spacer
(NebuChamber
®
), metal, 250
ml, no facemask
T2: pMDI + spacer
(Volumatic) polycarbonate,
750 ml + plastic connector to
fit pMDI
Drug: Budesonide 200 µg b.d.
(Pulmicort)
Filter between mouth and
spacer
Design: Randomised cross-
over
Jadad = 2
1 hospital,Australia
In: Stable asthma; no
exacerbation requiring
oral corticosteroids or
change in medication 
in last 1 month; age 
1–8 yr; no other lung
function related
disorder
Power calculation:
No
PP analysis:Assumed
At beginning:
Not stated
At end:
n = 16
Age: 83
months
(65–104)
M/F: 12/4
All used
pMDI/spacer >6
months: Breath-
a-Tech
®
3,
Volumatic 12,
Turbuhaler 1
Run-in: 1 weeks’
instruction and practice
with spacer and pMDI
FU: 2 weeks – 1 week
with each spacer + new
filters for every use
Primary: Filter dose
(budesonide deposited
on filter) as % of
nominal dose
Secondary:Asthma
symptom scores (from
diary)
Filter doses higher in T1 vs T2 (p < 0.0001)
Mean ±SD in % of nominal dose:
T1: 50.3 ± 9.2
T2: 19.4 ± 7.2
Children with higher filter doses for T1 also had 
higher filter doses for T2 (r = 0.79, p = 0.0003)
No correlation between filter dose and sample
number for T1 or T2
Within-patient variation was smaller for T1 than T2 
(p = 0.003), but children with higher variation in T1
also had higher variation in T2 (r = 0.7, p = 0.028)
No change with age.
Mean ±SD within-patient variation in % of nominal dose:
T1: 23.1 ± 9.1
T2: 34.0 ± 6.5
No difference in mean asthma scores for T1 vs T2
(0.4% not cooperative)
Some mistakes in use, no analysis by treatment
Split into 2 age
groups: 1–4, 5–8 yr
Results for second
group only included in
this table
Within-patient
variation considerable
and not spacer or age
dependent, but actual
doses delivered to
mouth higher with
metal spacer
Health Technology Assessment 2002; Vol. 6: No. 5
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Appendix 10
pMDIs with or without spacer vs DPIs,
delivering corticosteroids (randomised 
controlled trials, physiological and 
clinical outcomes)
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TABLE 17  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
Adler et al.,
1997
238
Design: Parallel, double-blind, double-dummy
RCT
Device: pMDI + Volumatic vs Clickhaler
Drug: Beclometasone
Dose: Up to 400 µg/day
Duration: 4 weeks
Participants: 144 asthmatic children, mean
age 10.9 yr, range 6–17
Study quality: Cochrane-B
No significant differences in: Change in
morning PEFR
Other outcomes unspecified and reported
as non-significant without details
Published in abstract form only
Agertoft and
Pedersen,
1993
239
Design: Parallel, open RCT
Device : pMDI + Nebuhaler vs Turbuhaler
Drug : Budesonide
Dose : pMDI + Nebuhaler: run-in dose
Turbuhaler: half of run-in dose
Duration : 9 weeks
Participants: 126 asthma patients, 87 M, 39
F, mean age 9.2 yr, range 4–15
241 children screened by halving their
steroid dosage
126 whose asthma control deteriorated
went forward to randomisation
Study quality: Cochrane-B
No significant differences in:
Clinic:
Change from baseline of: FEV
1
, FVC,
FEF
25–75%
, and % falls in FEV
1
, FVC, FEF
25–75%
and PEFR in response to exercise; 24-h
urinary cortisol
Home diary cards:
PEFR (a.m. and p.m.); day and night
symptom score
Statistical difference in: Relief
medication use, puffs/week
This study supports equivalence of pMDI
+ Nebuhaler vs Turbuhaler at half the
pMDI dose; this should not be taken to
mean that the device is twice as effective
There was no difference in 24-h urinary
cortisol between the groups, implying a
similar delivered dose of medication
Relief medication usage was statistically
different between groups but the effect
was small (less than 1 extra puff/week)
Ranked ahead of Edmunds, 1979 (below),
owing to much larger study size
Edmunds et al.,
1979
240
Design: Cross-over RCT, double-blind,
double-dummy
Device: pMDI vs Rotahaler
Drug: Beclometasone
Dose: 2 puffs q.d.s. vs 1 capsule q.d.s.
(presumed each 200 µg q.d.s.)
Duration: 2 × 1 month
Participants: 14 asthma patients, 7 M, 7 F,
mean age 9.7 yr, range 4.8–15.1
Study quality: Cochrane-A
No significant differences in: PEFR (a.m.
and p.m.), symptom-free days and relief
salbutamol use
Significant difference in: Mean symptom
scores in favour of pMDI (p = 0.04)
8 patients preferred aerosol, 2 preferred
Rotahaler
Poorly presented study with no statistical
results given (author states “no
significance”)
Rotahaler (Rotacaps) is an unusual device
to use now and would normally be
considered to need twice the pMDI
dosage
This study is presumed to be 1:1 dosing
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TABLE 18  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Agertoft et al.,
1999
242
T1: DPI (Turbuhaler)
T2: pMDI + spacer
(Nebuhaler, 750 ml)
Drug: Budesonide 200 µg
Design: Randomised, cross-
over, controlled
Filter between inhaler system
and lips to collect drug as
inhaled
Jadad = 2
1 outpatient clinic,
Denmark
In:Asthma requiring
continuous treatment
with ICS; age 3–15 yr;
no diseases that might
influence the ability to
inhale normally
Power calculation:
No
PP analysis:Assumed
At beginning:
Not stated
At end:
n = 198
Age: 9 (3–15)
M/F: 132/66
No. children in
each of the 
13 age groups
ranged from
15 to 24
Run-in: Demonstration
of correct use of pMDI
Nebuhaler and Turbu-
haler given by nurse
Each child given one try
All children received
continuous inhaled
therapy with pMDI
Nebuhaler for several
months before start
All children >5 yr had
experience of using
Turbuhaler for rescue
terbutaline or daily
budesonide treatment
FU: Not stated
Primary: Mean filter
doses
Secondary: PIF, fine-
particle fractions using
in-vitro test
A statistically significant correlation between dose
and age was seen for T1 (r = 0.51, p = 0.001) and 
T2 (r = 0.16, p = 0.03)
Filter dose via T1 = T2 for children aged 4 and 5 yr
In children >5 yr,T1 delivered a significantly higher
dose than T2 (p < 0.03 to p = 0.001)
Children with higher filter doses for T1 also had
higher filter doses for T2 (r = 0.79, p = 0.0003)
Within-patient variation for T1 = T2 for older
children who had experience of using both devices
The estimated inhaled dose of particle size with a
mass medium aerodynamic diameter of ≤5 µm was
higher in T1 than T2 for older children
Results for children
aged 3–4 yr not
included
No explanation of
why older children
had a significantly
higher dose delivered
with Turbuhaler than
with pMDI Nebuhaler
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TABLE 18 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Bateman et al.,
2001
243
T1: pMDI (HFA) and Diskus
placebo
T2: Diskus and pMDI (HFA)
placebo
T3: MDI (CFC) and Diskus
(HFA) placebo
Drug: Salmeterol/fluticasone
propionate 100/200 µg/day
Design: Randomised,
multicentre, double-blind,
double-dummy, parallel-group
Jadad = 3
69 centres, 10 countries
In:Age ≥12 years, mild
to moderate asthma,
reversible airway
obstruction, smoking
history of <10 pack-
years, used ICS (beclo-
metasone dipropionate,
budesonide/flunisolide
400–500 µg/day or
fluticasone propionate
200-250 µg/day) 
≥4 weeks before
entering study
During run-in period:
last 7 days, mean a.m.
PEF 50–85% after
inhaling salbutamol 
400 µg, symptomatic
(i.e. cumulative total
symptom score >8 
and taking salbutamol
≤800 µg/day), FEV
1
>50% predicted normal
Out: Had received a
long-acting/oral β
2
-
agonist ≤2 weeks of
run-in period; changed
asthma medication; had
a lower respiratory
tract infection at 
≤4 weeks of run-in
period; acute asthma
exacerbation requiring
hospitalisation
At beginning:
n = 724 but
497 randomised
T1: 165
T2: 167
T3: 165
At end:
n = 430
T1: 145
T2: 145
T3: 140
PP pop.:
n = 383
T1: 128
T2: 131
T3: 124
Age:
T1: 40.7
(11–78)
T2: 38.6
(11–79)
T3: 39.5
(12–76)
M/F:
T1: 73/92
T2: 79/88
T3: 67/98
Run-in: 2 weeks;
continued with usual 
ICS therapy and sympto-
matic relief with
salbutamol (Ventolin)
At end, discontinued
current ICS therapy
FU: 12 weeks treatment
+ 2 weeks FU
Primary: Mean a.m. PEF
over weeks 1–12
Secondary: p.m. PEF;
a.m. and p.m. symptom
scores; back-up
salbutamol use; clinic
FEV
1
No significant differences between T1 and T2
Improvements were similar in all variables: lung
function (a.m. and p.m. PEF), clinic FEV
1
, symptom
scores, use of rescue salbutamol, adverse events
T1 T2
During the 12-week period, 42 43
a.m. PEF increase (l/min)
Adjusted mean a.m. PEF 43 46
increase from baseline (l/min)
Mean p.m. PEF (l/min) 38 35
Clinic FEV
1
, increase from 17 15
baseline at week 12 (%)
Clinic FEV
1
, adjusted mean 10 10
change from baseline weeks 
1–12 (% predicted)
No. symptom-free a.m., 55 52
weeks 1–12, medium 
proportions (%)
No. symptom-free p.m., 71 78
weeks 1–12, medium 
proportions (%)
No. back-up salbutamol-free 73 75
a.m., weeks 1–12, medium 
proportions.(%)
No. back-up salbutamol-free 90 93
p.m., weeks 1–12, medium 
proportions (%)
Adverse event, no. patients (%) 82(50) 95(57)
Likely that majority of
patients aged >15 yrs
Included only data
comparing MDI (T1)
and Diskus (T2)
Patients were allowed
the use of a spacer 
(T1 24,T2 22,T3 26)
Comparable clinical
efficacy for HFA MDI
vs Diskus with same
medication and 
same dose
Drug-related adverse
event highest in 
T2 (18) vs T1 (13)
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TABLE 18 contd  Additional evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
PIF, peak inspiratory flow
continued
Bateman et al.,
2001
243
≤12 weeks of study
entry; prior treatment
with oral, depot/par-
enteral ICS/combination
therapy (containing β
2
-
agonist/ICS)
Power calculation:
At 90% power
Analysis: PP and ITT
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Appendix 11
DPIs vs DPIs, delivering corticosteroids
(randomised controlled trials, physiological 
and clinical outcomes)
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TABLE 19  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
continued
Peden et al.,
1998
245
T1: DPI (Diskus)
T2: DPI (Diskus)
T3: DPI (Diskhaler)
T4: DPI (Diskhaler)
T5: Placebo
Drug: Fluticasone
propionate
T1,T3: 50 µg b.d.
T2,T4: 100 µg b.d.
Patients had to withhold
theophylline treatment, if
any, for 24–36 h before
clinic visits and albuterol
use for ≥6 hours before
clinic visits
Design: Randomised,
double-blind, double-
dummy, parallel-group,
placebo-controlled
Jadad = 3
34 centres, USA
In: Children aged 4–11 yr, chronic
asthma, symptoms requiring
maintenance treatment >3 months
immediately before study, PEF ≤85%
(age 4–5 yr), FEV
1
50–85% (age
6–11 yr), ≥15% reversibility in FEV
1
within 30 minutes after 2 puffs of
albuterol or documentation of this
reversibility within 6 months before
study
Out: Life-threatening asthma or
other severe concurrent disease,
exposed to or had chickenpox 
≤3 weeks before study, lower
respiratory tract infection 
≤ previous 2 weeks, used oral or
parenteral corticosteroids 
≤1 month before study, used
methotrexate or gold salts or any
other prescriptions or over-the-
counter medication, participated in
previous clinical trial with Diskus or
Diskhaler devices, FEV
1
values 
< FEV
1
stability limit, PEF values 
< PEF stability limit at each clinic
visit and in 7 days preceding each
visit, ≤2 days of ≤12 puffs of
albuterol aerosol per day or
≤6 albuterol powder per day,
>2 night-time asthma awakenings
and requiring albuterol, and ≤2 days
with an a.m. or p.m. PEF above PEF
stability limit
At
beginning:
Not stated
At end:
n = 437
At end:
T1: 90
T2: 87
T3: 91
T4: 83
T5: 86
Age 4–5 yr:
n = 57
T1: 11
T2: 14
T3: 13
T4: 12
T5: 7
Age 6–11 yr:
n = 380
T1: 79
T2: 73
T3: 78
T4: 71
T5: 79
M/F (%):
T1: 59/41
T2: 68/32
T3: 55/45
T4: 60/40
T5: 71/29
Run-in: 2-week single-
blind, placebo
Instruction for proper
use of device given
Baseline:
Parents/caregivers
completed a device
satisfaction question-
naire rating the
importance of conven-
ience to carry, ease of
holding and operating,
ease of loading and
cleaning (Diskhaler
only), and ease of read-
ing remaining doses
FU: 12 weeks
Primary: FEV
1
,
a.m. PEF, p.m. PEF,
asthma symptoms,
night-time awakenings
requiring albuterol,
albuterol use
Secondary: Patient
compliance
No significant differences between T1,T2,T3,T4 for
FEV
1
mean (%) change from baseline and
% predicted, PEF, albuterol use, night-time awakenings
and asthma symptom scores
Mean % change ±SE, 50 µg b.d.:
Diskus Diskhaler Placebo 
(n = 90) (n = 91) (n = 86)
FEV
1
15.77 ± 1.97 17.89 ± 2.28 6.96 ± 2.45
PEF 26 ± 3 30 ± 3 14 ± 4
Albuterol use –0.75 ± 0.23 –1.02 ± 0.18 0.08 ± 0.23
(puffs/day)
Night-time –0.03 ± 0.01 –0.04 ± 0.01 0.07 ± 0.04
awakenings/night
Symptom scores –0.36 ± 0.07 –0.41 ± 0.07 –0.02 ± 0.09
Mean % change ±SE, 100 µg b.d.:
Diskus Diskhaler Placebo
(n = 90) (n = 91) (n = 86)
FEV
1
17.93 ± 2.44 18.61 ± 3.08 6.96 ± 2.45
PEF 27 ± 3 33 ± 4 14 ± 4
Albuterol use –1.04 ± 0.20 –0.90 ± 0.23 0.08 ± 0.23
(puffs/day)
Night-time –0.06 ± 0.02 –0.06 ± 0.02 0.07 ± 0.04
awakenings/night
Symptom scores –0.41 ± 0.07 –0.36 ± 0.07 –0.02 ± 0.09
(Symptom score: 0 = none, 1 = mild, 2 = moderate, 3 = severe)
Diskus and
Diskhaler were
comparable in
efficacy
Details on results
of device satisfac-
tion from parents/
caregivers not
included in article
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TABLE 19  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
continued
continued
Peden et al.,
1998
245
During the last 7 days’ run-in: ≥3
days ≥12 puffs/day albuterol, ≥6
doses/day of albuterol powder, ≥3
mornings of PEF decrease >20% of
the previous evening’s PEF, and ≥3
night-time awakenings requiring
albuterol
Non-compliance: ≤70% of placebo,
and did not complete diary cards
Power calculation: 80% power
Analysis: ITT
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TABLE 19 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Galant et al.,
1999
244
T1: DPI (Diskus) and
Diskhaler placebo
T2: DPI (Diskhaler) and
Diskus placebo
T3: Diskus and Diskhaler
placebo
Drug: Fluticasone
propionate 500 µg
Design: Randomised,
double-blind, double-
dummy, parallel-group,
placebo-controlled
Jadad = 4
16 sites, USA
In: Mild to moderate asthma,
children aged ≥12 yr, stratified 
by baseline therapy of ICS for 
3 months prior to study, or β
2
-
agonist therapy alone, forced FEV
1
= 50–80%,
≥15% reversibility FEV
1
(30 minutes
after up to 4 puffs of albuterol at
screening), or ≥15% variability in
FEV
1
≤6 months prior to study
Out: Pregnancy or lactation, severe
chronic disease, used methotrexate
or gold salts, nedocromil or sodium
cromolyn, oral or parenteral
corticosteroid <4 weeks prior to
study, any prescription or over-the-
counter medication that might
affect the course of asthma or its
treatment
Lack of efficacy after run-in period
(FEV
1
values > FEV
1
stability limit,
≤3 days where PEF < PEF stability
limit during 7 days preceding a
study visit, ≤2 days of ≥12 puffs
albuterol/day, or ≤2 night-time
awakenings requiring albuterol and
exacerbation requiring
hospitalisation and drug excluded
by study protocol)
Power calculation: 80% power
Analysis: ITT
At
beginning:
n = 229
At end:
n = 213
T1: 64
T2: 79
T3: 70
Age:
T1: 32 (12–62)
T2: 34 (12–76)
T3: 32 (13–73)
Patients
aged 12–17
yr:
T1: 10
T2: 7
T3: 13
M/F (%):
T1: 56/44
T2: 54/46
T3: 54/46
Baseline: 3 months’
therapy with ICS or 
β
2
-agonists alone
Run-in: 2 weeks,
single-blind, assessing
compliance and
familiarisation with
devices
FU: 12 weeks
Primary: a.m. predose
FEV
1
, probability of
remaining in study,
patient-rated asthma
symptoms for wheeze,
cough and breath
shortness, patient-
measured a.m. and p.m.
PEF, albuterol use and
night-time awakening
requiring albuterol,
adverse events
Secondary: Systemic
exposure to flutica-
sone propionate,
drug compliance
No significant differences between Diskus and
Diskhaler groups for FEV
1
, symptom scores, use of
albuterol, lung function (p ≥ 0.05) except for a.m.
PEF (p ≤ 0.05)
Mean change ± SE:
Diskus Diskhaler Placebo
FEV
1
a.m. 0.52 ± 0.06 0.40 ± 0.06 0.05 ± 0.07
predose (l) (n = 59) (n = 73) (n = 63)
FEV
1 
(%) 22.37 ± 2.38 16.61 ± 2.24 3.01 ± 3.03
(n = 59) (n = 73) (n = 63)
a.m. PEF (l/min) 12 ± 2 7 ± 1 –3 ± 1
(n = 58) (n = 71) (n = 62)
p.m. PEF (l/min) 6 ± 1 5 ± 1 –1 ± 1
(n = 59) (n = 71) (n = 60)
Albuterol –1.54 ± 0.36 –1.41 ± 0.32 0.76 ± 0.31
use (puffs/day) (n = 59) (n = 58) (n = 71)
Night-time –0.03 ± 0.02 0.00 ± 0.04 0.10 ± 0.05
awakenings (n = 60) (n = 58) (n = 72)
(no./week)
Total symptom –0.20 ± 0.05 –0.10 ± 0.05 0.04 ± 0.05
scores (n = 59) (n = 72) (n = 61)
(Total symptom score: 0 = none, 1 = mild, 2 = moderate,
3 = severe)
No significant differences in probability of remaining
in study over time between device groups
Potential drug-related adverse events were 14%, 16%
and 23% for placebo, Diskus and Diskhaler
respectively
Compliance rate for Diskus and Diskhaler = 94%
scheduled doses
Both Diskus and
Diskhaler produced
comparable bene-
fits with same
medication and
same dose
No age details of
withdrawn patients
Withdrawal from
study: 5% T1,T2;
34% T3
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Appendix 12
pMDIs with or without spacer vs 
breath-actuated devices delivering anti-
inflammatory drugs: sodium cromoglicate 
(randomised controlled trials, physiological 
and clinical outcomes)
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TABLE 20  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Arshad,
1993
215
T1: Breath-actuated
(Autohaler)
T2: MDI
Drug: Sodium
cromoglicate, 2 puffs 
(10 mg) q.d.s.
Design: Randomised,
open, cross-over,
controlled
Jadad = 1
Multicentre, UK
In: Stable asthma, airways
reversibility of ≥15% to an inhaled
bronchodilator, currently treated
with sodium cromoglicate, duration
10 weeks to 15 yr (mean 6.5 yr),
ability to use the MDI
Out: Not stated
Power calculation 150/group, at
power 90%
PP analysis
At
beginning:
n = 181
T1: 90
T2: 91
At end:
n = 166
Age: 10.4
(4–18) except
1 patient aged
39 yr
M/F: 181/0
Run in:All
medications for
treatment of asthma
permitted, but, apart
from inhaled broncho-
dilators, dose to
remain the same
throughout study
period
FU: 8 weeks (4-week
treatment period
before cross-over), 3
clinical visits
Primary: Spirometry
pre- and post-β
2
inhaler, daily diary
cards with 4 named-
symptom scores,
bronchodilator use and
PEFR twice a day,
overall assessment of
severity of asthma over
the previous 4 weeks
by clinician, treatment
efficacy assessed by
patient and clinician,
self-assessed
acceptability of device,
unusual events
Secondary: Ease of
use, coordination of
actuation with
inhalation and control
of asthma in the 2
treatment periods
No statistically significant differences for pulmonary
function tests (PEFR, FEV
1
, FEV
1
reversibility and
FVC) between T1 and T2
Morning PEFR and differential (a.m.–p.m. PEFR)
significantly higher (p < 0.05) for second device
period (whichever inhaler was used after 
cross-over)
No significant differences between devices could be
detected
No significant differences between devices or period
for mean numbers of puffs of inhaled bronchodilator
used during night and day
Clinician’s opinion: overall severity of asthma did not
differ for the 2 devices; no difference in number and
distribution of unusual events
Both patients’ and clinicians’ opinions of sodium
cromoglicate effectiveness significantly better for
Autohaler vs MDI (p < 0.01)
56 patients found Autohaler better; 67 found 
no difference; 35 found MDI better (assumed 
data missing)
No significant
differences in
clinical efficacy
found between
Autohaler and MDI
Health Technology Assessment 2002; Vol. 6: No. 5
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Appendix 13
pMDIs with or without spacer vs 
pMDIs with or without spacer, with 
different propellants, delivering the same 
bronchodilating drugs (randomised 
controlled trials, physiological and 
clinical outcomes)
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TABLE 21  Evidence reported by Brocklebank et al., 200120
Reference Methodology Details Results Comments
Custovic et al., 1995
247
Design: Randomised double-blind double-
dummy cross-over study
Computer-generated schedule
Histamine challenge used
Device: HFA pMDI alone vs CFC pMDI
alone
Drug: Salbutamol
Dose: 200 µg (both devices)
Duration: 30 minutes
Participants: 25 children, age range 6–14 yr,
mean age 10 yr
Pulmonary function test performed 30
minutes post-dose, then histamine challenge
performed and FEV
1
measured until FEV
1
decreased by 20% (PD
20
)
Study quality: Cochrane-A
No significant differences in: FEV
1
or
protection against histamine-induced
bronchoconstriction as measured by PD
20
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TABLE 22  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Shapiro et al.,
2000
249
T1: HFA pMDI
T2: CFC pMDI
T3: Placebo, HFA
propellant only
Drug:Albuterol, 2 puffs,
4–6 h (1 puff Ventolin
HFA (108 µg albuterol
sulphate) = 1 puff Ventolin
CFC (90 µg albuterol
base))
Design: Randomised,
double-blind, placebo-
controlled
Jadad = 3
11 sites (USA and Puerto
Rico)
In:Ages 4–11 yr, asthma
requiring physician-
prescribed chronic
pharmacotherapy ≥6mths,
no significant pulmonary
disease/serious chronic
disease, PEF or FEV
1
=
50–80% predicted, FEV
1
reversibility ≥15%
Out: Signs of unstable asthma
during run-in, life-threatening
asthma, not allowed
medications with potential
impact on the analyses of
cardiovascular end-points
Power calculation: 80%, a
difference of 10% in %
predicted FEV
1
, p ≤ 0.5
PP analysis:Assumed
At
beginning:
n = 135
T1: 46
T2: 46
T3: 43
At end:
n = 118
Age:
T1: 9.0
T2: 8.5
T3: 9.0
Sex (M%):
T1: 54
T2: 72
T3: 53
Run-in: 1–2 weeks,
instruction on proper
use of MDI and peak
flow meter
FU: 2 weeks
Primary: Mean %
predicted PEF during
6-h serial tests (day 1
and week 2)
Mean % predicted FEV
1
for patients aged 6–11
yr and 4–5 yr
Secondary: Daily self-
measured a.m. and p.m.
PEF, guardian/self-rated
asthma symptoms, %
nocturnal awakenings
requiring albuterol,
asthma exacerbation
frequency
T1 and T2 produced comparable bronchodilation as assessed by
mean increase in % predicted PEF: better than placebo
No significant differences between T1 and T2 in mean increases
Serial FEV
1
values similar to those calculated for PEF
Improvement in all diary card variables – no significant
differences between T1 and T2
6-h serial PEF (%):
T1                            T2                              T3
Day 1 Week 2 Day 1 Week 2 Day 1 Week 2
(n = 46) (n = 41) (n = 46) (n = 41) (n = 43) (n = 36)
Baseline PEF, 71.5 ± 2.4 78.5 ± 3.1 71.0 ± 2.2 76.7 ± 2.8 69.7 ± 2.1 72.3 ± 2.8
predicted
Changes in 13.9 ± 1.4 10.8 ± 1.4 12.6 ± 1.4 10.8 ± 1.4 6.3 ± 1.7 4.5 ± 0.9
PEF, predicted
Mean change from baseline in diary card variables:
T1 T2 T3
(n = 46) (n = 46) (n = 41)
a.m. PEF (l/min) 17 ± 4* 9 ± 4 2 ± 3
p.m. PEF (l/min) 15 ± 3* 11 ± 4 3 ± 3
Albuterol use (mean puffs/day) –1.8 ± 0.4* –2.0 ± 0.4* –0.8 ± 0.4
Days with no albuterol (%) 36.4 ± 6.1* 39.5 ± 5.6* 11.5 ± 6.2
Night-time without awakenings (%) 1 ± 4 4 ± 2 5 ± 4
Asthma symptom scores –0.3 ± 0.1* –0.1 ± 0.1 0.1 ± 0.1
(*p < 0.03 vs T3)
Ventolin HFA
produced
bronchodilation
that is clinically
comparable
with the effects
of inhaled
Ventolin CFC
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TABLE 22 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Colice et al.,
1999
250
T1: HFA pMDI
T2: CFC pMDI
T3: CFC pMDI
T4: Placebo HFA pMDI
Drug:Albuterol or
Ventolin, 2 puffs
Design: Randomised,
single-blind, placebo-
controlled, four-period
cross-over
Jadad = 3
1 site, USA
In:Age 6–11 yr; stable asthma (no
episode of emergency care within 4
weeks of pre-study visit) requiring
short-acting β
2
-agonists for control
of symptoms; chronic asthma (≥6
months); presence of EIB within 30
minutes after a standardised
exercise; withhold medication and
methylxanthine-containing foods
and beverages for ≥6 h; FEV
1
≥70%
predicted; demonstrated proper
technique in using a press and
breathe MDI; not obese; no
lower/upper respiratory tract
infections; not using salmeterol 
(48 h), theophylline products (48 h),
cromolyn sodium/nedocromil
sodium (1 week), oral/injectable
steroids (8 weeks), antihistamine
treatment (3 months) prior to pre-
study visit; no use of these
medications throughout study
Out: Failure to confirm EIB by pre-
study exercise challenge,
withdrawal of consent, and baseline
FEV
1
<70% predicted
Power calculation: No
PP analysis:Assumed
At
beginning:
n = 16
At end:
n = 15
Age: 9.4
(6–11)
M/F: 11/5
FU: 4 treatment visits
3–7 days apart
Primary: Smallest %
change from pre-dose
FEV
1
post-exercise
Secondary: % and
absolute change from
pre-dose FEV
1
post-
exercise
No significant differences found among active
treatment results
T1 T2 T3 T4
Smallest % 1.9 ± 16.4 –0.3 ± 11.4 –0.7 ± 13.5 –25.5 ± 16.0
change in FEV
1
post- exercise*
No. (%) patients 14 (93) 15 (100) 14 (93) 5 (33)
protected
from EIB
(*T1,T2 and T3 vs T4 all p < 0.001)
Albuterol HFA had
similar broncho-
dilator efficacy and
safety profile as
CFC albuterol
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TABLE 22 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
continued
Shapiro et al.,
2000
248
T1: HFA pMDI
T2: CFC pMDI
Drug:Albuterol, 2 puffs
Design: Open-label,
parallel-group, randomised
Jadad = 1
Multicentre, USA
In: Stable asthma, age 4–11 yr, using
short-acting inhaled β
2
-agonists for
6 months, FEV
1
≥50% predicted
after withholding short-acting
inhaled β
2
-agonists for 6 h, increase
in FEV
1
≥12% within 30 minutes
after 2 puffs CFC albuterol
Out: Other pulmonary disease;
clinically significant concomitant
non-pulmonary disease; upper
respiratory tract infection ≤4
weeks of screening; lower
respiratory tract infection ≤2
weeks of screening or a known
idiosyncratic reaction to sympatho-
mimetic drug; theophylline use (≤3
days); oral β
2
-agonists (≤1 week);
inhaled corticosteroid (≤4 weeks);
monoamine oxidase inhibitors,
tricyclic antidepressants and β
2
-
antagonist (≤6 wks); and antihista-
mine treatment (≤80 days) prior to
study entry; ipratropium bromide,
oral or nebulised β
2
-agonists,
salmeterol, nedocromil sodium
Power calculation: Requiring
30/group, at 90% power
PP analysis:Assumed
At
beginning:
n = 63
T1: 33
T2: 30
Age:
T1: (4–7)
(n = 9) and
(8–11)
(n = 24)
T2: (4–7) 
(n = 6) and
(8–11) 
(n = 24)
Run-in: ≥7 days
FU: 4 weeks
Primary: actual and 
% change from pre-
dose FEV
1
at study day
1 and week 4,AUC for
bronchodilation effect
Secondary: Symptom
scores, PEF a.m. and
p.m., nocturnal
awakenings scores,
average albuterol use
No significant differences between T1 and T2 for
FEV
1
at day 1 and week 4, a.m. and p.m. PEF
No significant differences between T1 and T2 for
individual asthma symptom scores, night-time asthma
sleep disturbance scores and rescue study drug use
over 4-week study period
No difference in
clinical benefit for
CFC vs HFA with
same medication
and dose
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TABLE 22 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Ethnicity
Lumry et al.,
2001
251
T1: CFC pMDI 
T2: HFA pMDI
T3: MDI placebo (HFA
propellant alone, q.d.s.)
Drug:Albuterol 180 µg
q.d.s.
Design: Randomised,
multicentre, double-blind,
parallel-groups
Jadad = 3
25 outpatient centres, USA
In: Mild to moderate bronchial
asthma, aged ≥12 yr, a 6-month
history of asthma, a medication-free
forced FEV
1
50–80% normal
predicted, ≥15% FEV
1
increase in 
30 minutes of Ventolin inhalation 
(2 puffs, 180 µg)
Out: Requiring asthma medication
other than Ventolin during study or
having significant other concurrent
illnesses
Power calculation: Requiring
80/group, at 80% power, p = 0.05
PP analysis:Assumed
At
beginning:
n = 313
T1: 108
T2: 101
T3: 104
At end:
n = 276
T1: 99
T2: 91
T3: 86
Age:
T1: 32 ± 14.8
T2: 30.6 ± 12.2
T3: 29.7 ± 13.8
M/F %:
T1: 56/44
T2: 55/45
T3: 50/50
Ethnicity %
(Caucasian/
Black/other):
T1: 79/13/8
T2: 75/13/12
T3: 81/12/7
Baseline period:
3 weeks,Ventolin CFC
via MDI, 180 µg q.d.s.
FU: 12 weeks
Primary: Serial
pulmonary function
testing
Secondary: Mean
change a.m. and p.m.
PEF, back-up Ventolin
use, asthma symptoms,
nocturnal awakenings
Pulmonary function, a.m. and p.m. PEFR values, back-
up Ventolin use, symptom scores and nocturnal
awakenings all remained unchanged relative to
baseline levels when switched from T1 to T2
Serial pulmonary function results: day 1
T1 T2 T3
(n = 100) (n = 91) (n = 95)
% patients 82 77 19
≥15% improvement
Median onset of 0.06 0.07 6.0
effect (h)
Mean duration (h) 3.26 (0.24) 3.07 (0.25) 0.57 (0.17)
of effect (SE)
% max effect (SE) 30.1 (1.83) 28.4 (1.34) 14.4 (1.05)
Median time 1.0 1.0 3.0
max effect (h)
Mean change from 0.84 (0.16) 2.48 (0.19) 2.65 (0.18)
baseline in AUC
l/h (SE)
No significant difference between T1 and T2 for all
serial pulmonary function results but difference with
placebo (p < 0.001) at day 1 (shown) and all other
visits (p < 0.001)
Likely that majority
of patients aged
>15 yr
Comparable clinical
efficacy for CFC vs
HFA propellant in
an MDI with same
medication and
same dose
Ventolin CFC and
Ventolin HFA have
similar adverse
event profiles
Treatment-related
adverse events
highest in T3 (9%)
vs T1 (2%),T2 (4%)
Health Technology Assessment 2002; Vol. 6: No. 5
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Appendix 14
pMDIs with or without spacer vs pMDIs 
with or without spacer, with different 
propellants, delivering corticosteroids 
or combined therapy (randomised 
controlled trials, physiological and 
clinical outcomes)
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TABLE 23  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
continued
Pearlman et
al., 1999
252
T1: MDI CFC (75 µg/puff),
150 µg/day, 1 puff b.d.
T2: MDI CFC (75 µg/puff),
300 µg/day, 2 puffs b.d.
T3: MDI CFC (75 µg/puff),
600 µg/day, 4 puffs b.d.
T4: MDI HFA (75 µg/puff),
150 µg/day, 1 puff b.d.
T5: MDI HFA (75 µg/puff),
300 µg/day, 2 puffs b.d.
T6: MDI HFA (75 µg/puff),
600 µg/day, 4 puffs b.d.
Drug:Triamcinolone
acetonide
A built-in spacer-
mouthpiece was used for
both the HFA and CFC
formulations
Design: Randomised,
double-blind
Jadad = 3
43 centres, USA
In:Age 6–13 yr, 1-yr history of
perennial asthma requiring daily
medication and inhaled β
2
-agonists
for at least previous month, FEV
1
=
50–100% of predicted
Out: Life-threatening asthma,
anoxic seizures, significant
hypercapnia, recent hospitalisation
for asthma, systemic corticosteroid
use once within previous month or
>2 courses during previous year,
any significant clinical/laboratory
abnormalities/clinical conditions
Power calculation: No
Analysis: ITT
At
beginning:
n = 473
T1: 75
T2: 82
T3: 82
T4: 76
T5: 83
T6: 75
At end:
n = 374
Age:
T1: 10.2
(6–13)
T2: 9.6
(6.1–13)
T3: 9.9
(6–26.1)a
T4: 9.9
(6.1–13)
T5: 9.7
(5.9–13)
T6: 9.6
(6.1–12.5)
M/F:
T1: 48/27
T2: 62/20
T3: 56/26
T4: 51/25
T5: 50/33
T6: 53/22
Baseline period:
3–28 days, instructions
given on the use of
portable meter to
measure a.m. and p.m.
PEFR
FU: 12-week
treatment period
Primary: Mean %
change from baseline
to end-point
Secondary: Mean %
change in FEF
25–75%
from baseline to end-
point, changes in a.m.
and p.m. PEFR, noctur-
nal awakenings, patient
efficacy ratings, asthma
symptom scores
Comparison between HFA and CFC formulations
within dose levels showed 2 formulations
therapeutically equivalent at all 3 doses for albuterol
use, a.m. and p.m. PEFR and nocturnal awakenings
Differences in FEV
1
and 24-h symptom scores
between formulations, but not significant
No significant differences for comparisons across
dose levels for albuterol use (rescue medication),
24-h symptom scores/nocturnal awakenings
Significant improvements in FEV
1
for all doses, both
formulations
FEV1 (mean ± SE):
Baseline (l) % change
CFC T1 1.59 ± 0.05 13.53 ± 3.24
T2 1.44 ± 0.05 19.40 ± 2.67
T3 1.45 ± 0.04 22.62 ± 2.67
HFA T4 1.48 ± 0.04 12.17 ± 3.24
T5 1.47 ± 0.04 21.39 ± 3.10
T6 1.43 ± 0.05 22.02 ± 3.26
PEFR (ml/min) PEFR (ml/min) FEF25–75%
a.m. p.m. % change
(mean ± SE) (mean ± SE) (mean ± SE)
CFC T1 19.0 ± 4.5 15.2 ± 4.2 23.2 ± 10.8
T2 23.0 ± 4.3 15.8 ± 4.2 42.8 ± 10.3
T3 30.2 ± 4.3 25.6 ± 4.1 42.3 ± 10.3
HFA T4 24.2 ± 4.3 20.2 ± 4.3 29.9 ± 8.7
T5 20.5 ± 4.0 18.8 ± 4.1 33.0 ± 8.3
T6 27.4 ± 4.3 24.3 ± 4.3 53.6 ± 8.7
Albuterol use decreased across dose levels for both
HFA and CFC, but overall treatment effect significant
with HFA formulation (p = 0.001), not CFC
formulation (p = 0.270)
Therapeutic
equivalent found at
all 3 dose levels
between HFA and
CFC propellants 
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TABLE 23 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
a
Age range actually 6–13 years; 1 older patient accidentally enrolled and subsequently excluded
continued
Pearlman 
et al., 1999
252
Significant improvements (p < 0.05) from baseline for
a.m. and p.m. asthma symptom scores, 24-h symptom
scores and no. nocturnal awakenings in HFA groups;
CFC groups demonstrated significant changes 
(p < 0.05) from baseline for only a.m. and p.m. asthma
symptoms and 24-h symptom scores
Change in asthma symptoms (mean ± SE):
a.m. symp- p.m. symp- 24-h symp- Nocturnal
tom score tom score tom score awakenings
(no./day)
CFC T1 –0.5 ± 0.1 –0.4 ± 0.1 –1.0 ± 0.2 –0.2 ± 0.1
T2 –0.7 ± 0.1 –0.6 ± 0.1 –1.3 ± 0.2 –0.4 ± 0.1
T3 –0.9 ± 0.1 –0.8 ± 0.1 –1.7 ± 0.2 –0.4 ± 0.1
p-value 0.044 0.044 0.045 0.105
HFA T4 –0.5 ± 0.1 –0.5 ± 0.1 –0.9 ± 0.2 –0.1 ± 0.1
T5 –0.8 ± 0.1 –0.7 ± 0.1 –1.6 ± 0.2 –0.2 ± 0.1
T6 –1.1 ± 0.1 –1.0 ± 0.1 –2.0 ± 0.2 –0.5 ± 0.1
p-value 0.002 0.007 0.002 0.001
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Appendix 15
Breath-actuated inhalers with different 
propellants, delivering corticosteroids 
(randomised controlled trials, physiological 
and clinical outcomes)
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TABLE 24  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
BDP, beclometasone dipropionate
Farmer et al.,
2000
253
T1: Breath-actuated MDI
HFA
T2: Breath-actuated MDI
CFC
Drug: BDP, 100 µg
Design: Randomised,
multicentre, double-blind,
parallel-group
Jadad = 4
44 general practice and hospital
sites, UK, South Africa, Czech
Republic,Yugoslavia, Hungary
In:Age 7–12 yr, FEV
1
≥60%
predicted for height and gender,
FEV
1
reversibility ≥10% after
inhaling 200 µg salbutamol via
pMDI, documented FEV
1
reversibility ≥10% in previous 12
months, currently using inhaled
bronchodilator β
2
-agonist/sodium
cromoglicate or constant dose of
nedocromil sodium
Out: Currently using inhaled/oral
corticosteroids, unstable asthma,
significant medical/psychological
conditions
Power calculation 90%, 105
patients/group
PP analysis:Assumed
At
beginning:
n = 229
At end:
n = 199
Age:
T1: 10.0
(7–12.9)
T2: 9.8
(6.6–12.8)
M/F:
T1: 71/45
T2: 75/38
Run-in: 2-week
placebo, 1 puff b.d.
from CFC placebo
Easi-Breathe inhaler
End of run-in,
required the use of
relief
bronchodilator (≥2
puffs on ≥3 of last 7
days of run-in)
FU: 4 treatment
visits: 1, 4, 8 and 12
weeks
Primary: Lung
function (PEF and
FEV
1
), self-recorded
symptom scores
and relief
medication use
Equivalent results for all lung function parameters obtained
for mean a.m. and p.m. PEF, with estimated treatment
difference being 2.6% and 2.1% respectively
Exception was mean daily variability in PEF, which decreased
from 21 to 16% in T1 and from 22 to 16% in T2
Compared with baseline, significant decreases in
proportions of patients reporting a.m. and p.m. symptoms
and use of relief medication in both T1 and T2
T1 mean T2 mean Estimate (95% CI):
(SD) (SD) HFA/CFC (%)
a.m. PEF Baseline 299 (56) 294 (62)
(l/min)
End-point 340 (61) 328 (54)
End-pointa 338 330 102.6 (99.1 to 106.2)
p.m. PEF Baseline 302 (57) 297 (61)
(l/min)
End-point 340 (61) 329 (51)
End-pointa 338 331 102.1 (98.1 to 105.6)
Clinic PEF Baseline 308 (60) 305 (69)
(l/min)
End-point 335 (59) 335 (59)
End-pointa 337 333 101.2 (97.3 to 105.1)
Clinic FEV1 Baseline 1.82 (0.42) 1.77 (0.42)
(l/min)
End-point 1.98 (0.45) 1.92 (0.40)
End-pointa 1.97 1.91 103.5 (99.6 to 107.5)
Daily variability Baseline 20.8 (11.7) 22.3 (11.6)
PEF (%)
End-point 16.1 (13.6) 16.5 (10.9)
End-pointa 16.2 16.3 99.4 (78.6 to 116.9)
a
Least square
HFA inhaler was
therapeutically
equivalent to
CFC inhaler at
similar dose
(BDP 100 µg
b.d.)
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Appendix 16
pMDIs with or without spacer vs pMDIs 
with or without spacer, with different propellants,
delivering cromoglicate therapy (randomised
controlled trials, physiological and 
clinical outcomes)
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TABLE 25  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Power calculation mean ± SD Outcomes
Jadad score Type of analysis (range) (primary,
M/F secondary)
Furukawa et
al., 1999
254
T1: MDI CFC
T2: MDI HFA
T3: Placebo with HFA
propellant
Drug: Cromolyn sodium,
2 mg q.d.s.
Albuterol MDI used as
needed in all groups
Design: Randomised,
double-blind placebo-
controlled parallel-group
Jadad = 3
29 sites, USA
In: Mild to moderate bronchial
asthma, age ≥12 yr, cromolyn
sodium use for ≥2 months, inhaled
β
2
-agonists use for ≥1 month, FEV
1
≥60% normal predicted
Out: Other clinically significant
respiratory disorders, current/ex-
smokers, history of life-threatening
asthma exacerbation, seasonal
allergic asthma, use of other named
medication within specific time-
frame of visit 1: ICS, oral or
parenteral steroid, theophylline,
ipratropium bromide, oral or
nebulised β
2
-agonists, salmeterol,
nedocromil sodium
Power calculation: Requiring
100/group, at 90% power
PP analysis:Assumed
At
beginning:
n = 280
T1: 91
T2: 94
T3: 95
At end:
n = 256
T1: 84
T2: 88
T3: 84
Age:
T1: 30.3
(12–79)
T2: 30 (12–62)
T3: 26.9
(12–68)
M/F:
T1: 40/51
T2: 39/55
T3: 48/47
Baseline period: 2–4
weeks
FU: 12 weeks
Primary: Symptom
summary score
(daytime + night-time
asthma scores)
Secondary: Lung
function, albuterol use,
symptom scores a.m.
and p.m., PEFs, self- and
clinician-rated
effectiveness or
treatment-related
events
No significant differences in symptom score
decreases, use of albuterol, lung function, treatment-
related events T1 vs T2 (p ≥ 0.05)
Mean change (%):
T1 (n = 84)         T2 (n = 88)
Symptom score –22 –27
Daytime score –25 –29
Night-time score –18 –23
a.m. PEF 1.3 5.3
p.m. PEF 0.1 4.7
Albuterol use –13 –27
Clinician-rated T1 effective for 63% patients vs T2
(56%) (p = 0.042); no difference for patient-rated T1
(73%) and T2 (77%) (p = 0.989)
Likely that majority
of patients were
aged >15 yr
No difference in
clinical benefit for
CFC vs HFA
propellant in an
MDI with same
medication and
same dose
Differences
between clinician
and patient ratings
on effectiveness
4 withdrawals for
treatment-related
adverse effects 
(T1 1,T2 2,T3 1)
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Appendix 17
Ease of use, patient/carer preference and
compliance for alternative devices
(randomised controlled trials and 
non-trial evidence)
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TABLE 26  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Milgrom et
al., 1996
262
Volunteer/convenience
sample for comparison of
diary records, electronic
monitoring and disease
exacerbation in relation
to adherence with inhaled
corticosteroids and β
2
-
agonists via pMDI
Outpatient clinic
In: Children requiring both ICS and
β
2
-agonists via pMDI, and who
reliably kept clinic appointments
Out: Known non-compliance
Use of spacers and nebulisers
β
2
-agonists only as needed
n = 24
14 M
Age: (8–12)
13 weeks
Diary records
compared with
electronic monitoring
Disease exacerbations
requiring oral
corticosteroids
Diary compliance records:
78.2% for β
2
-agonists
95.4% for corticosteroids
Electronic compliance records:
48.0% for β
2
-agonists
32.0% for corticosteroids
Compliance with inhaled steroids was 13.7% in 8
patients who needed additional oral steroids, and
68.2% in those who did not (p = 0.008)
Did not compare
devices
Small selective
sample
Kamps et al.,
2000
263
DPI or pMDI plus spacer
Case-control study
comparing effectiveness 
of repeated inhalation
instructions (control)
versus no systematic
inhalation instructions
(cases)
Outpatient clinic n = 66 newly
referred
patients
Age: 5 (1–14)
37 M
vs:
n = 29 in
clinical trial
(controls)
Age: 7 (5–10)
21 M
Inhalation technique
score according to
criteria defined by
Netherlands Asthma
Foundation
60 patients had received inhalation instructions prior
to referral:
29% using DPI correctly
67% using pMDI plus spacer correctly
(p < 0.01)
Repeated comprehensive inhalation instruction in
clinical trial setting or at the pharmacy resulted in:
79% using DPI correctly
93% using pMDI plus spacer correctly
versus 39% who had received a single instruction by
a GP
(p < 0.01)
Study not designed
to differentiate
between devices
Generalisability?
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TABLE 26 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Celano et al.,
1998
264
pMDI use and
pMDI/pMDI + spacer
technique
Urban hospital outpatient clinic
In:Age 6–17 yr with
moderate/severe asthma
Albuterol via pMDI + at least one
anti-inflammatory agent via pMDI
+spacer
Out: Current immunotherapy or
oral corticosteroids for significant
periods over previous year
n = 55 families
98% African-
American
Age 10.8 ± 2.7
(6–17)
Children 57%
M
FU 2–20 weeks 
(mean 10)
Estimated MDI
adherence (from
canister weight)
Self-reported
adherence
MDI/MDI + spacer
technique (from MDI
checklist)
Assessed at FU after
instruction at study
entry
34 sets of data for estimated adherence (range
0–100% (mean 44%))
Poor or no correlation between self-reported and
estimated use
MDI checklist available data for 49 patients: 27%
scored zero; remainder demonstrated varying
technique but achieved minimum criteria to ensure at
least some drug delivery
Interrelationship between measured adherence
behaviours not significant
Did not compare
inhaler devices
Several study
limitations
Zora et al.,
1989
265
Maintenance β
2
-agonists
(metaproterenol 2 sprays
3–5 times daily via pMDI
no spacer)
Study of compliance
assessed by canister
weighings and patient
records of daily inhaler
use and symptom scores
Outpatient clinic
In: Diagnosis of asthma confirmed
by 15% reversibility in the FEV
1
Maintenance β
2
-agonists
n = 17
Age: (5–13)
13 M
5 children for 2 weeks
12 children for 
2 consecutive 2-week
periods
Compliance as asses-
sed by canister weight
2/5 deemed compliant during 2-week study
1/12 deemed compliant during 4-week study
1/5 had diary correlating with actual use during 
2-week study
0/12 had diary correlating with actual use during 
4-week study
Symptom scores indicated a non-significant
improvement in relation to more compliant use
Non-comparative
Small study
numbers
Did not compare
inhaler devices
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TABLE 26 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Jonasson et
al., 1999
257
Turbohaler budesonide
100 µg or 200 µg or
placebo in 2 divided doses
Group I:
Budesonide 200 µg a.m.
and placebo 100 µg p.m.
Group II:
Budesonide 100 µg a.m.
and placebo 100 µg p.m.
Group III:
Budesonide 100 µg a.m. and
budesonide 100 µg p.m.
Group IV:
Placebo 100 µg a.m. and
placebo 100 µg p.m.
Double-blind randomised
study of patient compliance
assessed by diary/dose
count/symptom score
1 centre
In: Mild asthma (mean baseline
FEV
1
103% of predicted)
No documented power calculation
Compliance level assessed by
Student’s two-sample t-test
Analysis of co-variance was used to
determine the degree of
association with any demographic
variables
n = 163
Age: 9.9
(7–16)
107 M
2-week open run-in
period followed by 
12-week study period
Compliance assessed
by diary records and
dose counts
Results available from 161 participants
Significant difference between self-reported and
measured compliance
a.m.: 93% diary, 76% measured (p < 0.001)
p.m.: 94% diary, 77% measured (p < 0.001)
86% had higher self-reported than measured
compliance for a.m. medication compared with
94% for p.m. medication
No correlation between symptom scores and
adherence or placebo treatment and adherence
Mild asthma
Did not compare
devices
Jonasson et
al., 2000
258
(Extension
study of ref.
257 above)
As above As above n = 122
Age: (7–16)
80 M
27 months’ treatment
Measured drug
adherence at 6-month
intervals
Adherence decreased with time and with use of
placebo treatment (significant level of difference after
21 months)
Adherence better in p.m. than in a.m., a difference
that became significant after 3 months’ treatment
Adherence in two different age groups (7–9 versus
10–16 yr at baseline) was on all occasions higher in
the younger age group, but only significantly so during
the first 3 months’ treatment
As above
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TABLE 26 contd  Evidence from the current review
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Bender B et
al., 2000
266
Measured adherence in
relation to use of pMDI
Comparison between:
Mother’s report
Child’s report
Canister weight
Electronic measurement
(clinical trial: electronic
doser attached to inhaled
steroid pMDI)
1 centre
In: Mild to moderate asthma
including at least twice-weekly
asthma symptoms and requiring
daily inhaled anti-inflammatory
medicines
Out: Severe asthma or other
serious medical conditions
Non-randomised, non-
controlled study
n = 27
Age: 10.9 ±
2.5 (7–12)
16 M
African-
American
n = 6
Hispanic n = 4
6 months with
assessment at 2-month
intervals
Mothers and children reported, on average, over 80%
adherence with the prescribed inhaled steroid
Canister weight revealed, on average, adherence of
69%, significantly lower than self-report
Adherence: showed trend towards lower adherence
in older children, children with poorer functioning
families, boys, children in homes with a smoker or 
a pet, and non-white children (significant difference)
Favours electronic doser as means of 
estimating adherence
Did not compare
devices
Small sample size
Generalisability?
Goren et al.,
1994
267
Use of Turbohaler
terbutaline by children
aged 3–6 yr
Open, non-controlled
study
Consecutive attenders at
outpatient asthma clinic
n = 59
Age: (3–6)
39 M
Efficiency of inhalation
technique (scored)
after instruction/
demonstration and
pharmacological effect
of the terbutaline 
(sum of clinical
symptom scores) in
the inhaler, measured
at a single visit
0%, 43%, 67% and 80% of 3-, 4-, 5- and 6-year-olds
respectively used the Turbohaler efficiently
(statistically significant between 3-year-olds and
combined other age groups)
50%, 79%, 92% and 100% of 3-, 4-, 5- and 6-year-olds
respectively demonstrated clinical improvement of
asthma symptoms after inhalation (statistically
significant in all age groups; 3 asymptomatic patients
not included)
Did not compare
devices
Small sample size
Selective sample
Restricted age
range
Generalisability?
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Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Yeatts et al.,
2000
268
Study of barriers to
inhaler use amongst non-
white (African-American)
and white adolescents
Population-based sample 
(public school system in North
Carolina, USA)
n = 2056
296 had used
an inhaler in
the previous
year
185 had been
diagnosed with
asthma
Age: (13–14)
34% African-
American
Sociodemographics of
inhaler users
14% reported using an inhaler in the previous 12
months, with no differences among African-American
and white children
26% were not allowed to carry their inhaler at school
Girls were more likely to be allowed to carry their
inhalers at school and diagnosed asthmatic girls had a
higher prevalence of wheezing in the last year (47%)
compared with diagnosed asthmatic boys (26%)
Smoking prevalence was higher in inhaler users (26%)
compared with the study population (19%) (p = 0.001)
African-Americans were slightly more likely to take
their inhaler medication only when needed (83%)
compared with white children (75%) (Note: only
small numbers involved)
Did not compare
devices
Relevance to the
UK?
Vichyanond
et al., 1994
269
Turbohaler terbutaline
500 µg t.d.s.
Open non-comparative
study of handling and
efficacy (symptom scores
and PEFR) after verbal
and written instruction
Multicentre outpatient clinics
throughout East Asia
In: Children with mild to moderate
asthma, as classified according to
the international consensus for the
diagnosis and treatment of asthma
Out: Hypersensitivity to 
β
2
-agonist drugs
Concomitant conditions, such as
cardiovascular, renal or hepatic
disease
83 included in PP analysis
n = 86
(58 had used
pMDIs
previously)
Age: 8.7
(5–14)
Asian children
1 week run-in
4-week study
Handling assessed
objectively by
investigator and
subjectively by
patient/parent
Efficacy from PEFR (%
predicted) and asthma
symptom score (diary
records and clinic
assessment)
Maximum scores for inhalation were achieved by 73%
of patients after combined verbal and written instruc-
tions at the start of the study and by 99% (p < 0.001) 
at the end of the 4-week treatment period
Verbal instructions yielded better results for
inhalation technique scores than written instructions
at all times (p < 0.001)
90% considered use of Turbohaler to be easy and
effective in affording symptom relief
Improvements in PEFR (p < 0.01) and reduction in
asthma symptom scores (p < 0.005 for a.m. scores;
p ≤ 0.0001 for p.m. scores) were observed during
treatment
All patients tolerated the study medication well
without any serious adverse events
Did not compare
devices
Generalisability?
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Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Winkelstein
et al., 2000
271
Convenience sample of 
30 families whose children
were using daily inhaled
asthma medication via
MDI, participating in a 
US community-based
research study
Domiciliary, structured interviews
relating to usage, technique and
knowledge of asthma medication 
by both parent and child
n = 30
School-age
(6–14) urban
African-
American
children
18 M
Medication concor-
dance and discordance
between parent and
child and parent and
physician reports of
asthma medications
Sociodemographic
factors associated 
with early self-
administration
93% took inhaled medication without parental
supervision
Early self-administration was associated with parental
employment status and childhood behaviours
Only 7% had effective MDI skills
Considerable discordance between parent/child and
parent/physician reports of asthma medications
Did not compare
devices
Small sample size
Generalisability?
Kesten et al.,
1994
270
Albuterol via DPI
(Diskhaler) at equivalent
dose in place of usual β
2
-
agonist (78% were using
pMDI alone)
Non-comparative open
assessment
Primary and respiratory practices
In: Patients aged >6 yr requiring
inhaled β
2
-agonist for stable
reversible obstructive airways
disease
Open, non-randomised study
No documented power calculation
Fisher’s exact test used for
comparisons among 3 age groups;
significance level was <0.05
n = 4529
Age: 39 ± 22
653 between 
6 and 12 yr
Age bands:
<13
13–64
>64
43 excluded
on initial
screening
2219 M
2 weeks
Patient preference
over usual inhaler
device
Adequate demon-
stration of 6 device-
handling steps after
initial instruction and
at end of study period
The majority of paediatric patients preferred the disk
delivery system to their previous inhalation device 
(p < 0.001)
After instruction 98.5% demonstrated adequate
technique at the initial visit
At the conclusion of the trial, incorrect use was
noted in 10.2% of the elderly patients and 3.2% 
of all other age groups combined (p ≤ 0.001)
112 patients withdrawn owing to adverse events
(100 non-major, 12 major, 88 considered drug related)
3 major adverse events considered to be drug related
Did not directly
compare devices
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Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
Type of analysis M/F secondary)
Ethnicity
continued
Gracia-
Antequera
and Morales
Suarez-
Varela,
1999
276
DPI vs pMDI vs pMDI 
+ extension chamber
Non-randomised
intervention study
After baseline assessment,
intervention was instruc-
tion (structured sessions
of correct use and
handling of inhalers with
new assessment at FU)
Paediatric outpatient department
142 included in PP analysis 
(i.e. remained on same inhaler
device)
n = 255
Age: 10.5
7–12-year-olds
made up 57%
of the sample
103 M
Mean FU period 
10.5 months
An increase in correct manoeuvres was observed for
all 3 devices:
Relative risk and 95% CI of incorrect
post-intervention use:
DPI 0.59 (0.38 to 0.92)
MDI 0.23 (0.10 to 0.56)
MDI/spacer 0.54 (0.32 to 0.90)
Multivariate analysis suggests that the improvement
was observed irrespective of gender and age interval
and was better when parents cooperated with
nursing and medical staff
Kelloway et
al., 1993
277
Autohaler
Use and design of PII
n = 40
Naive n = 20
Previous pMDI
n = 20
Adults and
children
Age: (12–17)
Using only PII for guidance, 5/20 (25%) failed to
trigger the device
Using revised PII (based on patient feedback) 
1/20 (5%) of different participants failed to trigger 
the device
85% thought that the device was easier to use than
an MDI
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Ethnicity
continued
Pedersen 
et al., 1986
278
DPI (Rotahaler) vs pMDI
vs pMDI + spacer
Open, non-randomised
study
Outpatient clinic with recruitment
over a 4-month period
In: Children with perennial asthma
who agreed, with informed
consent, to participate
Receiving inhalation therapy on 
a regular basis with the inhaler
prescribed since treatment 
was started
n = 256
Age: 9.7
(4–16)
MDI n = 132
MDI + spacer
n = 85
Rotahaler 
n = 39
172 M
Baseline assessment of
FEV
1
+ demonstration
and details of inhaler
technique and
instruction
If FEV
1
≥15% 
10 minutes after the
demonstration, then
inhalation technique
assessed as efficient;
evaluated only in
children with pre-
treatment FEV
1
≤85% of predicted
on day of study
In 43%, demonstration of inhaler technique 
deemed efficient
In 52%, demonstration of inhaler technique 
deemed inefficient
5% did not have reversible asthma on the day of 
the study
No statistically significant, systematic variation with
age found when results for all inhaler types grouped
together or considered separately
Comparison of results from those aged <6 yr with 
all other age groups showed a significantly lower
frequency of efficient technique (0% vs 47%) and 
a higher mean % of errors (5.9% vs 3.3%) in the
lower age group (p < 0.01) for both variables
Nasal inhalation in particular was more common 
in younger than older children (p < 0.01)
Important variables:
Person who had taught the child how to use 
the inhaler
Initial choice of inhaler device controlled by use 
of pulmonary function tests
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Arshad,
1993
215
T1: Breath-actuated
(Autohaler)
T2: MDI
Drug: Sodium
cromoglicate, 2 puffs 
(10 mg) q.d.s.
Design: Randomised,
open, cross-over,
controlled
Jadad = 1
Multicentre, UK
In: Stable asthma, airways
reversibility of >15% to an inhaled
bronchodilator, currently treated
with sodium cromoglicate, duration
of asthma varied between 10
weeks and 15 yr (mean 6.5 yr),
ability to use the MDI
Study participants considered good
coordinators for pMDI technique
Out: Not stated
Power calculation: 150/group,
at power 90%
PP analysis
At
beginning:
n = 181
T1: 90
T2: 91
At end:
n = 166
Age: 10.4
(4–18) (except
1 patient aged
39 yr)
M/F: 181/0
Run in:All medica-
tions for treatment of
asthma permitted but,
apart from inhaled
bronchodilators, dose 
to remain the same
throughout study period
FU: 8 weeks (4-week
treatment period
before cross-over); 3
clinical visits
Primary: Lung 
function, daily diary
cards with 4 named
symptom scores,
bronchodilator use;
PEFR b.d., clinician
assessment of severity,
treatment efficacy
assessed by patient and
clinician, self-assessed
acceptability of device,
unusual events
Secondary: Ease of
use, coordination of
actuation with inhala-
tion, control of asthma
in the 2 treatment
periods
In the clinicians’ opinion, overall severity of asthma
did not differ for the 2 devices, nor were there 
any differences in the number and distribution of
unusual events
Both patients’ and clinicians’ opinions of sodium
cromoglicate effectiveness were significantly better
for Autohaler vs MDI (p < 0.01)
56 patients found Autohaler better; 67 found no
difference between devices; 35 found MDI better
90 patients found Autohaler to be more acceptable
than MDI, 24 found MDI more acceptable 
(p < 0.001); 43 found both devices equally acceptable
No significant
differences in
clinical efficacy
found between
Autohaler and MDI
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Edmunds et
al., 1979
240
T1: pMDI and DPI
placebo
T2: DPI (Rotahaler) and
pMDI placebo
Drug: BDP 2 puffs of
aerosol q.d.s.; 1 capsule in
the Rotahaler q.d.s.
Design: Randomised,
double-blind, cross-over
Jadad = 2
1 site, UK
In: Severe asthma; all children
requiring treatment with BDP
Out: Not stated
PP analysis: No
At
beginning:
n = 14
Age: 9.7
(4.8–15.1)
M/F: 7/7
Run in:All patients
taught how to use the
pMDI and Rotahaler
before study
FU: 2 months; each
month, 1 device con-
tained active drug and
the other a placebo
Primary:Ability to use
device, sum of diary
recorded symp-toms,
no. symptom-free days,
a.m. and p.m. PEFR, and
rescue salbutamol use
Mean symptom score was significantly less with T1 vs
T2 (p = 0.04)
No significant differences between the 2 periods for
any of the other recorded parameters
“Younger” children preferred to use Rotahaler (not a
predefined outcome)
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Dal Col et
al., 1995237
T1: DPI (Pulvinal,
multidose)
T2: DPI (Rotahaler, single
dose)
T3: Placebo via Pulvinal
T4: Placebo via Rotahaler
Drug: Salbutamol powder,
single dose, 200 µg
Design: Randomised,
cross-over
Jadad = 1
1 site, USA
In: Stable asthma, at screening visit
FEV
1
and PEFR >75% predicted
normal, history of exercise-
induced asthma and reversible
airway obstruction
On day 1 of study, with no
treatment, patients had to have
≥15% maximum fall in FEV
1
vs
baseline values to continue trial
Out: In case of possible exposure
to sensitising agents during the
study: acute attacks of asthma in
the 2 months prior to study;
presence of concomitant disease,
or of cardiac, hepatic, renal or
endocrine disorders; use of oral
steroids during the previous 
2 months; and impossibility of
discontinuing concomitant
treatments 24 h before testing
Power calculation: No
PP analysis
At
beginning:
n = 13
Age: 10.9
(8–12)
M/F: 9/4
Run in: Standard
exercise same time on
each trial day: 6
minutes on treadmill
with 10° slope
Use of sodium
cromoglicate,
nedocromil sodium,
bronchodilators and
antihistamines stopped
≥24 h before test;
inhaled steroid use
permitted, dose fixed
Instruction on how to
use inhalers, with
drawings on correct
technique
FU: 4 consecutive days
Primary: FEV
1
and
PEFR before and after
treatment and exercise
challenge, ease of use,
correct handling
technique
No significant difference between T1 and T2 
(p > 0.05)
Investigator’s opinion on ease of use for T1 was
excellent for 10 patients and good for 3
The opinion for T2 was excellent for 3 patients, good
for 8 and fair for 2
No patient reported a verdict of “poor” for ease of
use for either T1 or T2
11 patients preferred T1 while 1 preferred T2; 2
patients had no preference (data as presented 
by authors)
No adverse events reported throughout study
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Boulet et al.,
1995
236
T1: Diskus and placebo
via Diskhaler
T2: Diskhaler and placebo
via Diskus
Drug: Salmeterol,
50 µg b.d.
Design: Randomised,
double-blind, double-
dummy, parallel-group,
multicentre
Jadad = 3
16 sites, USA
In:Aged ≥12 yr, FEV
1
between 
60% and 90% predicted normal,
receiving adequate anti-inflam-
matory and inhaled β
2
-agonist
Last 7 days of baseline period, mean
a.m. PEFR 60–80% 15 minutes after
inhalation of 800 µg albuterol
No methylxanthines, anti-
cholinergics, oral/parenteral
corticosteroids/other routine 
β
2
-agonist during study
Power calculation: 90%
PP analysis:Assumed
At
beginning:
n = 463
At end:
n = 380
T1: 190
T2: 190
Age:
T1: 39 (12–70)
T2: 39 (12–69)
M/F:
T1: 77/113
T2: 78/112
Run-in: 2-weeks,
instruction leaflet and
taught by physician on
the use of study
devices given
FU: 4 weeks
Primary: Self-filled
daily record of a.m. and
p.m. PEFR, a.m. and
p.m. asthma symptom
scores, and use of
albuterol; clinic-
recorded pulmonary
function tests and
adverse effects
For all ease of use, ease of monitoring remaining
doses and preference, Diskus > Diskhaler (p < 0.001)
Ease of use Diskus (%) Diskhaler (%)
Use correctly after 1st training >80 70
Use correctly at end of treatment 99 98
Very easy to use 85 45
Easier to count remaining doses 91 61
Preference 73 15
(12% with no preference)
No unexpected adverse events
Majority of patients
aged >15 yr
Diskus rated as
easier to use and to
tell remaining doses
than Diskhaler
Diskus also rated as
easier to learn to
use than Diskhaler
Becker et al.,
1985
226
T1: pMDI + spacer (tube
80 ml, 10 × 3.2 cm) and
placebo via pMDI
T2: pMDI and placebo via
pMDI + spacer
T3: Placebo via both
devices
Drug:Terbutaline, 250 µg/
actuation, given in a total
dose of 500 µg
Placebo was the CFC pro-
pellant–surfactant mixture
used in the active inhaler
Design: Randomised,
double-blind, placebo-
controlled
Jadad = 2
1 hospital, Canada
In: History of asthma, documented
reversibility of obstruction to
airflow previously (increase 
FEV
1
>20% after bronchodilator
aerosol), FEF
25–75%
<70% predicted
normal
Out: Severe acute asthma on study
day
Power calculation: No
PP analysis:Assumed
At
beginning:
n = 34
T1: 12
T2: 12
T3: 10
At end:
n = 34
Age:
T1: 11.7 ± 0.8
T2: 10.2 ± 0.6
T3: 10.5 ± 0.6
M/F: Not
stated
Run-in: Stopped oral
medication for 12 h or
inhaled bronchodilator
aerosol for 6 h before
study
Demonstration and
supervision given by
investigator
FU: 3 occasions, 2–7
days apart and within
14 days
Primary: Pulmonary
function
4/34 (11.7%) had no errors in inhaler technique
No. patients who pMDI pMDI + spacer
failed to: (n = 34) (n = 34)
Remove cap 0 N/A
Shake inhaler 3 7
Position device correctly 0 4
Extend neck slightly 12 17
Close lips 0 0
Exhale completely 2 3
Hold breath while actuating N/A N/A
Co-ordinate actuation and 13 1
inspiration early
Co-ordinate actuation and 9
inspiration late
Inhale slowly, deeply 9 7
Hold breath (10 s) 3 3
Breathe out 3 2
Wait 30 s before repeat 1 1
Both pMDI +
spacer and pMDI
were equally effec-
tive in improving
pulmonary function
from the base-
line state
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van der Palen
et al., 1998
260
T1: DPI (Turbuhaler)
T2: DPI Diskus
(Accuhaler)
Drug: Not stated
Design: Open,
randomised, cross-over
Jadad = 1
1 site, Belgium
In:Aged ≥15 yr, naive to
Diskus/Accuhaler and Turbuhaler,
but currently using inhaled
medication
Out: Limited ability to understand
and speak Dutch
Power calculation: No
PP analysis: Not stated
At
beginning:
n = 50
At end:
n = 50
Age: 49
(15–74)
Baseline period: None
FU: Same-day assess-
ment: patients shown
and asked to read
inhaler-specific instruc-
tion leaflet and then
use the inhaler
Inhalation technique
assessed using a pur-
pose-designed inhaler-
specific checklist
Same procedure
repeated for second
inhaler
Patients asked to scale
the importance of the
inhaler’s features and
state preference
Primary: Ease of use
and preference
Mean checklist scores
of inhalation technique
Mean checklist scores of inhalation technique were
not significant between Diskus/Accuhaler (92.7%) 
and Turbuhaler (92.0%) (p = 0.52)
From the essential checklist items, statistical
difference in errors with “loading” the device:
Turbuhaler (93.5%) < Diskus/Accuhaler (97.3%) 
(p = 0.045)
% patients performing all items correctly:
Diskus/Accuhaler (25, 50%) and Turbuhaler (23, 46%)
(p = 0.75)
% patients performing all essential items correctly:
46 (92%) for Diskus/Accuhaler vs 37 (74%) for
Turbuhaler
98% patients considered a clear instruction leaflet to
be important/very important
>90% considered important: ease of holding the
device, overall perceived ease of use, ease of use in
acute exacerbation, and a clear counting mechanism
Preference: 17 patients Diskus/Accuhaler vs 25
Turbuhaler; 8 no preference (p > 0.05)
Significant differences (p < 0.001): favoured
Turbuhaler > Diskus/Accuhaler for ease of carrying,
size, inconspicuousness, and reading remaining doses
Inhalation tech-
nique with both
devices was 
equally good
Error in loading
device > for
Turbuhaler than
Diskus/Accuhaler
(Turbuhaler
requires 2 critical
steps in loading,
while Diskus has 
1 correct action)
More patients
preferred Turbu-
haler than Diskus/
Accuhaler for size,
ease of carrying
and counting
remaining doses
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Mahajan and
Okamoto,
1997
259
T1: DPI Diskus and
placebo via Diskhaler
T2: Diskhaler and placebo
via Diskus
T3: placebo via Diskus
and Diskhaler
Drug: Fluticasone
propionate 500 µg
Design: Randomised,
double-blind, double-
masked, placebo-controlled
Jadad = 3
16 sites, USA
In:Age ≥12 yr, FEV
1
between 
50% and 80% predicted
Power calculation: No
PP analysis:Assumed
At
beginning:
n = 213
T1: 64
T2: 79
T3: 70
At end:
n = 155 (but
only 154
completed
questionnaire
at week 12)
T1: 33
T2: 54
T3: 68
Age: 33
(12–76)
M/F: Not
stated
Run-in: 2-week
familiarisation with
placebo via Diskhaler
and Diskus inhalers 
in single-masked
manner and to assess
compliance
FU: 12 weeks:
questionnaires
completed on 4 visits
(screening visit, after
run-in period, the 6th
week and 12th week 
of study)
Primary: Performance
assessment based on
criteria: convenient to
carry, durability, ease of
use, ease of loading,
ease of holding and
operating, ease of
cleaning, ease of telling
number of doses left
Performance assessment of the 7 attributes 
(% satisfied/very satisfied):
Diskhaler Diskus
At screening, 60–95 72–95
1st exposure (n = 210)
After week 12 of use 57–88 76–96
(n = 154)
Week 12/at time of 60–89 74–95
withdrawal (n = 154)
Global assessments (%):
Diskhaler Diskus
Comfortable/very comfortable:
At screening, 60 72
1st exposure (n = 210)
Week 12 (n = 154) 79 85
Like/strongly like:
Week 12 (n = 154) 67 85
Satisfied/very satisfied:
Week 12 (n = 154) 72 82–84
Preference for device (n = 189):
Week 12 (13% had 25 61
no preference)
No statistically significant difference between T1 and
T2 for treatment effects
Also showed that patients were rating only devices,
not the medication they received
Diskus inhaler was
preferred over
Diskhaler, possibly
due to character-
istics of Diskus
inhaler (conven-
ience of not having
to load Diskus with
medication)
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Ahlström 
et al., 1989
218
T1: DPI Turbuhaler
T2: pMDI + spacer
(Nebuhaler)
Drug:Terbutaline
T1: 0.5 mg/dose;
1 inhalation t.d.s.
T2: 0.25 mg/dose,
2 inhalations t.d.s.
Design: Open, cross-over,
randomised
Jadad = 2
2 centres, Sweden
In: Not stated
Power calculation: No
PP analysis:Assumed
At
beginning:
n = 26
At end:
n = 21
Age: 3.9 (2–5)
M/F: 14/7
Run-in: 1 week
Patients and their
parents acquainted
themselves with 
the diaries
Patients were trained
how to use device
All treatment, except
β
2
-agonists, kept
constant during the
study
FU: 2 treatment
periods, each of 
14 days
Primary:Asthma
symptom score, PEF,
extra inhalation of
same drug, side-effects
Secondary: Children
and parents’
preference for the 2
devices
Inhalation with T1 and T2 resulted in a significant
increase in PEF (p < 0.001)
PEF values 15 minutes after inhalation in a.m. for  
T1 > T2 (p = 0.046)
Baseline PEF values after inhalation in p.m. for
T1 > T2 (p = 0.03)
No statistical difference found between T1 and 
T2 for asthma symptoms when present and 
extra medication
Mild side-effects experienced by few children; no
significant difference between T1 and T2
Parents’ assessments of efficacy, side-effects and ease
of use for each treatment period:
Significantly fewer side-effects found with T1 vs T2
No significant difference in efficacy between T1 and
T2, but  was considered easier to use (p = 0.002)
19 parents wanted their children to use T1 in the
future while 2 parents preferred T2 (p < 0.001)
Turbuhaler was as
effective as pMDI +
Nebuhaler in
treatment of
bronchial asthma
in small children
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Sharma RK
et al., 1996
280
Accuhaler versus Turbo-
haler in “powder naive”
asthmatic children 
aged 4–14 yr
Cross-over assessment 
at a single visit of each
device in turn
Randomised with respect
to order in which devices
presented
Outpatient clinic
In: Children aged 4–14 yr requiring
ICS and/or β
2
-agonists via pMDI
“Powder naive”
n = 162
n = 84 
(4–9 yr)
n = 78 (10–14
yr) 
95 M
Spontaneous and
prompted assessment
of pMDI
Views on properties of
ideal inhaler
(prompted)
Comparison of Accu-
haler and Turbohaler:
Attractiveness
Attached cover
Indicator of doses left
Shape
Perceived ease of use
Ease of holding
Mouthpiece
Hygiene
Instructions
Weight
Discreetness
Ease of carrying
Size
Patients/parents stated ease of use and effectiveness
as desirable features of current pMDI
With prompting, the most desirable features of an
ideal inhaler included ease of use and the presence of
a dose counter
The Accuhaler scored more highly than the
Turbohaler on all prompted features apart from size
Most commonly
cited reason for
overall preference
was perceived ease
of use among the
parents of 4–9-
year-olds and
overall design
amongst the
10–14-year-olds
Reference Treatment inhaler type Location, setting No. patients Run-in Results Comments
Drug and dose Inclusion/exclusion Age (yr) FU 
Study design Non-compliance mean ± SD Outcomes
Jadad score Power calculation (range) (primary,
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Northfield et
al., 1991
275
Turbohaler terbutaline
p.r.n. in inhaler naive
asthmatics
Open study to assess
efficacy, acceptability and
effect on lifestyle
General practice
In: Newly diagnosed or receiving
oral bronchodilator alone and not
in need of urgent treatment
n = 1133
adults and
children
n = 345 
(6–16 yr)
1-week run-in
4-week treatment
period
Efficacy:
PEFR
Symptom diary
Lifestyle index changes
After terbutaline treatment, PEFR rose significantly
and severity (scored) of each asthma symptom was
reduced by between 45% and 47% (all p < 0.001)
The purported adverse effect of asthma on lifestyle
was reduced by 51% (p <0.001)
These results were comparable for all age-related
subgroups
Physicians’ assessment of inhaler technique 
indicated that:
It was easy or fairly easy to teach the technique to
96% of patients;
99% learnt the correct technique;
99% demonstrated a good or acceptable technique 
at the end of the study
Patients’ assessment of terbutaline treatment via
Turbohaler indicated that:
90% found it to be beneficial;
98% found it easy to use
Terbutaline
preferred by 91%
of the patients who
had previously
received oral anti-
asthma therapy
p < 0.001 for all of
the findings
Williams and
Richards,
1997
197
Randomised, multicentre
open-label, parallel-
group study
Accuhaler fluticasone
500 µg b.d.
versus
Turbohaler budesonide
200 µg b.d.
UK hospitals and UK general
practice
In: Children aged 4–11 yr who
were receiving or had symptoms
indicating a clinical requirement for
ICS at a daily dose of 400 µg
budesonide or 200 µg fluticasone
n = 323
Age: (4–11)
Primary efficacy
parameter was mean 
% predicted a.m. PEF
Secondary measures
included patient
assessment of 
device handling
Change from baseline to week 4 of treatment in
mean % predicted a.m. PEF was higher in the
fluticasone propionate Accuhaler group (median
100.2% vs 98.8%, p < 0.012)
Accuhaler was rated more favourably than Turbohaler
in terms of:
Ease of use
Ease of telling no. doses left
Ease of knowing whether the dose had been inhaled
Overall liking of the device
More patients in the Accuhaler (85%) than in the
Turbohaler (58%) group said that they would be
happy to receive the same device again, while 8% and
25% respectively said that they would not
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Baciewicz
and Kyllonen,
1989
273
Ability of children aged
4–18 yr to use a
pressurised inhaler
Open assessment
regardless of drug type
Sample of outpatients attending
paediatric respiratory clinic over
3-month study period
In: Children who had used
pressurised inhalers for >6 months
Out: Children who had received
formal instruction in the use of the
inhaler during the previous 6
months and children who used
tube spacers
n = 25
Age: (7.5–18)
13 M
Assessment by a
clinical pharmacist 
of steps required to
ensure efficient
inhaler technique
No child was observed to have completed all 
inhaler techniques correctly; patients had an average
of 5.1 errors
Small sample size
Some subjectivity in
assessment
Hawksworth
et al., 2000
274
Open intervention
(counselling) with aim 
of improving inspiratory
flow rates for patients
using Turbohaler
Sample of patients attending
community pharmacy with
prescription for inhalers
n = 24
Age: 59 ± 19.2
(10–76)
Measured inspiratory
inhalation rate via
Turbohaler converted
to cumulative inspired
volume followed by
FEV
1
(best of 
3 manoeuvres)
Mean (SD) inhalation rate (l/min):
Pre-counselling: 48.0 (16.8)
Post-counselling: 54.7 (17.6)
Mean (SD) inhaled volume (l):
Pre-counselling: 1.75 (0.68)
Post-counselling: 1.94 (0.62)
Mean (SD) FEV
1
(% of predicted):
Inspiration rate ≥60 l/min: 60.3 (20.2)
Inspiration rate <60 l/min: 53.7 (19.4)
Median difference –9.0 (95% CI –26.0 to 10.0)
Small sample size
Mean age suggests
inclusion of few
patients relevant to
current review
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PII, package insert instructions; N/A, not applicable
(Yamanouchi provided confidential information, which was included in the version of the report that was sent to the Appraisals Committee, but this information has been removed from this current document)
Ng et al.,
1999
279
Open study comparing
three breath-actuated
inhalation devices in
terms of perception of
ease of use and
preference by patients,
and the perception of
ease of teaching by nurses
Accuhaler (Diskus)
Autohaler
Turbohaler
Sample of paediatric inpatients,
Kwong Wah Hospital, Hong Kong
In: Children (not necessarily
asthmatic) aged >6 yr who had
never been taught to use or had
ever used any inhalation device
before the study
n = 31
Age: 10.6 ±
2.8
19 M
Perception of ease of
use and preference by
patients
Perception of ease of
teaching by nurses
Ease of use by patients:
Accuhaler 22 (p = 0.0311 vs Autohaler)
Autohaler 6 (p = 0.2516 vs Turbohaler)
Turbohaler 3 (p = 0.002 vs Accuhaler)
Patient preference:
Accuhaler 23 (p = 0.0104 vs Autohaler)
Autohaler 6 (p = 0.2289 vs Turbohaler)
Turbohaler 2 (p = 0.0008 vs Accuhaler)
Ease of teaching by nurses:
Accuhaler 15 (p = 0.7024 vs Autohaler)
Autohaler 15 (p = 0.019 vs Turbohaler)
Turbohaler 1 (p = 0.0048 vs Accuhaler)
Small sample size
Health Technology Assessment 2002; Vol. 6: No. 5
145
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TABLE 27  QALY thresholds for salbutamol (assumed 100 µg dose equivalence): cost per QALY threshold £5000
Cost per annum (£) 3.14 3.60 3.60 3.60 4.20 7.88 7.88 9.70 10.99 11.50 11.53 11.54 11.54 12.00 17.37 18.32 18.43 30.00 30.42
Device name(s)
3.14 Maxivent 0.00000 0.00009 0.00009 0.00009 0.00021 0.00095 0.00095 0.00131 0.00157 0.00167 0.00168 0.00168 0.00168 0.00177 0.00285 0.00304 0.00306 0.00537 0.00546
3.14 Asmaven 0.00009 0.00009 0.00009 0.00021 0.00095 0.00095 0.00131 0.00157 0.00167 0.00168 0.00168 0.00168 0.00177 0.00285 0.00304 0.00306 0.00537 0.00546
3.60 Salamol 0.00000 0.00000 0.00012 0.00086 0.00086 0.00122 0.00148 0.00158 0.00159 0.00159 0.00159 0.00168 0.00275 0.00295 0.00297 0.00528 0.00536
3.60 Airomir 0.00000 0.00012 0.00086 0.00086 0.00122 0.00148 0.00158 0.00159 0.00159 0.00159 0.00168 0.00275 0.00295 0.00297 0.00528 0.00536
3.60 Salbulin 0.00012 0.00086 0.00086 0.00122 0.00148 0.00158 0.00159 0.00159 0.00159 0.00168 0.00275 0.00295 0.00297 0.00528 0.00536
4.20 Ventolin Evohaler 0.00074 0.00074 0.00110 0.00136 0.00146 0.00147 0.00147 0.00147 0.00156 0.00263 0.00283 0.00285 0.00516 0.00524
7.88 Airomir with AeroChamber 0.00000 0.00036 0.00062 0.00072 0.00073 0.00073 0.00073 0.00082 0.00190 0.00209 0.00211 0.00442 0.00451
7.88 Salbulin with AeroChamber 0.00036 0.00062 0.00072 0.00073 0.00073 0.00073 0.00082 0.00190 0.00209 0.00211 0.00442 0.00451
9.70 Ventolin Evohaler with Nebuhaler 0.00026 0.00036 0.00037 0.00037 0.00037 0.00046 0.00153 0.00173 0.00175 0.00406 0.00414
10.99 Airomir Autohaler 0.00010 0.00011 0.00011 0.00011 0.00020 0.00128 0.00147 0.00149 0.00380 0.00389
11.50 Salamol Easi-Breathe 0.00001 0.00001 0.00001 0.00010 0.00117 0.00137 0.00139 0.00370 0.00378
11.53 Asmasal Clickhaler 0.00000 0.00000 0.00009 0.00117 0.00136 0.00138 0.00369 0.00378
11.54 Maxivent with Able Spacer 0.00000 0.00009 0.00117 0.00136 0.00138 0.00369 0.00378
11.54 Asmaven with Able Spacer 0.00009 0.00117 0.00136 0.00138 0.00369 0.00378
12.00 Salamol with Able Spacer 0.00107 0.00127 0.00129 0.00360 0.00368
17.37 Ventolin Rotahaler (200)
a
0.00019 0.00021 0.00253 0.00261
18.32 Aerolin Autohaler 0.00002 0.00233 0.00242
18.43 Pulvinal 0.00231 0.00240
30.00 Ventodisks (200)
a
0.00008
30.42 Ventolin Accuhaler (200)
a
a
These devices provide 200 µg equivalent of salbutamol; the costs of the other drugs must be doubled where 200 µg is provided
(Yamanouchi provided confidential information, which was included in the version of the report that was sent to the Appraisals Committee, but this information has been removed from this current document)
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TABLE 28  QALY thresholds for salbutamol (assumed 100 µg dose equivalence): cost per QALY threshold £20,000
Cost per annum (£) 3.14 3.60 3.60 3.60 4.20 7.88 7.88 9.70 10.99 11.50 11.53 11.54 11.54 12.00 17.37 18.32 18.43 30.00 30.42
Device name(s)
3.14 Maxivent 0.00000 0.00002 0.00002 0.00002 0.00005 0.00024 0.00024 0.00033 0.00039 0.00042 0.00042 0.00042 0.00042 0.00044 0.00071 0.00076 0.00076 0.00134 0.00136
3.14 Asmaven 0.00002 0.00002 0.00002 0.00005 0.00024 0.00024 0.00033 0.00039 0.00042 0.00042 0.00042 0.00042 0.00044 0.00071 0.00076 0.00076 0.00134 0.00136
3.60 Salamol 0.00000 0.00000 0.00003 0.00021 0.00021 0.00031 0.00037 0.00040 0.00040 0.00040 0.00040 0.00042 0.00069 0.00074 0.00074 0.00132 0.00134
3.60 Airomir 0.00000 0.00003 0.00021 0.00021 0.00031 0.00037 0.00040 0.00040 0.00040 0.00040 0.00042 0.00069 0.00074 0.00074 0.00132 0.00134
3.60 Salbulin 0.00003 0.00021 0.00021 0.00031 0.00037 0.00040 0.00040 0.00040 0.00040 0.00042 0.00069 0.00074 0.00074 0.00132 0.00134
4.20 Ventolin Evohaler 0.00018 0.00018 0.00028 0.00034 0.00040 0.00037 0.00037 0.00037 0.00039 0.00066 0.00071 0.00071 0.00129 0.00131
7.88 Airomir with AeroChamber 0.00000 0.00009 0.00016 0.00018 0.00018 0.00018 0.00018 0.00021 0.00047 0.00052 0.00053 0.00111 0.00113
7.88 Salbulin with AeroChamber 0.00009 0.00016 0.00018 0.00018 0.00018 0.00018 0.00021 0.00047 0.00052 0.00053 0.00111 0.00113
9.70 Ventolin Evohaler with Nebuhaler 0.00006 0.00009 0.00009 0.00009 0.00009 0.00011 0.00038 0.00043 0.00044 0.00101 0.00104
10.99 Airomir Autohaler 0.00003 0.00002 0.00003 0.00003 0.00005 0.00032 0.00037 0.00037 0.00095 0.00097
11.50 Salamol Easi-Breathe 0.00000 0.00000 0.00000 0.00002 0.00029 0.00034 0.00035 0.00092 0.00095
11.53 Asmasal Clickhaler 0.00000 0.00000 0.00002 0.00029 0.00034 0.00034 0.00092 0.00094
11.54 Maxivent with Able Spacer 0.00000 0.00002 0.00029 0.00034 0.00034 0.00092 0.00094
11.54 Asmaven with Able Spacer 0.00002 0.00029 0.00034 0.00034 0.00092 0.00094
12.00 Salamol with Able Spacer 0.00027 0.00032 0.00032 0.00090 0.00092
17.37 Ventolin Rotahaler (200)
a
0.00005 0.00005 0.00063 0.00065
18.32 Aerolin Autohaler 0.00001 0.00058 0.00060
18.43 Pulvinal 0.00058 0.00060
30.00 Ventodisks (200)
a
0.00002
30.42 Ventolin Accuhaler (200)
a
a
These devices provide 200 µg equivalent of salbutamol; the costs of the other drugs must be doubled where 200 µg is provided
(Yamanouchi provided confidential information, which was included in the version of the report that was sent to the Appraisals Committee, but this information has been removed from this current document)
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TABLE 29  QALY thresholds for 200 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £5000
Cost per annum (£) 28.73 28.73 28.73 30.08 30.08 31.41 31.41 33.01 33.01 35.69 37.67 38.48 38.51 40.73 43.17 47.05 55.21 69.06
Device name(s)
18.73
a
Beclazone Easi-Breathe 0.00200 0.00200 0.00200 0.00227 0.00227 0.00254 0.00254 0.00286 0.00286 0.00339 0.00379 0.00395 0.00396 0.00440 0.00489 0.00566 0.00730 0.01007
28.73 Qvar (50)
b
0.00000 0.00000 0.00027 0.00027 0.00054 0.00054 0.00086 0.00086 0.00139 0.00179 0.00195 0.00196 0.00240 0.00289 0.00366 0.00530 0.00807
28.73 Qvar Autohaler (50)
b
0.00000 0.00027 0.00027 0.00054 0.00054 0.00086 0.00086 0.00139 0.00179 0.00195 0.00196 0.00240 0.00289 0.00366 0.00530 0.00807
28.73 Filair (100) 0.00027 0.00027 0.00054 0.00054 0.00086 0.00086 0.00139 0.00179 0.00195 0.00196 0.00240 0.00289 0.00366 0.00530 0.00807
30.08 Beclazone (100) 0.00000 0.00027 0.00027 0.00059 0.00059 0.00112 0.00152 0.00168 0.00169 0.00213 0.00262 0.00339 0.00503 0.00780
30.08 Beclazone Easi-Breathe (100) 0.00027 0.00027 0.00059 0.00059 0.00112 0.00152 0.00168 0.00169 0.00213 0.00262 0.00339 0.00503 0.00780
31.41 Qvar (100)
b
0.00000 0.00032 0.00032 0.00086 0.00125 0.00141 0.00142 0.00187 0.00235 0.00313 0.00476 0.00753
31.41 Qvar Autohaler (100)
b
0.00032 0.00032 0.00086 0.00125 0.00141 0.00142 0.00187 0.00235 0.00313 0.00476 0.00753
33.01 Qvar (50) with AeroChamber
b
0.00000 0.00054 0.00093 0.00109 0.00110 0.00155 0.00203 0.00281 0.00444 0.00721
33.01 Filair (100) with AeroChamber 0.00054 0.00093 0.00109 0.00110 0.00155 0.00203 0.00281 0.00444 0.00721
35.69 Qvar (100) with AeroChamber
b
0.00040 0.00056 0.00056 0.00101 0.00150 0.00227 0.00390 0.00667
37.67 Becotide (100) 0.00016 0.00017 0.00061 0.00110 0.00188 0.00351 0.00628
38.48 Beclazone (100) with Able Spacer 0.00001 0.00045 0.00094 0.00171 0.00335 0.00612
38.51 Asmabec Clickhaler (100) 0.00045 0.00093 0.00171 0.00334 0.00611
40.73 Pulvinal (100) 0.00049 0.00126 0.00289 0.00566
43.17 Becotide (100) with Volumatic 0.00078 0.00241 0.00518
47.05 AeroBec Autohaler (100) 0.00163 0.00440
55.21 Becotide Rotacaps (100) 0.00277
69.06 Becodisks Diskhaler (100)
a
Assuming a £10 cost offset compared with the cheapest pMDI is validated
b
Not licensed for children aged under 12 yr
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TABLE 30  QALY thresholds for 200 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £20,000
Cost per annum (£) 28.73 28.73 28.73 30.08 30.08 31.41 31.41 33.01 33.01 35.69 37.67 38.48 38.51 40.73 43.17 47.05 55.21 69.06
Device name(s)
18.73
a
Beclazone Easi-Breathe 0.00050 0.00050 0.00050 0.00057 0.00057 0.00063 0.00063 0.00071 0.00071 0.00085 0.00095 0.00099 0.00099 0.00110 0.00122 0.00142 0.00182 0.00252
28.73 Qvar (50)
b
0.00000 0.00000 0.00007 0.00007 0.00013 0.00013 0.00021 0.00021 0.00035 0.00045 0.00049 0.00049 0.00060 0.00072 0.00092 0.00132 0.00202
28.73 Qvar Autohaler (50)
b
0.00000 0.00007 0.00007 0.00013 0.00013 0.00021 0.00021 0.00035 0.00045 0.00049 0.00049 0.00060 0.00072 0.00092 0.00132 0.00202
28.73 Filair (100) 0.00007 0.00007 0.00013 0.00013 0.00021 0.00021 0.00035 0.00045 0.00049 0.00049 0.00060 0.00072 0.00092 0.00132 0.00202
30.08 Beclazone (100) 0.00000 0.00007 0.00007 0.00015 0.00015 0.00028 0.00038 0.00042 0.00042 0.00053 0.00065 0.00085 0.00126 0.00195
30.08 Beclazone Easi-Breathe (100) 0.00007 0.00007 0.00015 0.00015 0.00028 0.00038 0.00042 0.00042 0.00053 0.00065 0.00085 0.00126 0.00195
31.41 Qvar (100)
b
0.00000 0.00008 0.00008 0.00021 0.00031 0.00035 0.00035 0.00047 0.00059 0.00078 0.00119 0.00188
31.41 Qvar Autohaler (100)
b
0.00008 0.00008 0.00021 0.00031 0.00035 0.00035 0.00047 0.00059 0.00078 0.00119 0.00188
33.01 Qvar (50) with AeroChamber
b
0.00000 0.00013 0.00023 0.00027 0.00028 0.00039 0.00051 0.00070 0.00111 0.00180
33.01 Filair (100) with AeroChamber 0.00013 0.00023 0.00027 0.00028 0.00039 0.00051 0.00070 0.00111 0.00180
35.69 Qvar (100) with AeroChamber
b
0.00010 0.00014 0.00014 0.00025 0.00037 0.00057 0.00098 0.00167
37.67 Becotide (100) 0.00004 0.00004 0.00015 0.00028 0.00047 0.00088 0.00157
38.48 Beclazone (100) with Able Spacer 0.00000 0.00011 0.00023 0.00043 0.00084 0.00153
38.51 Asmabec Clickhaler (100) 0.00011 0.00023 0.00043 0.00083 0.00153
40.73 Pulvinal (100) 0.00012 0.00032 0.00072 0.00142
43.17 Becotide (100) with Volumatic 0.00019 0.00060 0.00129
47.05 AeroBec Autohaler (50) 0.00041 0.00110
55.21 Becotide Rotacaps (100) 0.00069
69.06 Becodisks Diskhaler (100)
a
Assuming a £10 cost offset compared with the cheapest pMDI is validated
b
Not licensed for children aged under 12 yr
Q
v
a
r
 
(
5
0
)
b
Q
v
a
r
 
A
u
t
o
h
a
l
e
r
(
5
0
)
b
F
i
l
a
i
r
 
(
1
0
0
)
B
e
c
l
a
z
o
n
e
 
(
1
0
0
)
B
e
c
l
a
z
o
n
e
 
E
a
s
i
-
B
r
e
a
t
h
e
 
(
1
0
0
)
Q
v
a
r
 
(
1
0
0
)
b
Q
v
a
r
 
A
u
t
o
h
a
l
e
r
(
1
0
0
)
b
Q
v
a
r
 
(
5
0
)
 
w
i
t
h
A
e
r
o
C
h
a
m
b
e
r
b
F
i
l
a
i
r
 
(
1
0
0
)
 
w
i
t
h
A
e
r
o
C
h
a
m
b
e
r
Q
v
a
r
 
(
1
0
0
)
 
w
i
t
h
A
e
r
o
C
h
a
m
b
e
r
b
B
e
c
o
t
i
d
e
 
(
1
0
0
)
B
e
c
l
a
z
o
n
e
 
(
1
0
0
)
w
i
t
h
 
A
b
l
e
S
p
a
c
e
r
A
s
m
a
b
e
c
C
l
i
c
k
h
a
l
e
r
 
(
1
0
0
)
P
u
l
v
i
n
a
l
 
(
1
0
0
)
B
e
c
o
t
i
d
e
 
(
1
0
0
)
w
i
t
h
 
V
o
l
u
m
a
t
i
c
A
e
r
o
B
e
c
A
u
t
o
h
a
l
e
r
 
(
1
0
0
)
B
e
c
o
t
i
d
e
R
o
t
a
c
a
p
s
 
(
1
0
0
)
B
e
c
o
d
i
s
k
s
D
i
s
k
h
a
l
e
r
 
(
1
0
0
)
(100)
A
p
p
en
d
ix 1
8
1
5
0
TABLE 31  QALY thresholds for 800 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £5000
Cost per annum (£) 114.46 114.90 114.90 114.90 119.18 119.18 120.30 120.30 122.86 125.63 125.63 126.73 128.70 128.99 129.91 133.27 133.65
Device name(s)
104.46
a
Beclazone Easi-Breathe (100) 0.00200 0.00209 0.00209 0.00209 0.00294 0.00294 0.00317 0.00317 0.00368 0.00423 0.00423 0.00445 0.00485 0.00491 0.00509 0.00576 0.00584
114.46 Beclazone (200) 0.00009 0.00009 0.00009 0.00094 0.00094 0.00117 0.00117 0.00168 0.00223 0.00223 0.00245 0.00285 0.00291 0.00309 0.00376 0.00384
114.90 Filair (100) 0.00000 0.00000 0.00086 0.00086 0.00108 0.00108 0.00159 0.00215 0.00215 0.00237 0.00276 0.00282 0.00300 0.00367 0.00375
114.90 Qvar (50)
b
0.00000 0.00086 0.00086 0.00108 0.00108 0.00159 0.00215 0.00215 0.00237 0.00276 0.00282 0.00300 0.00367 0.00375
114.90 Qvar Autohaler (50)
b
0.00086 0.00086 0.00108 0.00108 0.00159 0.00215 0.00215 0.00237 0.00276 0.00282 0.00300 0.00367 0.00375
119.18 Qvar (50) with AeroChamber
b
0.00000 0.00022 0.00022 0.00074 0.00129 0.00129 0.00151 0.00190 0.00196 0.00215 0.00282 0.00289
119.18 Filair (100) with AeroChamber 0.00022 0.00022 0.00074 0.00129 0.00129 0.00151 0.00190 0.00196 0.00215 0.00282 0.00289
120.30 Beclazone (100) 0.00000 0.00051 0.00107 0.00107 0.00128 0.00168 0.00174 0.00192 0.00259 0.00267
120.30 Beclazone Easi-Breathe (100) 0.00051 0.00107 0.00107 0.00128 0.00168 0.00174 0.00192 0.00259 0.00267
122.86 Beclazone (200) with Able Spacer 0.00055 0.00055 0.00077 0.00117 0.00123 0.00141 0.00208 0.00216
125.63 Qvar (100)
b
0.00000 0.00022 0.00061 0.00067 0.00086 0.00153 0.00160
125.63 Qvar Autohaler (100)
b
0.00022 0.00061 0.00067 0.00086 0.00153 0.00160
126.73 Beclazone Easi-Breathe (50) 0.00040 0.00045 0.00064 0.00131 0.00138
128.70 Beclazone (100) with Able Spacer 0.00006 0.00024 0.00091 0.00099
128.99 Filair (250) 0.00018 0.00086 0.00093
129.91 Qvar (100) with AeroChamber
b
0.00067 0.00075
133.27 Filair (250) with AeroChamber 0.00008
133.65 Becodisks Diskhaler (400)
143.15 Becotide (200)
148.65 Becotide (200) with Volumatic
148.99 Pulvinal (400)
150.23 Pulvinal (200)
150.67 Becotide (100)
154.03 Asmabec Clickhaler (100)
156.17 Becotide (100) with Volumatic
162.94 Pulvinal (100)
188.19 AeroBec Autohaler (100)
209.48 Becotide Rotacaps (200)
209.66 Asmabec Clickhaler (50)
220.83 Becotide Rotacaps (100)
266.16 Becodisks Diskhaler (200)
266.16 Becotide Rotacaps (400)
272.80 Becodisks Diskhaler (100)
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TABLE 31 contd  QALY thresholds for 800 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £5000
Cost per annum (£) 143.15 148.65 148.99 150.23 150.67 154.03 156.17 162.94 188.19 209.48 209.66 220.83 266.16 266.16 272.80
Device name(s)
104.46
a
Beclazone Easi-Breathe (100) 0.00774 0.00884 0.00891 0.00915 0.00924 0.00991 0.01034 0.01169 0.01675 0.02100 0.02104 0.02327 0.03234 0.03234 0.03367
114.46 Beclazone (200) 0.00574 0.00684 0.00691 0.00715 0.00724 0.00791 0.00834 0.00969 0.01475 0.01900 0.01904 0.02127 0.03034 0.03034 0.03167
114.90 Filair (100) 0.00565 0.00675 0.00682 0.00707 0.00715 0.00783 0.00825 0.00961 0.01466 0.01892 0.01895 0.02118 0.03025 0.03025 0.03158
114.90 Qvar (50)
b
0.00565 0.00675 0.00682 0.00707 0.00715 0.00783 0.00825 0.00961 0.01466 0.01892 0.01895 0.02118 0.03025 0.03025 0.03158
114.90 Qvar Autohaler (50)
b
0.00565 0.00675 0.00682 0.00707 0.00715 0.00783 0.00825 0.00961 0.01466 0.01892 0.01895 0.02118 0.03025 0.03025 0.03158
119.18 Qvar (50) with AeroChamber
b
0.00479 0.00589 0.00596 0.00621 0.00630 0.00697 0.00740 0.00875 0.01380 0.01806 0.01809 0.02033 0.02939 0.02940 0.03072
119.18 Filair (100) with AeroChamber 0.00479 0.00589 0.00596 0.00621 0.00630 0.00697 0.00740 0.00875 0.01380 0.01806 0.01809 0.02033 0.02939 0.02940 0.03072
120.30 Beclazone (100) 0.00457 0.00567 0.00574 0.00599 0.00607 0.00675 0.00717 0.00853 0.01358 0.01784 0.01787 0.02010 0.02917 0.02917 0.03050
120.30 Beclazone Easi-Breathe (100) 0.00457 0.00567 0.00574 0.00599 0.00607 0.00675 0.00717 0.00853 0.01358 0.01784 0.01787 0.02010 0.02917 0.02917 0.03050
122.86 Beclazone (200) with Able Spacer 0.00406 0.00516 0.00523 0.00547 0.00556 0.00623 0.00666 0.00801 0.01307 0.01732 0.01736 0.01959 0.02866 0.02866 0.02999
125.63 Qvar (100)
b
0.00350 0.00460 0.00467 0.00492 0.00501 0.00568 0.00611 0.00746 0.01251 0.01677 0.01680 0.01904 0.02810 0.02811 0.02943
125.63 Qvar Autohaler (100)
b
0.00350 0.00460 0.00467 0.00492 0.00501 0.00568 0.00611 0.00746 0.01251 0.01677 0.01680 0.01904 0.02810 0.02811 0.02943
126.73 Beclazone Easi-Breathe (50) 0.00329 0.00439 0.00445 0.00470 0.00479 0.00546 0.00589 0.00724 0.01229 0.01655 0.01659 0.01882 0.02789 0.02789 0.02922
128.70 Beclazone (100) with Able Spacer 0.00289 0.00399 0.00406 0.00431 0.00439 0.00507 0.00549 0.00685 0.01190 0.01616 0.01619 0.01842 0.02749 0.02749 0.02882
128.99 Filair (250) 0.00283 0.00393 0.00400 0.00425 0.00434 0.00501 0.00544 0.00679 0.01184 0.01610 0.01613 0.01837 0.02743 0.02743 0.02876
129.91 Qvar (100) with AeroChamber
b
0.00265 0.00375 0.00382 0.00406 0.00415 0.00482 0.00525 0.00660 0.01166 0.01591 0.01595 0.01818 0.02725 0.02725 0.02858
133.27 Filair (250) with AeroChamber 0.00198 0.00308 0.00314 0.00339 0.00348 0.00415 0.00458 0.00593 0.01098 0.01524 0.01528 0.01751 0.02658 0.02658 0.02791
133.65 Becodisks Diskhaler (400) 0.00190 0.00300 0.00307 0.00332 0.00340 0.00408 0.00450 0.00586 0.01091 0.01517 0.01520 0.01744 0.02650 0.02650 0.02783
143.15 Becotide (200) 0.00110 0.00117 0.00142 0.00150 0.00218 0.00260 0.00396 0.00901 0.01327 0.01330 0.01553 0.02460 0.02460 0.02593
148.65 Becotide (200) with Volumatic 0.00007 0.00032 0.00040 0.00108 0.00150 0.00286 0.00791 0.01217 0.01220 0.01443 0.02350 0.02350 0.02483
148.99 Pulvinal (400) 0.00025 0.00034 0.00101 0.00144 0.00279 0.00784 0.01210 0.01213 0.01437 0.02343 0.02343 0.02476
150.23 Pulvinal (200) 0.00009 0.00076 0.00119 0.00254 0.00759 0.01185 0.01188 0.01412 0.02318 0.02319 0.02451
150.67 Becotide (100) 0.00067 0.00110 0.00245 0.00750 0.01176 0.01180 0.01403 0.02310 0.02310 0.02443
154.03 Asmabec Clickhaler (100) 0.00043 0.00178 0.00683 0.01109 0.01113 0.01336 0.02243 0.02243 0.02375
156.17 Becotide (100) with Volumatic 0.00135 0.00640 0.01066 0.01070 0.01293 0.02200 0.02200 0.02333
162.94 Pulvinal (100) 0.00505 0.00931 0.00934 0.01158 0.02064 0.02064 0.02197
188.19 AeroBec Autohaler (100) 0.00426 0.00429 0.00653 0.01559 0.01559 0.01692
209.48 Becotide Rotacaps (200) 0.00003 0.00227 0.01133 0.01134 0.01266
209.66 Asmabec Clickhaler (50) 0.00223 0.01130 0.01130 0.01263
220.83 Becotide Rotacaps (100) 0.00907 0.00907 0.01040
266.16 Becodisks Diskhaler (200) 0.00000 0.00133
266.16 Becotide Rotacaps (400) 0.00133
272.80 Becodisks Diskhaler (100)
a
Assuming a £10 cost offset compared with the cheapest pMDI is validated
b
Not licensed for children aged under 12 yr
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TABLE 32  QALY thresholds for 800 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £20,000
Cost per annum (£) 114.46 114.90 114.90 114.90 119.18 119.18 120.30 120.30 122.86 125.63 125.63 126.73 128.70 128.99 129.91 133.27 133.65
Device name(s)
104.46
a
Beclazone Easi-Breathe (100) 0.00050 0.00052 0.00052 0.00052 0.00074 0.00074 0.00079 0.00079 0.00092 0.00106 0.00106 0.00111 0.00121 0.00123 0.00127 0.00144 0.00146
114.46 Beclazone (200) 0.00002 0.00002 0.00002 0.00024 0.00024 0.00029 0.00029 0.00042 0.00056 0.00056 0.00061 0.00071 0.00073 0.00077 0.00094 0.00096
114.90 Filair (100) 0.00000 0.00000 0.00021 0.00021 0.00027 0.00027 0.00040 0.00054 0.00054 0.00059 0.00069 0.00070 0.00075 0.00092 0.00094
114.90 Qvar (50)
b
0.00000 0.00021 0.00021 0.00027 0.00027 0.00040 0.00054 0.00054 0.00059 0.00069 0.00070 0.00075 0.00092 0.00094
114.90 Qvar Autohaler (50)
b
0.00021 0.00021 0.00027 0.00027 0.00040 0.00054 0.00054 0.00059 0.00069 0.00070 0.00075 0.00092 0.00094
119.18 Qvar (50) with AeroChamber
b
0.00000 0.00006 0.00006 0.00018 0.00032 0.00032 0.00038 0.00048 0.00049 0.00054 0.00070 0.00072
119.18 Filair (100) with AeroChamber 0.00006 0.00006 0.00018 0.00032 0.00032 0.00038 0.00048 0.00049 0.00054 0.00070 0.00072
120.30 Beclazone (100) 0.00000 0.00013 0.00027 0.00027 0.00032 0.00042 0.00043 0.00048 0.00065 0.00067
120.30 Beclazone Easi-Breathe (100) 0.00013 0.00027 0.00027 0.00032 0.00042 0.00043 0.00048 0.00065 0.00067
122.86 Beclazone (200) with Able Spacer 0.00014 0.00014 0.00019 0.00029 0.00031 0.00035 0.00052 0.00054
125.63 Qvar (100)
b
0.00000 0.00005 0.00015 0.00017 0.00021 0.00038 0.00040
125.63 Qvar Autohaler (100)
b
0.00005 0.00015 0.00017 0.00021 0.00038 0.00040
126.73 Beclazone Easi-Breathe (50) 0.00010 0.00011 0.00016 0.00033 0.00035
128.70 Beclazone (100) with Able Spacer 0.00001 0.00006 0.00023 0.00025
128.99 Filair (250) 0.00005 0.00021 0.00023
129.91 Qvar (100) with AeroChamber
b
0.00017 0.00019
133.27 Filair (250) with AeroChamber 0.00002
133.65 Becodisks Diskhaler (400)
143.15 Becotide (200)
148.65 Becotide (200) with Volumatic
148.99 Pulvinal (400)
150.23 Pulvinal (200)
150.67 Becotide (100)
154.03 Asmabec Clickhaler (100)
156.17 Becotide (100) with Volumatic
162.94 Pulvinal (100)
188.19 AeroBec Autohaler (100)
209.48 Becotide Rotacaps (200)
209.66 Asmabec Clickhaler (50)
220.83 Becotide Rotacaps (100)
266.16 Becodisks Diskhaler (200)
266.16 Becotide Rotacaps (400)
272.80 Becodisks Diskhaler (100)
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TABLE 32 contd  QALY thresholds for 800 µg daily dose (or equivalent) of beclometasone: cost per QALY threshold £20,000
Cost per annum (£) 143.15 148.65 148.99 150.23 150.67 154.03 156.17 162.94 188.19 209.48 209.66 220.83 266.16 266.16 272.80
Device name(s)
104.46
a
Beclazone Easi-Breathe (100) 0.00193 0.00221 0.00223 0.00229 0.00231 0.00248 0.00259 0.00292 0.00419 0.00525 0.00526 0.00582 0.00808 0.00808 0.00842
114.46 Beclazone (200) 0.00143 0.00171 0.00173 0.00179 0.00181 0.00198 0.00209 0.00242 0.00369 0.00475 0.00476 0.00532 0.00758 0.00758 0.00792
114.90 Filair (100) 0.00141 0.00169 0.00170 0.00177 0.00179 0.00196 0.00206 0.00240 0.00366 0.00473 0.00474 0.00530 0.00756 0.00756 0.00790
114.90 Qvar (50)
b
0.00141 0.00169 0.00170 0.00177 0.00179 0.00196 0.00206 0.00240 0.00366 0.00473 0.00474 0.00530 0.00756 0.00756 0.00790
114.90 Qvar Autohaler (50)
b
0.00141 0.00169 0.00170 0.00177 0.00179 0.00196 0.00206 0.00240 0.00366 0.00473 0.00474 0.00530 0.00756 0.00756 0.00790
119.18 Qvar (50) with AeroChamber
b
0.00120 0.00147 0.00149 0.00155 0.00157 0.00174 0.00185 0.00219 0.00345 0.00452 0.00452 0.00508 0.00735 0.00735 0.00768
119.18 Filair (100) with AeroChamber 0.00120 0.00147 0.00149 0.00155 0.00157 0.00174 0.00185 0.00219 0.00345 0.00452 0.00452 0.00508 0.00735 0.00735 0.00768
120.30 Beclazone (100) 0.00114 0.00142 0.00143 0.00150 0.00152 0.00169 0.00179 0.00213 0.00339 0.00446 0.00447 0.00503 0.00729 0.00729 0.00763
120.30 Beclazone Easi-Breathe (100) 0.00114 0.00142 0.00143 0.00150 0.00152 0.00169 0.00179 0.00213 0.00339 0.00446 0.00447 0.00503 0.00729 0.00729 0.00763
122.86 Beclazone (200) with Able Spacer 0.00101 0.00129 0.00131 0.00137 0.00139 0.00156 0.00167 0.00200 0.00327 0.00433 0.00434 0.00490 0.00716 0.00716 0.00750
125.63 Qvar (100)
b
0.00088 0.00115 0.00117 0.00123 0.00125 0.00142 0.00153 0.00187 0.00313 0.00419 0.00420 0.00476 0.00703 0.00703 0.00736
125.63 Qvar Autohaler (100)
b
0.00088 0.00115 0.00117 0.00123 0.00125 0.00142 0.00153 0.00187 0.00313 0.00419 0.00420 0.00476 0.00703 0.00703 0.00736
126.73 Beclazone Easi-Breathe (50) 0.00082 0.00110 0.00111 0.00118 0.00120 0.00137 0.00147 0.00181 0.00307 0.00414 0.00415 0.00470 0.00697 0.00697 0.00730
128.70 Beclazone (100) with Able Spacer 0.00072 0.00100 0.00101 0.00108 0.00110 0.00127 0.00137 0.00171 0.00297 0.00404 0.00405 0.00461 0.00687 0.00687 0.00721
128.99 Filair (250) 0.00071 0.00098 0.00100 0.00106 0.00108 0.00125 0.00136 0.00170 0.00296 0.00402 0.00403 0.00459 0.00686 0.00686 0.00719
129.91 Qvar (100) with AeroChamber
b
0.00066 0.00094 0.00095 0.00102 0.00104 0.00121 0.00131 0.00165 0.00291 0.00398 0.00399 0.00455 0.00681 0.00681 0.00714
133.27 Filair (250) with AeroChamber 0.00049 0.00077 0.00079 0.00085 0.00087 0.00104 0.00115 0.00148 0.00275 0.00381 0.00382 0.00438 0.00664 0.00664 0.00698
133.65 Becodisks Diskhaler (400) 0.00048 0.00075 0.00077 0.00083 0.00085 0.00102 0.00113 0.00146 0.00273 0.00379 0.00380 0.00436 0.00663 0.00663 0.00696
143.15 Becotide (200) 0.00028 0.00029 0.00035 0.00038 0.00054 0.00065 0.00099 0.00225 0.00332 0.00333 0.00388 0.00615 0.00615 0.00648
148.65 Becotide (200) with Volumatic 0.00002 0.00008 0.00010 0.00027 0.00038 0.00071 0.00198 0.00304 0.00305 0.00361 0.00588 0.00588 0.00621
148.99 Pulvinal (400) 0.00006 0.00008 0.00025 0.00036 0.00070 0.00196 0.00302 0.00303 0.00359 0.00586 0.00586 0.00619
150.23 Pulvinal (200) 0.00002 0.00019 0.00030 0.00064 0.00190 0.00296 0.00297 0.00353 0.00580 0.00580 0.00613
150.67 Becotide (100) 0.00017 0.00028 0.00061 0.00188 0.00294 0.00295 0.00351 0.00577 0.00577 0.00611
154.03 Asmabec Clickhaler (100) 0.00011 0.00045 0.00171 0.00277 0.00278 0.00334 0.00561 0.00561 0.00594
156.17 Becotide (100) with Volumatic 0.00034 0.00160 0.00267 0.00267 0.00323 0.00550 0.00550 0.00583
162.94 Pulvinal (100) 0.00126 0.00233 0.00234 0.00289 0.00516 0.00516 0.00549
188.19 AeroBec Autohaler (100) 0.00106 0.00107 0.00163 0.00390 0.00390 0.00423
209.48 Becotide Rotacaps (200) 0.00001 0.00057 0.00283 0.00283 0.00317
209.66 Asmabec Clickhaler (50) 0.00056 0.00283 0.00283 0.00316
220.83 Becotide Rotacaps (100) 0.00227 0.00227 0.00260
266.16 Becodisks Diskhaler (200) 0.00000 0.00033
266.16 Becotide Rotacaps (400) 0.00033
272.80 Becodisks Diskhaler (100)
a
Assuming a £10 cost offset compared with the cheapest pMDI is validated
b
Not licensed for children aged under 12 yr
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TABLE 33  QALY thresholds for 400 µg daily dose (or equivalent) of budesonide: cost per QALY threshold £5000
Cost per annum (£) 69.35 97.24 135.05 135.05 135.05
Device name(s)
69.35 Pulmicort Aerosol 0.00000 0.00558 0.01314 0.01314 0.01314
69.35 Pulmicort Aerosol with Nebuhaler 0.00558 0.01314 0.01314 0.01314
97.24 Pulmicort LS 0.00756 0.00756 0.00756
135.05 Pulmicort Turbohaler (100) 0.00000 0.00000
135.05 Pulmicort Turbohaler (200) 0.00000
135.05 Pulmicort Turbohaler (400)
(Yamanouchi provided confidential information, which was included in the version of the report that was sent to the Appraisals Committee, but
this information has been removed from this current document)
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TABLE 34  QALY thresholds for 400 µg daily dose (or equivalent) of budesonide: cost per QALY threshold £20,000
Cost per annum (£) 69.35 97.24 135.05 135.05 135.05
Device name(s)
69.35 Pulmicort Aerosol 0.00000 0.00139 0.00329 0.00329 0.00329
69.35 Pulmicort Aerosol with Nebuhaler 0.00139 0.00329 0.00329 0.00329
97.24 Pulmicort LS 0.00189 0.00189 0.00189
135.05 Pulmicort Turbohaler (100) 0.00000 0.00000
135.05 Pulmicort Turbohaler (200) 0.00000
135.05 Pulmicort Turbohaler (400)
(Yamanouchi provided confidential information, which was included in the version of the report that was sent to the Appraisals Committee, but
this information has been removed from this current document)
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TABLE 35  QALY thresholds for 200 µg daily dose (or equivalent) of fluticasone: cost per QALY threshold £5000
Cost per annum (£) 71.18 76.68 76.68 116.80 139.07 139.07 144.57 144.57 166.86 166.86 166.93 166.93 166.93 172.43 172.43
Device name(s)
71.18 Flixotide (50) 0.00000 0.00110 0.00110 0.00912 0.01358 0.01358 0.01468 0.01468 0.01914 0.01914 0.01915 0.01915 0.01915 0.02025 0.02025
71.18 Flixotide Evohaler (50) 0.00110 0.00110 0.00912 0.01358 0.01358 0.01468 0.01468 0.01914 0.01914 0.01915 0.01915 0.01915 0.02025 0.02025
76.68 Flixotide (50) with Accuhaler 0.00000 0.00802 0.01248 0.01248 0.01358 0.01358 0.01804 0.01804 0.01805 0.01805 0.01805 0.01915 0.01915
76.68 Flixotide Evohaler (50) with Accuhaler 0.00802 0.01248 0.01248 0.01358 0.01358 0.01804 0.01804 0.01805 0.01805 0.01805 0.01915 0.01915
116.80 Flixotide Accuhaler (100) 0.00445 0.00445 0.00555 0.00555 0.01001 0.01001 0.01003 0.01003 0.01003 0.01113 0.01113
139.07 Flixotide (125) 0.00000 0.00110 0.00110 0.00556 0.00556 0.00557 0.00557 0.00557 0.00667 0.00667
139.07 Flixotide Evohaler (125) 0.00110 0.00110 0.00556 0.00556 0.00557 0.00557 0.00557 0.00667 0.00667
144.57 Flixotide (125) with Accuhaler
a
0.00000 0.00446 0.00446 0.00447 0.00447 0.00447 0.00557 0.00557
144.57 Flixotide Evohaler (125) with Accuhaler
a
0.00446 0.00446 0.00447 0.00447 0.00447 0.00557 0.00557
166.86 Flixotide Diskhaler (100) 0.00000 0.00001 0.00001 0.00001 0.00111 0.00111
166.86 Flixotide Diskhaler (50) 0.00001 0.00001 0.00001 0.00111 0.00111
166.93 Flixotide (25) 0.00000 0.00000 0.00110 0.00110
166.93 Flixotide Evohaler (25) 0.00000 0.00110 0.00110
166.93 Flixotide Accuhaler (50) 0.00110 0.00110
172.43 Flixotide (25) with Accuhaler 0.00000
172.43 Flixotide Evohaler (25) with Accuhaler
a
Not indicated for children
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TABLE 36  QALY thresholds for 200 µg daily dose (or equivalent) of fluticasone: cost per QALY threshold £20,000
Cost per annum (£) 71.18 76.68 76.68 116.80 139.07 139.07 144.57 144.57 166.86 166.86 166.93 166.93 166.93 172.43 172.43
Device name(s)
71.18 Flixotide (50) 0.00000 0.00028 0.00028 0.00228 0.00339 0.00339 0.00367 0.00367 0.00478 0.00478 0.00479 0.00479 0.00479 0.00506 0.00506
71.18 Flixotide Evohaler (50) 0.00028 0.00028 0.00228 0.00339 0.00339 0.00367 0.00367 0.00478 0.00478 0.00479 0.00479 0.00479 0.00506 0.00506
76.68 Flixotide (50) with Accuhaler 0.00000 0.00201 0.00312 0.00312 0.00339 0.00339 0.00451 0.00451 0.00451 0.00451 0.00451 0.00479 0.00479
76.68 Flixotide Evohaler (50) with Accuhaler 0.00201 0.00312 0.00312 0.00339 0.00339 0.00451 0.00451 0.00451 0.00451 0.00451 0.00479 0.00479
116.80 Flixotide Accuhaler (100) 0.00111 0.00111 0.00139 0.00139 0.00250 0.00250 0.00251 0.00251 0.00251 0.00278 0.00278
139.07 Flixotide (125) 0.00000 0.00028 0.00028 0.00139 0.00139 0.00139 0.00139 0.00139 0.00167 0.00167
139.07 Flixotide Evohaler (125) 0.00028 0.00028 0.00139 0.00139 0.00139 0.00139 0.00139 0.00167 0.00167
144.57 Flixotide (125) with Accuhaler
a
0.00000 0.00111 0.00111 0.00112 0.00112 0.00112 0.00139 0.00139
144.57 Flixotide Evohaler (125) with Accuhaler
a
0.00111 0.00111 0.00112 0.00112 0.00112 0.00139 0.00139
166.86 Flixotide Diskhaler (100) 0.00000 0.00000 0.00000 0.00000 0.00028 0.00028
166.86 Flixotide Diskhaler (50) 0.00000 0.00000 0.00000 0.00028 0.00028
166.93 Flixotide (25) 0.00000 0.00000 0.00028 0.00028
166.93 Flixotide Evohaler (25) 0.00000 0.00028 0.00028
166.93 Flixotide Accuhaler (50) 0.00028 0.00028
172.43 Flixotide (25) with Accuhaler 0.00000
172.43 Flixotide Evohaler (25) with Accuhaler
a
Not indicated for children
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TABLE 37  QALY thresholds for 20 mg daily dose (or equivalent) of sodium cromoglicate: cost per QALY threshold £5000
Cost per annum (£) 32.71 34.68 34.68 60.77 60.77
Device name(s)
24.31 Cromogen 0.00168 0.00207 0.00207 0.00729 0.00729
32.71 Cromogen with Able Spacer 0.00039 0.00039 0.00561 0.00561
34.68 Cromogen Easi-Breathe 0.00000 0.00522 0.00522
34.68 Intal 0.00522 0.00522
60.77 Intal with Synchroner 0.00000
60.77 Intal Spincaps
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TABLE 38  QALY thresholds for 20 mg daily dose (or equivalent) of sodium cromoglicate: cost per QALY threshold £20,000
Cost per annum (£) 32.71 34.68 34.68 60.77 60.77
Device name(s)
24.31 Cromogen 0.00042 0.00052 0.00052 0.00182 0.00182
32.71 Cromogen with Able Spacer 0.00010 0.00010 0.00140 0.00140
34.68 Cromogen Easi-Breathe 0.00000 0.00130 0.00130
34.68 Intal 0.00130 0.00130
60.77 Intal with Synchroner 0.00000
60.77 Intal Spincaps
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